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The ZFP36 proteins are a family of post-transcriptional regulator proteins that bind to adenine uridine 
rich elements (AREs) in 3’ untranslated (3’UTR) regions of mRNAs. The members of the human 
family, ZFP36L1, ZFP36L2 and ZFP36 are able to degrade mRNAs of important cell regulators that 
include cytokines, cell signalling proteins and transcriptional factors. This project investigated two 
proposed targets for the protein family that have important roles in B cell biology, BCL2 and CD38 
mRNAs. BCL2 is an anti-apoptotic protein with key roles in cell survival and carcinogenesis; CD38 is 
a membrane protein differentially expressed in B cells and with a prognostic value in B chronic 
lymphocytic leukaemia (B-CLL), patients positive for CD38 are considered to have a poor prognosis.  
 
This project provides evidence of a functional interaction between the three ZFP36 proteins and the 
3’UTR AREs of BCL2 and CD38 mRNAs. 3’UTR dual luciferase reporter assay results showed that 
the three ZFP36 proteins bound the 3’UTR ARE of BCL2 mRNA and CD38 mRNA. Zinc finger mutant 
versions of ZFP36L1 failed to bind the 3’ UTR AREs for each target, proving that intact zinc finger 
domains are the functional binding domains of the protein and are required for interaction with AREs. 
A complete ARE sequence is also needed and when mutated BCL2 3’UTR ARE was tested, lacking 
the adenine uridine rich core element, the BCL2 transcript was not bound by ZFP36L1 protein. For 
CD38 further experiments have demonstrated that down regulation of ZFP36L1 by siRNAs in HeLa 
cells resulted in an increase in CD38 expression as measured by immunofluorescence and flow 
cytometry and by Western blot analysis. These results provide further evidence that ZFP36L1 
negatively regulates CD38 mRNA. 
 
Analysis of BCL2, CD38 and ZFP36L1 protein expression in primary B-CLL cells by Western blot 
analysis did not show an inverse relationship between the proposed targets and ZFP36L1. Protein 
expression analysis in B-CLL for the whole family of ZFP36 proteins showed that ZFP36L1 was 
heterogeneously expressed; ZFP36L2 was detected at very low levels or was undetectable and 
ZFP36 was low and homogeneously expressed. In cell lines representing different B cell stages, but 
mainly representing mature and plasma cell stages, ZFP36L2 was detected at relatively high levels 
but also heterogeneously and there was very low or undetectable expression of ZFP36L1 in all cells. 
Immunohistochemistry analysis of ZFP36L1, BCL2 and CD38 in normal lymphoid tissue and FL 
indicated that areas of normal lymphoid tissues associated with highest levels of BCL2 and CD38 
were associated with low or undetectable levels of ZFP36L1. In FL (FL) ZFP36L1 was detected in 
follicular centre cells, where BCL2 is also reported to be highly expressed due to a translocation that 
leads to over expression of BCL2. CD38 expression was also detected within FL follicle centres with 
some cells showing a high level of expression within the neoplastic follicle and amongst scattered 
cells outside of it. 
 
Overall, the results support the hypothesis that ZFP36L1 (and also ZFP36 and ZFP36L2) negatively 
regulates BCL2 and CD38 mRNAs. In a wider context, the results of this project support the view that 
ZFP36L1, and perhaps other ZFP36 family proteins, play important roles in controlling mature B cell 
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1.1 The Zinc Finger Protein 36 (ZFP36) family 
 
The ZFP36/Tis11/Tristetraprolin is a protein family composed of 4 mammalian members, 3 of them 
are found in humans: ZFP36L1/Tis11b/Berg36/BRF1/ERF1/cMG1, ZFP36L2/Tis11d/BRF2 and 
ZFP36/Tis11/ Nup475/GOS24, also known as TTP, tris-tetra-proline, the prototype protein giving 
the name to the family for its three Pro-Pro-Pro-Pro repeats (Lai et al. 1990).  ZFP36L3, the fourth  
member of the family was not found in humans but  in the mouse placenta and yolk sac of rodents 
(Blackshear et al. 2005). A fifth member, ZFP36L4, xC3H-4 (Noiret et al. 2013, Tréguer et al. 2013) 
has been reported in frogs and fish and yeast (Blackshear 2002, Blackshear et al. 2005). Amongst 
species, the ZFP36 family have orthologs in all vertebrates, although not in birds which do not have 
a version of ZFP36 (Blackshear and Perera 2014). The relevance of the presence of the proteins 
amongst different species highlights their importance within the machinery for control of gene 
expression.  
 
The human gene encoding the prototype protein, ZFP36, located in chromosome 19q13.1, was 
cloned and identified by different groups as an early response gene (DuBois et al. 1990, Lai et al. 
1990, Taylor et al. 1991). Initially a partial sequence had been published after a study using 
fibroblasts stimulated with 12-O-tetradecanoylphorbol-13-acetate (TPA) (Varnum et al. 1989, 
Varnum et al. 1991) and later the full length sequence was described as a result of cloning of the 
mouse cDNA from 3T3- L1 fibroblasts stimulated with insulin. Shortly after that, another study 
published the same sequence description as Nup475 also isolated from fibroblasts but stimulated 
with serum (DuBois et al. 1990, Lai et al. 1990). The final version of the protein sequence was 
corrected in another paper (Ma and Herschman 1991) and later on other studies described the DNA 
sequence in human cells (Taylor et al. 1991).  
 
The second family member, ZFP36L1, had been identified in murine cells (Varnum et al. 1991); with 
chromosome location 14q22-24, it was identified from cDNAs representing early response genes 
from activated B cells and cloned from chronic lymphocytic cells after TPA treatment (Murphy and 
Norton 1990, Ning et al. 1996). The name ERF1, early response factor 1, was given after cloning 
and characterizing the ZFP36L1 gene isolated from cDNA libraries using a as a probe a rat 
homologue, rat cMG1 (Bustin et al. 1994), that had been reported earlier (Gomperts et al. 1990). 
The coding sequence of ZFP36L1 was published (Barnard et al. 1993). The sequence of ZFP36L1 
gene was reported to have 2 exons (Bustin et al. 1994) and mapped to its chromosome location 
using FISH (Maclean et al. 1995). Ning et al. (1996) cloned ZFP36L1 identifying it as B cell early 
response gene of 36kD (BERG36), and reported that the protein contained 338 amino acids. The 
group also investigated its gene function in regulating Ramos B cell apoptosis. They showed that 
the gene could be induced by calcium ionophore in Ramos B cells and that IL4 could block it but 
this was not the case for CD40 ligation. Taken together, these observations indicated that ZFP36L1 
induction promoted B cell apoptosis and IL4 signalling inhibited ZFP36L1 induction and promoted B 




ZFP36L2, 2p22.3-p21, the third member of the family in mammals was identified in mice (Varnum et 
al. 1991) and later was isolated from cDNA libraries probed with mouse Zfp36l2 mRNA (Nie et al. 
1995). It was suggested the protein was 52 KDa, and about 493 amino acids. Other group also 
cloned ZFP36L2, naming it TIS11D, TPA-inducible sequence 11, proposing the protein to have 492 
amino acids and two binding motifs, detected at variable levels in all tissues and also in leukemic 
cells (Ino et al. 1995). The gene was reported to have 2 exons, being CG rich, apart from the 3’ 
untranslated (3’ UTR) region which was reported  to have 5 repeats of ATTTA, the adenine uridine 
(AU) rich element (ARE) (Ino et al. 1995). 
 
The gene sequences of the three ZFP36 family members are very similar especially in their zinc 
finger structure (Varnum et al. 1991), wich is the most conserved region as opposed to the C and N 
terminal domains which have less amino acids in common (Lai et al. 2000) (fig. 1). The genes differ 
mainly in the non-coding regions- introns and 3’UTR- (Blackshear et al. 2003b). A polymorphism in 
ZFP36 causing a C to T modification, is known to be associated with rheumatoid arthritis in African 
Americans (Carrick et al. 2006); ZFP36L1 has a single nucleotide polymorphism (SNP) in its intron 
(Blackshear et al. 2003b), but its effect or function is not yet known. A ZFP36L1 SNP is also linked 
to multiple sclerosis (MS) (Gourraud et al. 2012) and its uses as a molecular biomarker for the 
disease are being discussed (Paap et al. 2013). Recently an application for patent regarding MS 
prediction markers was published using ZFP36L1 polymorphisms as an indicator (within a number 
of other genes) to assess the course (benign, poor) of MS (Achiron and Gurevich 2010).  ZFP36L1 
is increasingly being looked at in MS. Another  2010 study showed that there are changes in the 
genetic signature of MS during pregnancy, the study looked at a number of individuals and 
concluded that expression of inflammation related genes is changed in pregnant women, where 
ZFP36L1 showed no pregnancy-related regulation (Gilli et al. 2010). 
 
Table 1-1 The ZFP36 gene family. 
 




Figure 1-1 Similarities between the members of the ZFP36 family.   
A. ZFP36L1 has a zinc finger domain (ZFD) protein sequence similarity of about 70% with ZFP36L2 and 90% with ZFP36. B. 
The 3 proteins have a nuclear localization sequence (NLS) within the ZFD; a nuclear export signal sequence (NES) for 
ZFP36L1 and ZFP36L2 is present in the C termini, for ZFP36 it is found in its N terminus. The N terminus of ZFP36 differs 
more from those of the other two proteins which are closely related with each other. Reproduced from Ciais et al. (2013). 
 
The three ZFP36 family mRNAs are expressed at different levels in a variety of tissues. The 
expression level of all three mRNA transcripts was quantitated in a variety of normal human tissues, 
and in the National Cancer Institute 60 cell lines, showing that each mRNA may be found in 
different tissues where another member of the family might not be expressed, or/and if more than 
one family member is found in a tissue their level of expression would often differ (Carrick and 
Blackshear 2007). The highest level for each mRNA was found as follows: ZFP36 highest 
expression level in cervix, ZFP36L1 highest expression level in lung and ZFP36L2 highest 
expression level in the thymus. Figure 1- 2 summarises the expression profiles of the three mRNAs 
in a variety of tissues. 
 
Figure 1-2 ZFP36 family members mRNA levels in normal human tissues. 
mRNA levels were measured using qPCR, the levels of expression found for each mRNA in different normal tissues varied 
among tissues and between proteins. Levels shown in tehfigure are normalised for total cDNA content. Figure modified form 




1.1.2 ZFP36 proteins in post-transcriptional gene regulation 
1.1.2.1 ZFP36 proteins RNA binding motifs 
The three human ZFP36 proteins have shared characteristics; they all have two tandem zinc finger 
motifs separated by 18 amino acids. There are different classes of ZFD, and they may be present in 
many DNA and RNA binding proteins; figure 1-3 shows a schematic representation of a ZFD 
showing zinc atoms that stabilise the motif and a beta sheet and an alpha helix as part of its 
structure. The zinc atoms are co-ordinated by two cysteine residues on the beta sheet, and two 
histidine residues on the alpha helix. A single zinc finger binds only to a few DNA or RNA bases 
hence these domains appear usually in tandem repeats (fig.1- 3). In the DNA binding ZFD the alpha 
helix binds to the bases in the target site through amino acid side chain interactions, the identity of 
these side chains determines the recognition of the target sequence (Krishna et al. 2003). CCCH 
zinc fingers can bind single and double stranded RNA. The CCCH motif of ZFP36L2 shed light in 
the binding mode of the proteins to single stranded RNA (Brown 2005). CCCH zinc fingers are 
thought to use sequence-specific recognition of single-stranded RNA through an interaction 
between hydrogen bonds and Watson-Crick edges of the RNA bases (Stefl et al. 2005).  
 
A                                                                  B 
                      
        
Figure 1-3 Representation of zinc finger motifs.  
(A)A prototype DNA binding zinc finger motif, C2H2, it has an alpha helix (shown in blue), a short antiparallel beta sheet 
(purple) and coordinating zinc atoms. Histidine and cysteine residues are shown bonded to a zinc ion. C2H2 zinc fingers are 
arguably the best studied. The image  is from Kadrmas and Beckerle (2004) . (B) The ZFP36 proteins have a ZFD that is 
made up of Proposed model of tandem ZFD bound to the 9-mer sequence UUAUUUAUU. The amino-terminal  of zinc finger 
is on the right, the C-terminal zinc finger is on the left. The RNA oligonucleotide runs from left to right in the 5′ to 3′ 
orientation. The zinc residues are highlighted, as are certain bases in the RNA.  The model is based on the ZFP36L2 ZFD 
structure and the colours show level of identity between the model shown here for ZFP36 and ZFP36L2, being cool colours, 
blue and green, significant of a greater chemical similarity between ZFP36L2 and ZFP36. The image is from Brooks and 




Figure 1-4 Two zinc finger domains of ZFP36  
ZFP36/Tis11/TTP, ZFP36L1/Tis11b/Berg36 and ZFP36L2/Tis11d/BRF2 share structural characteristics including two zinc-
binding domains of the form Cys-X8-Cys-X5-Cys-X3-His. The image is from Brewer et al. (2004b) . 
 
1.1.2.2 Mechanism of mRNA degradation by ZFP36 proteins via adenine-uridine-rich 
elements  
AREs regulate mRNA decay by interacting with ARE-binding factors. Many mRNAs including many 
encoding oncoproteins and inflammatory mediators contain AREs in their 3’ UTR. Although, more 
recently, evidence has been found of the role of ZFP36 in regulating gene expression via an ARE 
independent pathway (Liang et al. 2009, Schichl et al. 2009) their main reported role in studies to 
date is their function as post-transcriptional regulators by promoting mRNA degradation through 
recognizing and binding to AREs in 3’ UTR regions of mRNAs via their ZFD.  
 
Following binding of AREs ZFP36 proteins induce deadenylation and decapping leading to 
recruitment of the mRNA by the exosome for 3’-5’ degradation or 5’-3’ degradation via exonuclease 
activity, XRN1. These processes result in the destruction of the RNA transcript (Blackshear 2002) 
hence performing a central role in post-transcriptional gene expression. 
 
The proposed model by which ZFP36 proteins promote degradation of the mRNA transcripts follows 
deadenylation, shortening of the poly A tails of their targets. Removal of the poly A tail is necessary 
for mRNA degradation with engagement of Poly A specific ribonuclease activity (Lai et al. 2003). 
Initial reports of ZFP36 shortening the Poly A tails of mRNA transcripts derived from TNFα by (Lai et 
al. 1999) and GMCSF by (Carballo et al. 2000).  Poly A RNAse (PARN) deadenylation seems to be 
enhanced by the ZFD of ZFP36, and it did not occur in presence of mutated ZFP36 which was 
unable to bind to the ARE (Lai et al. 2003). Although deadenylation is thought to be promoted by 
the action of PARN, immunoprecipitation studies showed that this action is not performed by direct 
contact with ZFP36 or ZFP36L1 (Lai et al. 2003, Lykke-Andersen and Wagner 2005).  Other 
deadenylation enzymes reported to interact with ZFP36 are CAF1a and CAF1b, an interaction that 
is prevented when ZFP36 is phosphorylated resulting in lack of deadenylation activity (Marchese et 
al. 2010). NOT1 association via ZFP36’s C terminal seems to be required for CAF1s recruitment by 
the protein (Sandler et al. 2011). The recruitment of deadenylation complex (CCR4-NOT) has also 
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been confirmed for ZFP36L1 and ZFP36L2 on binding to the 3’UTR mRNA of low density 
lipoprotein receptor (LDLR) (Adachi et al. 2014).  
 
Decapping by decapping enzymes has also been reported in ZFP36 led mRNA degradation.  
A number of enzymes (hDcp1, hDcp2-decapping enzymes); hXrn1, (5’-3’ exonuclease), hCcr4 (a 
deadenylase) and components of the exosome such as hRrp4, were seen to co-immunoprecipitate 
with ZFP36 (Fenger-Grøn et al. 2005, Lykke-Andersen and Wagner 2005); a number of groups 
further reported ZFP36 interacting with XRN and DCP1 and CDP2 (Hau et al. 2007, Kim et al. 
2010b); and involvement of the exosome had been further supported by (Chen et al. 2001). Co-
immunoprecipitation of ZFP36 with the enzymes mentioned happened via N terminal proposing that 
localisation of ZFP36 proteins within processing bodies (PBs) happens via C terminal (Lykke-
Andersen and Wagner 2005). The three ZFP36 proteins have been reported to localise within PBs, 
which are sites of mRNA degradation, containing decapping enzymes (Stoecklin and Anderson 
2007). Degradation of the mRNA transcript is also reported to occur via exosome and Xrn1 
exonuclease (Wilusz et al. 2001). The suggested mechanism of action of ZFP36 proteins is mRNA 
degradation is shown in figure 1-5.  
 
 
Figure 1-5 Pathways and major components of ARE-mediated mRNA decay by TIS11/ZFP36 family of proteins.  
Reproduced with permission from Baou et al. 2009. Proteins bound to 3’ UTR, deadenylases (hCcr, 4 PARN) are recruited; 
deadenylated mRNA to exosome containing Rrp4, Rrp40, Rrp41, PM-Scl75 (3′ to 5′ exoribonuclease complex). Decapping 




There is still some debate as to what the optimal ARE recognition sequence is for the ZFP36 
protein family. Some authors have proposed a nonamer as the optimal target sequence, 
UUAUUUAUU (Worthington et al. 2002, Blackshear et al. 2003a, Cao 2004, Hudson et al. 2004, Lai 
et al. 2005, Lin et al. 2008, Hodson et al. 2010), many reports indicated that the minimal sequence 
required for mediated mRNA degradation was a nonamer rather than a pentamer (Lagnado et al. 
1994, Zubiaga et al. 1995).  but other studies reported that only about 44% of ZFP36’s mRNAs 
targets showed the nonamer as their binding sequence (Stoecklin et al. 2008). Other groups have 
reported that the pentamer AUUUA is the target sequence, and other sequences such as 
UUUAUUU or UUUAUUUAUU (Michel et al. 2003, Brewer et al. 2004a, Kim et al. 2010a) have also 
been proposed. Further studies challenged the idea of the nonamer being the basic minimal 
sequence or minimal consensus sequence in all AREs; more so since many early response genes 
with known functional AREs do not have it (Chen and Shyu 1994). ZFP36L1 is reported able to bind 
to class II AREs, as already reported for TNF (Lai et al. 2000) and VEGF (Bell et al. 2006).  
 
AREs are the most common determinants of RNA stabilisation (Chen and Shyu 1995),  they serve 
as binding sites for micro RNAs (miRNAs) and RNA binding proteins (RBPs). RBPs exert their 
regulatory effect, for instance, stabilisation (HuA, HuB, HuC, HuD, HuR) or degradation (AUF1, 
ZFP36, ZFP36L1,TIA-1, TIAR, and KSRP) of transcripts, by recognising and binding to these AREs 
which are present in about 8% of human mRNAs (Bakheet et al. 2001). The AU segment can cover 
from 50 and up to 150 nucleotides and it is common the presence of  repeats of the pentameric 
AUUUA sequence (Caput et al. 1986, Shaw and Kamen 1986). 
 
AREs tend to be composed of varying numbers of the AUUUA or UUAUUUAUU sequences, an 
initial classification of AREs was done looking at the presence or lack of AUUUA (Chen and Shyu 
1994). After this type of classification a second attempt  was done looking at categorising the 
diverse AREs depending on whether they contained a few copies of the pentamers scattered along 
the ARE with U rich sequences, or whether AREs in which  various copies of AUUUA would be 
present clustered together (Chen and Shyu 1995).   Another group classified AREs into 3 different 
groups experimentally (Xu et al. 1997) and more recently, researchers produced the ARE 
containing mRNA database (ARED); the database compilation based on repeats of AUUUA , 
comprising of five subsets of AREs under class II relating to the number of nonamers  (Bakheet et 
al. 2006), class II in the experimental based classification by Xu et al. (1997).  A final effort in 
classifying the AREs and trying to join both prior groupings together was attempted leading to the 









Table 1-2 Classification of AREs.  
 
Proposed classification of AREs based on two previous groups, modified from Wilusz et al. 2001.  
 
 
1.1.3 Phosphorylation of ZFP36 proteins  
The proteins in this family have a high proportion of serines and threonines, wich are amino acids 
susceptible of phosphorylation (Cao 2004, Benjamin et al. 2006). The phosphorylation of ZFP36 
proteins impacts their localization, stability and mRNA decay function (Brook et al. 2006, Hitti et al. 
2006, Maitra et al. 2008). ZFP36 is phosphorylated by mitogen–activated protein kinase activated 
protein kinase 2 (MAPKAPK2) which promotes binding of 14-3-3 proteins and this hinders 
deadenylation by preventing the binding of deadenylation proteins to ZFP36 (Johnson et al. 2002, 
Chrestensen et al. 2004, Stoecklin et al. 2004, Marchese et al. 2010, Clement et al. 2011, Sandler 
et al. 2011). In the case of ZFP36L1 and ZFP36  phosphorylation of the proteins in two serines 
leads to the binding of 14-3-3 proteins protecting against dephosphorylation and impeding mRNA 
decay activity (Schmidlin et al. 2004, Benjamin et al. 2006, Sun et al. 2007). Previous reports had 
already highlighted that ZFP36L1 mRNA degradation function was regulated by kinases, 
specifically, kinase B (PKB/Akt)  (Schmidlin et al. 2004, Benjamin et al. 2006) which  stabilises ARE 
transcripts by phosphorylating ZFP36L1. They observed in vtro mRNA decay by a recombinant 
ZFP36L1 but if the protein was phosphorylated by PKB/Akt the transcript was stabilised, the 
stabilisation was not down to inhibition of binding of ZFP36L1 to the 3’ UTR but the phosphorylation 
induced a complex formation with the scaffold protein 14-3-3. In vivo and in vtro data support a 
model (fig. 1-6) where PKB/Akt causes ARE-mRNA stabilization by inactivating ZFP36L1 through 
binding to 14-3-3 (Schmidlin et al. 2004, Benjamin et al. 2006).   
 
Figure 1-6 Phosphorylation of ZFP36 proteins impacts their function.  
Schematic representation of ZFP36 proteins function regulated by phosphorylation. Phosphosylated ZFP36L1 bind 14-3-3 




Stress granules (SGs) form in the cell cytosol when the cell undergoes stress conditions, such as, 
hypoxia or heat shock. The SGs contain untranslated mRNA or silenced mRNA. It is thought that 
the function of SGs could be the protection of these mRNAs under unfavourable circumstances for 
the cell. It has been reported that in cells under stress ZFP36 might be recruited to the SGs 
(Kedersha and Anderson 2002), however phosphorylation and subsequent formation of the 
complex with the 14-3-3 proteins halted ZFP36 entering the SGs (Stoecklin et al. 2004, Rigby et al. 
2005). Furthermore  a mutated ZFD in ZFP36 protein also prevented the protein entering SGs 
(Murata et al. 2005). SGs can physically associate with PBs, places of RNA degradation, and this 
association may facilitate the degradation of selected mRNAs within SGs which are passed to the 
PBs (Kedersha and Anderson 2002, Kedersha et al. 2005). The three ZFP36 proteins are reported 
to localise within PBs, alongside decapping enzymes (Stoecklin and Anderson 2007), and it has 
been proposed that transporter protein Transportin has a role in delivering ZFP36 between SG and 
PBs (Gallouzi and Di Marco 2009). 
 
1.1.4 ZFP36 family proteins physiological roles 
Besides the shared characteristics of the three human ZFP36 family members: highly similar gene 
sequences, conserved ZFDs and the ability to recognise similar AREs within the 3’ UTR of mRNA 
transcripts, these three proteins have different expression patterns in different tissues and also 
might differ in the ARE type they preferentially bind to. The biological roles of the ZFP36 family have 
been highlighted through a variety of studies showing involvement in processes such as cell 
proliferation (Shimada et al. 2000), cell differentiation (Wegmüller et al. 2007, Busse et al. 2008), or 
cell death (Ning et al. 1996, Johnson et al. 2000).  
 
Recently the diversity of the targets these proteins reportedly bind to has increased with confirmed 
targets in lipid metabolism where ZFP36L1 and ZFP36L2 have been found to have a role in 
controlling the mRNA of the unstable low density lipoprotein receptor (LDLR), by binding to its 
3’UTR, recruiting a deadenylase complex, CCR4-nOT, and destabilising this mRNA transcript 
(Adachi et al. 2014). The homology between the proteins is obvious, but there is evidence that each 
of the three ZFP36 proteins may also target distinct but over-lapping mRNAs. Results from gene 
knockout studies in mice indicate that some of their individual functions might be non-redundant 
where the deletion of each ZFP36 protein has had different effects. Although normal at birth mice 
with knockout Zfp36 developed a variety of symptoms: cachexia, patchy alopecia, arthritis, 
conjunctivitis, autoimmune syndrome, myeloid hyperplasia, as a result of TNF mRNA extended 
half-life; the symptoms were alleviated if anti-TNFα antibody was administered (Taylor et al. 1996).  
In the case of ZFP36, inflammatory signals lead to expression of the protein which can negatively 
regulate the pro-inflammatory mediators resulting in an anti-inflammatory function in macrophages 
(Carrick et al. 2004). Zfp36l1 knockout mice died in utero due to failure in chorioallontoic fusion 
(Stumpo et al. 2004).  Zfp36l2 knockout mice showed defects in haematopoiesis (Stumpo et al. 
2009). Mice with a truncated version of ZFP36L2, due to deletion of the first exon (but leaving the 
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RNA binding domain and nuclear export signal intact) seemed normal at birth and presented a 
normal phenotype but the females were infertile. A mutation in Zfp36l2 leading to decreased 
expression of a form of zfp36l2  (with the 29 N-terminal amino acid residues deleted), ΔN-zfp36l2, 
resulted in fertilised eggs being arrested in early development. Female mice homozygous for that 
truncated version ovulated normally and the eggs were fertilized, but embryos did not develop and 
were seen to arrest at the 2 cell stage, females also released 40% fewer eggs than the WT 
littermates (Ramos et al. 2004). The wild type version of the zfp36l2 protein and mRNA was down-
regulated faster that its mutated version (ΔN-zfp36l2) in response to lipopolysaccharide (LPS) 
exposure in bone marrow macrophages, it suggested that the embryonic arrest connected to the 
truncated zfp36l2 might be linked to its resistance to stimulus induced down regulation, and so the 
truncation (lacking of a leucine repeat) stabilises the protein (Ramos 2012). 
 
The role of ZFP36L2 influencing ovulation and oocyte maturation has been further researched and 
it has been proposed that it has a role in the molecular basis for unexplained human female 
infertility (Ball et al. 2014). Ovulation and oocyte maturation are both triggered by luteinizing 
hormone receptor (LHR) signalling, its activation is necessary for the proper hormonal functioning 
during reproduction. ZFP36L2 interacts with the 3′UTR of LHR mRNA and lowers levels 
of Zfp36l2  expressed correlating with increased levels of LHR mRNA (Ball et al. 2014), whilst over 
expressing zfp36l2 in the MLTC-1 cell line lowered LHR mRNA levels. The group proposed that  
lack of the physiological down regulation of LHR mRNA levels by ZFP36L2 in the ovaries is 
associated with anovulation and oocyte meiotic arrest and the low levels of ZFP36L2 (70% 
decrease in the ovary) in ΔN-Zfp36l2 females might be insufficient to properly down-regulate the 
LHR mRNA induced by the LHR surge, thus resulting in anovulation (Ball et al. 2014). 
 
Mice lacking ZFP36L1 and ZFP36L2 during thymotopoiesis developed T- Acute 
lymphoblastic leukaemia (T-ALL) and showed a higher expression of Notch1 (Hodson et al. 2010). 
Cells accumulated after having passed the β selection checkpoint and before the development of T-
ALL. The 3’ UTR ARE of Notch1 mRNA was targeted by ZFP36L1 and ZFP36L2 leading to 
suppression of Notch1 expression, the opposite was seen in untransformed thymocytes where 
higher Notch1 levels was observed (Hodson et al. 2010). 
 
ZFP36L1 is expressed in all human hematopoietic cells but not in erythroid cells (Vignudelli et al. 
2010). ZFP36L1 overexpression in human cord blood CD34+ progenitor cells arrested red blood 
cell differentiation (Vignudelli et al. 2010). The inhibition in erythroid differentiation was linked to a 
down regulation of the signal transducer and activator of transcription 5b (Stat5b) protein through 
targeting and degradation of its mRNA (Vignudelli et al. 2010). Over expression of ZFP36 also 
inhibited erythroid differentiation; and the over expression of ZFP36 and  ZFP36L1 seemed to have 
a cumulative effect in stopping red blood cell differentiation (Vignudelli et al. 2010). Also, both 
ZFP36 and ZFP36L1, were seen to bind to the ARE in the 3’UTR of Stat5b mRNA. IRF8, a 
transcription factor of the IFN family is a pro-apoptotic factor was also seen to increase when 
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ZFP36L1 was over expressed (Vignudelli et al. 2010). ZFP36L1 has been shown have a role in 
keeping the undifferentiated state of myeloid cells during differentiation (Shimada et al. 2000) and  
similarly in pluripotent stem cells (Wegmüller et al. 2007). The protein also negatively regulates 
plasmacytoid differentiation by targeting B lymphocyte-induced maturation protein-1 (BLIMP1) 
(Nasir et al. 2012).  
 
Studies have shown a role for ZFP36L1 in promoting B cell apoptosis. In Ramos Burkitt’s lymphoma 
B cells the presence of this protein seems to be needed for apoptosis induced by calcium signalling 
(Ning et al. 1996); ZFP36L1 expression was also reported to be required for Rituximab-induced 
apoptosis in B-Chronic Lymphocytic Leukaemia cells (B-CLL) (Baou et al. 2009b). 
  
ZFP36L2 is found down regulated in red blood cell differentiation; knockdown of ZFP36L2 in 
transplanted erythroid progenitor cells prevented expansion of erythroid (Zhang et al. 2013). The 
protein binds to mRNAs highly expressed in terminal inmature red blood cell differentiation and 
negatively regulates the expression level of those mRNAs (Zhang et al. 2013).  
 
The prototype, ZFP36, has been well studied in inflammation, especially its relationship with TNF 
and its role in destabilising the TNF mRNA transcript (Taylor et al. 1996, Johnson and Blackwell 
2002). The involvement of ZFP36L1 and ZFP36L2 negatively regulating inflammatory processes is 
less clear. A recent study reported that ZFP36L1 is greatly induced by infection but that it does not 
seem to be the main player in repressing inflammatory mediators (Hyatt et al. 2014). This group 
created myeloid deficient ZFP36L1 mice and concluded that in these mice the lung cytokine 
production, bacterial clearance or increased lung inflammation was not altered compared to wild-
type mice. It was concluded that the prototype ZFP36 protein is the main player as a negative 
regulator of cytokines in macrophages and that it may compensate the loss of ZFP36L1 presence 
(Hyatt et al. 2014). 
 
Recently ZFP36L1 has been found to destabilise pluripotency transcripts hence maintaining the 
pluripotency of mouse embryonic stem cells (mESCs) (Tan and Elowitz 2014). The authors of this 
study determined that ZFP36L1 is able to post-transcriptionally regulate both, pluripotency and 
differentiation, responses downstream of Erk MAP kinase. Activation of the FGF-Erk signalling 
pathway stimulates mESC differentiation and it also leads to up regulation of ZFP36L1, this 
overexpression impaired proliferation under pluripotency conditions, but under differentiation 
conditions it promoted mesodermal determination (Tan and Elowitz 2014). The pluripotency 
associated mRNAs that ZFP36L1 regulates in mESCs after stimulation included Nanog, ZFP36L1 
regulates Nanog’s abundance and localization which leads to perturbing the network of transcription 
factors without inducing differentiation but arresting self-renewal. The same paper announced a 
number of pluripotency mRNAs targets for ZFP36L1 pulled out using RNA immunoprecipitation and 






1.1.5 mRNA targets for the ZFP36 protein family 
 
The mRNA ARE that each family member targets may be distinct for each ZFP36 protein or 
overlapping targets where the proteins may recognise a subset of identical mRNA targets. A review 
of the roles of this protein family in mRNA regulation can be found in several papers showing the 
role of these proteins in a large variety of functions (Baou et al. 2009a, Sanduja et al. 2011, Ciais et 
al. 2013) .  
 
A number of mRNA targets for ZFP36 family members have been identified in several studies. Most 
studies have focused on identifying candidate mRNAs for the prototype family member, ZFP36. 
Some mRNA targets have been identified in knockout mice models and/or in studies focused on 
different cell types where genes have been silenced (Emmons et al. 2008, Stumpo et al. 2009). 
Information on proposed targets published for ZFP36 family members can be seen in the appendix 
due to its length. Literature listing putative targets for the 3 proteins or a single family member, 
ZFP36 in this case, include research groups proposing 137 mRNAs (Stoecklin et al. 2008) and 
identifying 250 potential targets (Lai et al. 2006). Recently, Brooks and Blackshear, 2013 reviewed 
current mRNA binding targets for the prototype ZFP36 protein and the methods used to identify 
mRNA targets, this review highlights that since the first studied targets for ZFP36 in 2000 up to 293 
papers have been published identifying mRNA targets for the protein or proteins, although the 
paper shows a table only for ZFP36.  
 
Recently, data was published for pro-survival mRNA targets identified by in silico and in vtro 
analysis and identified BCL2, one of the putative targets researched in this thesis, as a candidate 
target for ZFP36L1 (Zekavati et al. 2014). Microarray expression profiling and ARACNe (Algorithm 
for the Reconstruction of Accurate Cellular Networks) (Margolin et al. 2006) in silico analysis of 
ZFP36L1 in B cells resulted in data showing possible mRNA targets with a role in B cell 
differentiation (Nasir et al. 2012). Some targets identified by this analysis like MCSF, VEGFA and 
IL-3 were already validated targets. Importantly this data identified a key factor in B cell maturation, 
BLIMP1, and led the way to the confirmation that ZFP36L1 regulates BLIMP1 mRNA via the ARE 
(Nasir et al. 2012). This analysis also proposed CD38 mRNA, the other candidate studied in this 
thesis, as a mRNA that is regulated by ZFP36L1. ZFP36L1 targets inferred from ARACNe analysis 
can be seen in Nasir et al. 2012, and a table is shown in the appendix. 
 
TNF is possibly the most studied mRNA target for this family of proteins; initially TNF mRNA was 
reported a target for ZFP36 by Carballo et al. (1998), confirmed later by other groups (Maclean et 
al. 1998, Lai et al. 1999, Johnson and Blackwell 2002, Chen 2006, Jalonen et al. 2006b, Suzuki et 
al. 2006, Hau et al. 2007, Patil et al. 2008) establishing the degradation of TNF mRNA via binding 
of ZFP36 to its ARE. For ZFP36 even its own mRNA has been reported as a target, suggesting a 
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potential for auto-regulation via negative feedback (Brooks et al. 2004; Lin, N.Y. et al. 2007; Tchen 
et al. 2004). TNF mRNA ARE is also a target for ZFP36L1 and ZFP36L2, as are GMCSF and 
VEGF mRNAs (Lai et al. 2000, Stoecklin et al. 2002, Lai et al. 2003, Ciais et al. 2004, Fukae et al. 
2005). The angiogenic gene, Dll4, was reported a target for ZFP36L1 only:  silencing of the protein 
in endothelial cells led to up-regulation of DII4 (Desroches-Castan et al. 2011) Other reported 
mRNA targets for ZFP36L1 include; steroidogenic acute regulator protein (STAR) (Duan et al. 
2009) and Stat5b (Vignudelli et al. 2010). For a recent review of the post-transcriptional regulation 
of angiogenesis via AREs and its potential for cancer therapeutics please see Planel et al. (2014). 
In this review, the role of ZFP36L1 is mentioned as one of the proteins with potential use in therapy, 
they based this on their previous work where they researched the potential role of ZFP36L1 in 
angiogenic and anti-tumor therapy.  In their 2010 paper the group looked at developing a therapy 
using ZFP36L1’s role as mRNA destabiliser. They further researched the role of ZFP36L1 as a 
negative post-transcriptional regulator of VEGF mRNA and obtained evidence of decreased VEGF 
mRNA half life and protein levels by a cell penetrating ZFP36L1 internalised into living cells of mice 
adrenal gland. In the same study they injected ZFP36L1 in Lewis Lung carcinoma cells implanted in 
mice showing  a decreased in various inflammatory and angiogenic cytokines and reduction of 
vascularisation of the tumor (Planel et al. 2010), This work followed the  earlier findings identifying  
VEGF mRNA decay by ZFP36L1 (Ciais et al. 2004, Bell et al. 2006). 
 
1.1.6 ZFP36 proteins and miRNAs  
miRNAs are short strands of RNA present in plants and animals and first described by Lee et al. 
(1993) although the term microRNA was not used until 2001 (Ruvkun 2001). They are initially coded 
as longer strands with a hairpin structure and processed by enzymes (Drosher) (Wu et al. 2000, 
Han et al. 2004) and Dicer  (Bernstein et al. 2001) into shorter lengths. The result is a double 
stranded RNA of about 22 nucleotides, one strand is incorporated into the RNA induced silencing 
complex (RISC) by argonaute proteins. Argonaute proteins can function as endonucleases directed 
to the mRNA complementary to the miRNA they are bound to (Meister 2013). The strand bound to 
the argonaute protein is called the guide strand, selected by the argonaute protein by its 5’ end 
stability; the passenger strand is destroyed within the RISC. Once integrated into the RISC miRNA 
bind to the 3’UTR of target mRNAs and this double stranded RNA eventually leads to translational 
repression (fig. 1-8). A more comprehensive review of miRNA biology can be found in Hammond 
(2015). 
 
There is increasing evidence of miRNAs having roles in regulation of cell growth, development, 
differentiation and also in cancer and other diseases. Furthermore, recent evidence indicates that 
miRNAs can regulate multiple functionally related genes in specific biological pathways (Sirotkin et 
al. 2010). miRNAs have been reported as oncogenes or tumour suppressor genes, however some 
groups also highlight a number of miRNA as playing both roles making  miRNAs  an interesting field 
for diagnostic, prognosis and even therapeutic research that includes haematological malignancies 
(for further details Mazan-Mamczarz and Gartenhaus, 2013 and Di Lision et al. 2012). In B cell 
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malignancies, for example, it is known that some miRNAs are found upregulated in Burkitts and 
other B cell lymphomas (Metzler et al. 2004, Kluiver et al. 2005, Sandhu et al. 2011) . miR-29a is 
thought to target MCL1, myeloid leukaemia cell differentiation protein, and anti-apoptotic protein of 
the BCL2 family, and also the oncogene TCL1A which is found disrupted in many T cell leukaemias 
((Pekarsky et al. 2006, Mott et al. 2007) 
 
 
Figure 1-7 RNA silencing pathway.  
Depiction of miRNA pathway leading to translational repression and mRNA cleavage. Pri miRNAs in nucleaous are exported 
to cytoplasm by protein exportin 5, in the cytoplasm the pre-miRNA is shortened by Dicers resulting in double stranded RNA 
of about 22 nucleotides long. These strands of these RNAs are separated and, after unwinding one strand will be 
incorporated into the RISC  via Argonoute protein, and the other strand will be degraded. The miRNA-RISC is then ready to 
bind to specific sequences in the target mRNAs and induce cleavage or translational repression preventing the binding of 
ribososmes. Image modified from  Oliveira-Carvalho et al. (2012) 
 
Elements of the miRNA pathway might be needed for ZFP36 degradation of mRNA. Dicer was seen 
to be required for ZFP36 to induce degradation of TNF mRNA. The same paper showed that 
miRNA16 could pair with bases of the ARE of TNF mRNA and furthermore that this pairing of 8 
bases was actually required for mRNA  degradation to occur, absence of either ZFP36 or miR16 did 
not lead to degradation of TNF mRNA suggesting that both RNA binding factors are needed for 
degradation to occur (Jing et al. 2005) 
    
Some predicted miRNA targets can be found in ZFP36 genes indicating a potential inter-regulatory 
relationship (Asirvatham et al. 2009). miRNA profiling in breast cancer samples showed that miR-29 
levels were increased in cells with ZFP36 loss, and in fact over expression of the miRNA resulted in 
suppressed ZFP36 expression (Gebeshuber et al. 2009); ZFP36 mRNA was reported as a target 
for miR29a  (Gebeshuber et al. 2009, Sanduja et al. 2011, Liu et al. 2013). miR29a, and miR29b, 
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could also possibly target ZFP36L1, since previous studies had shown that over-expression of both 
miRNAs decreased levels of ZFP36 and ZFP36L1 (Gebeshuber et al. 2009, Sinha et al. 2009). 
 
In the simian inmmunodefiency virus model ZFP36 is downregulated during infection and 
maintained at low levels in the asymptomatic phase, using this model regulation of ZFP36 by 
miR29a was confirmed although the negative correlation between miR29a was not observed in the 
brain (Liu et al. 2013).  Another group examining the relationship between miRNAs  and AU binding 
proteins (AUBPs) showed that  HuR antagonised the binding of miR27 to the zfp36 3’UTR mRNA, 
and as a result hindered the suppression of ZFP36 by miR27 (Lu et al. 2014).Taken together, there 
is evidence that ZFP36 proteins and miRNAs may exhibit cross-regulation and that mRNA 
degradation pathways of ZFP36 proteins and miRNAs may be inter-related but the interplay 
between ZFP36 proteins and miRNAs is not yet clear. 
 
1.1.7 Other RNA binding proteins  
RBPs are key regulators of gene expression; they are involved in transport, stability, maturation and 
translation of RNAs. Eukaryotic genomes in vertebrates can code thousands of RBP (Glisovic et al. 
2008) and the functional characterisation of the vast number of these proteins is still unknown. The 
diversity in RNA and RBP interactions is determined by the different RBPs and the variety of their 
RB motifs (often several RBDs are present in one RBP). That vast array of interactions poses a 
challenge to systematically study protein and RNA targets. The data available is still short but there 
is an increasing effort in identifying motifs and sequence preferences. Ray et al. 2013 aimed at 
profiling a small number of RBPs that would allow the assessment of sequence preferences of 
RBPs in eukaryotes. They analysed the sequence preferences of over 200 RBPs by incubating 
RBPs with a pool of RNAs in excess (RNAcompete) and recovering the proteins with its associated 
targets, these were then studied using microarrays. They concluded that RBPs do have sequence 
preferences, they also highlighted evolutionary conservation and selection of motifs in relation to 
function and ultimately they observed that closely related proteins have preference for similar 
targets (Ray et al. 2013). Overall, the motifs in RBPs can be used to infer the post transcriptional 
mechanism these proteins exert and the group created a compendium of motifs as a resource to aid 
in understanding interactions of RBPs and RNA transcripts, post transcriptional regulation, and 
health and disease processes. A web tool is available where users browse or bulk download motifs 
for all eukaryotic RBPs including direct measured motifs for more than 200 RBPs, as well as more 
motifs inferred by homology. Another group created a census of over 1500 RBPs manually curated 
and they analysed their interaction with different classes of RNAs, to what extent they have been 
conserved, their abundance and tissue expression (Gerstberger et al. 2014). In 2015 over 1300 
genes that code for RBPs were also catalogued (Neelamraju et al. 2015). A web server for mapping 
RNA binding sites of RBPs has also been created and is freely available (Paz et al. 2014). A table 
with some of the web resources available regarding RBPs binding sites was published in a 2014 




mRNA transcripts containing AREs can be regulated by proteins binding to the ARE that may lead 
to mRNA degradation or to its stabilisation. These AUBPs have a key role in post-transcriptional 
gene regulation and hence their expression can impact the stability of gene products whilst 
impairment of their function can lead to diseases, such as, cancer (Audic and Hartley 2004). ZFP36 
proteins are one family of AUBPs that mediate mRNA degradation and are the major focus of this 
thesis. Briefly, the role of other AUBP proteins that regulate the stability of mRNA transcripts, 
namely HuR and AUF will be considered here   
 
HuR/ELAVL1 is an AUBP that can stabilize important mRNAs such as p53 or VEGF (Audic and 
Hartley 2004) and also BCL2 (Ishimaru et al. 2009), but has been reported to destabilise other 
mRNAs such as TNF or STAT3 (Papadaki et al. 2009). HuR is also regulated by miRNAs, as 
miRNAs such as miR-16 repressed its translation (Xu et al. 2010). HuR is also known to play a 
positive role in cancer formation (Hacker et al. 2010). On comparing the binding preferences of 
ZFP36 and HuR (Mukherjee et al. 2014) found thousands of overlapping binding sites for both 
proteins ZFP36 binds and degrades mRNA via specific AREs that are actually a subset of the 
uracyl rich sequences that HuR interacts with to stabilise transcripts (Mukherjee et al. 2014). 
 AUF1 proteins also regulate BCL2 (Lapucci et al. 2002) and TNF (Wilson et al. 2003) stabilising 
the mRNA transcripts. A key role of AUF1 is performed in hematopoiesis, the mice knockout for 
AUF1 show decreased T and B splenic cells, and this low number of cells was thought to be as a 
result of decreased pro-survival proteins like Bcl2 (Sadri et al. 2010). 
 
Some AUBPs share the same mRNA targets as ZFP36 family members. The final balance in 
mRNA levels may be the result of the interplay of ZFP36 members and other AUBPs such as HuR 
which stabilise mRNA transcripts, leading to the idea of a network of AUBPs with inputs into the 
final balance in the levels of mRNA transcripts (Zanocco-Marani 2010). Targets mRNAs may be 





1.2 B lymphocytes 
 
B cells may be defined as a population of clones expressing clonally diverse immunoglobulins (Ig) 
aimed at the recognition of specific antigen epitopes. The initial landmarks in B cell discovery took 
place using animal models (chicken and mice) and studying immunodeficient patients (Good and 
Zak 1956) 
The detection of  immunoglobin in serum  led to the discovery of B cells (Tiselius and Kabat 1938), 
although the idea of an antibody producing plasma cell came about later on (Fagraeus 1948). The 
connection between B cells and antibody production was possible as technology advanced, and 
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eventually cell marker characterization technology allowed for a number of studies showing that 
immunoglobulin expression could serve as a marker to characterize normal and malignant B, and T, 
cells (Raff 1973) 
 
1.2.1 B cell development 
Normal B cell development starts in the foetal liver. Hemocytoblasts, multipotent hematopoietic 
stem cells in the embryo, develop into two types of progenitor cells, myeloid and lymphoid cells. B 
cells arise from a lymphoid progenitor cell that give rise to NK cells, T cells and B cells. From the 
foetal liver, as gestation advances, their site of production moves to the bone marrow (Tavian and 
Peault 2003). After birth B cell development continues in primary and secondary lymphoid organs. 
The bone marrow provides a specialised microenvironment for the initial stages of B cell 
development where stromal cells have a key role to the immature B cell stage (Nagasawa 2006). A 
series of interactions occur between stromal cells and B cells through adhesion molecules starting 
B cell proliferation. B cells in the bone marrow change the level of contact with stromal cells as they 
develop. The early stem cells are found within the bone marrow area closest to the inner bone 
surface, later they migrate within the marrow moving towards the centre of the marrow cavity. As 
development takes place the need for stromal cell contact decreases and eventually B cells leave 
the marrow as immature B cells to further develop into mature B cell in the peripheral lymphoid 
organs. Stromal cell IL7 signalling was discovered as a key cytokine in stromal cell marrow, needed 
in mice for B cell development for V to DJ rearrangementand transmitting survival and proliferating 
signals (Milne and Paige 2006).  
 
In early B cell development the heavy (H) and light (L) chain of the immunoglobulin are rearranged 
(ALT et al. 1986). Recombination of the V, D and J genes H chain segments and V, J in the light 
chain (Brack et al. 1978) via RAG1/2 takes place mainly in the fetal liver and adult marrow leading 
to a diverse range of VDJH and VJL functional rearrangement to encode the B cell receptor (BCR) 
(Schatz et al. 1989, Oettinger et al. 1990). A surrogate light chain is first formed, a two protein 
heterodimer (Sakaguchi and Melchers 1986) that with the H chain form a pre-B cell receptor, 
characterizing the pre-B cell stage (Melchers 2005) following a pro-B cell stage. Pro-B cells do not 
express Ig or a pre-BCR. Pre-BCR is needed for B cell development as much as the BCR is needed 
for survival in the periphery (Lam et al. 1997, Bankovich et al. 2007) 
 
B cells leaving the bone marrow acquire IgD and are CD21, CD22 positive (Chung et al. 2003) IgM 
IgD positive B cells enter the blood and migrate to the periphery, here and in the spleen the vast 
majority of B cells are mature IgM IgD positive B cells. At this stage these cells respond to T cell 
independent antigens, e.g. LPS, giving rise to a quick immune response lacking the intervention of 
MHC (major histocompatibility complex) class II T cells (Coutinho and Möller 1975). A range of 
transcription factors control early B cell development, importantly: E2A, EBF, Pax 5 in B cell lineage 
commitment and differentiation (Nutt and Kee 2007); a figure with indications to key transcription 
factors in B cell development can be found in the appendix. Amongst transcription factors with a 
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role in late B cell stages BCL6 has a key part in GC (GC) formation, BLIMP1 and STAT3 in plasma 
cell differentiation, Pax5 although not expressed in plasma cells has a key role in driving and 
maintaining B cell identity. BCL6 is suggested to negatively regulate other late B cell development 
transcription factors; BCL6 overexpression actually inhibits plasma cell differentiation suggestion 
that BCL6 inhibits STAT3 dependent expression of BLIMP1 (Reljic et al. 2000). And the inhibitory 
effect of overexpression of BCL6 was later observed in primary human B cells (Diehl et al. 2008). 
IRF4 is another factor present in late B cell stages, it is detected in plasma cells and centrocytes, 
not in centroblasts and GC B cell seem unable to differentiate into plasm in the absence of IRF4 
(Klein et al. 2006). IRF4 ectopic expression in GC derived cell lines, Raji and Daudi, Burkitts 
lymphoma cells, has shown as a result an up regulation in the plasma cell marker studied in this 
project, CD38 (Teng et al. 2007). 
 
Most B cells not residing in gut associated lymphoid tissue are found in lymphoid follicles and in the 
spleen and lymph nodes ready to encounter T cell dependent antigens bound to dendritic cells. B 
cells expressing CD40 interact and are activated by activated T cells through CD40L (CD154), 
proliferate and differentiate to plasma cells or form generate GCs which are composed of rapidly 
proliferating centroblasts. GCs are the main site for the generation of high affinity antibody secreting 
plasma cells and memory B cell generation (Coutinho and Möller 1975). Somatic hyper mutation 
(SHM) takes place in GCs and the highest affinity clones are selected to form either plasma cells or 
memory B cells (Jacob et al. 1991, Kelsoe 1996). B cells going through SHM of their Ig variable 
domains introduce microdeletions and single nucleotide modifications creating clones with different 
and varied antigen affinities. Class switching also takes place and B cells with the highest affinity 
antibody will survive with the remaining B cells apoptosising due to their lower antibody affinity and 
also B cells will express different classes (isotypes) of antibody (Nemazee et al. 1999). 
 
 
Figure 1-8 Stages in B cell development.  
The figure shows the pathways in  B cell development and expression of different cell surface markers and IgM and IgD. 




B cells enter the spleen via the blood and are found in the white pulp follicles, these may have GCs 
if the B cells have actively engaged in an immune response. In the marginal zone, within the white 
pulp, there are marginal zone B cells, a different set of resting B cells that also express different 
markers to follicular B cells, these cells are somewhat similar to B1 cells. B-1 cells are B 
lymphocytes not involved in the humoral response, are not part of the adaptive immune system and 
nor have B cell memory function, they do produce antibodies and also act as antigen presenting 
cells. B1 cells are present in the peritoneal and pleural cavity (Tangye 2013). In the mantle zone of 
lymph nodes there are CD5+ or CD5- B1 cells (Hayakawa et al. 1983; Hardy and Hayakawa, 2003). 
B1 cells assist in the innate immune system by protecting against bacteria in naïve hosts. B1 CD5- 
cells have a role in long-term adaptive immune response to LPS and T independent antigens (Haas 
et al. 2005). Marginal zone B cells do not seem to need T cell involvement to become activated 
(similar to B1 cells which are T cell independent cells). Marginal Zone B cells are thought to 
possess antibodies with low antigen specificities and more affinity for self-antigens, they provide a 
rapid response for antigen entering via the bloodstream. As opposed to B1 cells which do express 
high levels of CD5, marginal zone B cells do not express this cell surface marker.  
 
Lymph nodes regulalrly show follicles of B cells generating GCs upon activation. B cells enter the 
lymph node, also via the blood, passing though the T cell area to the follicles, here they proliferate, 
undergo somatic mutation and class-switching and go through affinity maturation and cell selection 
after encountering antigens held on follicular dendritic cells, then the cells become either memory B 
cells or plasmablasts. A highly affinity mutated BCR will fast react upon a second antigen exposure 
rapidly differentiating into antibody producing plasma cells (McHeyzer-Williams and McHeyzer-
Williams 2005). Plasmablasts leave the lymph node via the efferent lymphatic back to the blood. 
Plasma cell development is tightly regulated by factors such as BCL6 and BLIMP1 (Shapiro-Shelef 
and Calame 2005). Plasma cells become resident in the bone marrow.  
  
Some immune pathologies arise from errors in the B cell maturation process, for instance, defects 
in CD40;CD40L interaction result in Hyper IgM syndrome. Class switching and SHM are tightly 
controlled and errors in these processes can lead to activation of oncogenes, for instance Burkitts 
lymphoma, where there is over-expression of the c-Myc gene (Vale and Schroeder 2010). One of 
the factors that influence survival of a B cell is its pre-B cell receptor (BCR), its development and 
correct function is essential for the development of B cells pass the pre-B cell stage. 
 
1.2.3 B cell Malignancies 
The balance in B cells by the continuous production of new B cells and their loss ensures a healthy 
homeostatic state and a variety in the receptor possibilities for recognising new antigens. 
The B cell development stages depicted in the previous section are those of a normal B cell; 
however, those development stages may present a variety of problems that include immune 
pathologies (e.g. Hyper IgM syndrome) or malignant versions of each stage where a dominant 




We have knowledge of gene expression due to profile studies in normal and malignant B cells 
(Staudt and Dave 2005); one key protein, which is the centre of a chapter in this thesis, is BCL2. In 
follicular lymphoma (FL) the anti-apoptotic BCL2 is translocated with IgH loci and BCL2 is 
overexpressed (Tsujimoto et al. 1984). The ZFP36 proteins have been reported to be involved in 
cancerous processes; a deletion in chromosome 14(q) has been reported to be present in different 
B cell Malignancies; this deletion affects the ZP36L1 gene (Pospisilova et al. 2007). 
 
Blood malignancies are usually grouped in three main categories: lymphomas, myelomas and 
leukaemias, although the boundaries within and between each category may not be clearly defined 
especially when patients show symptom across the three categories. 
 
Lymphoma, specially non-Hodgkin, and leukaemia are common haematological malignancies in 
the UK. Myeloma is less commonly found but still prevalent (Cancer.gov, 2015). Lymphoma affects 
the lymphoid system, divided in non-Hodgkin (NHL) and Hodgkin lymphoma (HL) the latter type is 
the most common amongst the two. In both cases the number of lymphocytes is increased. NHL 
can be of T or B cell whereas HL is diagnosed if Reed-Steingberg cells are detected, these are 
malignant B cells that almost in all cases arise from GC B cells that cannot synthesize 
immunoglobulin (Bräuninger et al. 2006, Mathas et al. 2006) 
 
Leukaemias affect white blood cells, B and T lymphocytes and are further classified depending on 
the aggressiveness of the disease, acute or chronic. The cell development stage at which 
leukaemia arises has an impact on the life course of the disease determining a slow, insidious 
progression or a rapid, acute onset of the disease. B-CLL is further discussed later on. 
 
And finally Myeloma, or Multiple Myeloma (MM), affects terminally differentiated plasma cells and 
ultimately Ig production; the prevalence in the UK is less than that of lymphoma and leukaemia 
(Cancer.gov, 2015). The bone marrow is also thought to play an important role in the development 
and maintenance of this cancer, even on therapy resistance although a direct link and how this may 
happens remains to be known (Hideshima et al. 2007).  The initial phase of myeloma is usually 
characterised by asymptomatic monoclonal gammopathy of undetermined significance (MGUS) 
followed by MM, and eventually the more aggressive plasma cell leukaemia. In myeloma plasma 
cells have accumulated genetic hits. The genetic aberrations are classified as initiation (IgH 
translocations) and progression events (chromosomal deletions and gains) (Boyd et al. 2012). The 
first genetic abnormalities are thought to occur at the time of SHM and isotype switch within GCs. 
Further genetic mutations take place on transformation of MGUS into a myeloma cells and on 
progression of the disease (Bianchi and Munshi 2015).Besides the low frequency of BCL2 
translocation t(14;18) in MM patients the protein itself is actually found at increased levels in primary 
and cell lines of MM (Spets et al. 2002). Symptoms and survival varies from patient to patient, 
varying from 5 to 10 years. MM is treatable although there is no cure and the incidence is the 
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disease is low with about only 15000 to 20000 people suffering from the condition at a  given time in 
the UK, about 4800 are newly diagnosed each year, making the second most common bone 
marrow cancer but only 1% of total cancers (myeloma.org.uk 2015). 
 
Figure 1-9 shows cell type/development stage affected by malignancy and classification 
 
Figure 1-9 Malignancies characteristic of each B cell development stage.  
Reproduced and modified from Rickert (2013) New insights into pre-BCR and BCR signalling with relevance to B cell 
malignancies, Nature reviews/Immunology 
 
1.2.4 B cell chronic lymphocytic leukaemia 
B-CLL is a common B cell malignancy, characterised by accumulation of anti-apoptotic mature B 
cells. It is the most common type of leukaemia in the Western world; with an incidence that rises 
alongside age it is usually seen in older patients and males (Hernández et al. 1995, Sant et al. 
2010) although diagnosis in younger individuals is not uncommon (Hernández et al. 1995) 
Because B-CLL cells express mostly CD19+ B-lineage phenotype the disease is called B-CLL but 
CLL also affects T lymphocytes although just a small proportion compare to the incidence of B-CLL 
 
This type of B cell malignancy is characterised by significant accumulation of apoptosis-resistant 
monoclonal B-lymphocytes in peripheral blood and lymphoid organs. Although there are B-CLL 
cases called familial, the pattern of inheritance is not clear although it is estimated that one in every 
10 patients with B-CLL has either a family history of B-CLL or there are links to other 
lymphoproliferative disorders within the  family, calculating a 30 fold increment in the risk of 
developing B-CLL with first degree relatives (Johnston JB 2009). 
 
Diagnosis of B-CLL, as revised by the international workshop in B-CLL, 2008, is based on 5 x 109/L  
monoclonal B lymphocytes peripheral blood for  at least 3 months and the clonality of circulating B 
lymphocytes needs to be confirmed by flow cytometry. Typical immunophenotype of B-CLL 
lymphocyte is CD5+, CD23+, CD43+/-, CD10-, CD19+. CD20 dimly expressed in B cells is also 
characteristic in B-CLL, expression of this marker and of surface Ig assist in distinguishing B-CLL 
from mantle cell lymphoma in CD23 is not expressed. Whilst flow cytometry is essential for correct 
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diagnosis, bone marrow examination and a CT scan might be required for diagnosis and or staging 
(Hallek et al. 2008) 
 
Two different staging systems are used in B-CLL. The Rai system  (Rai et al. 1975) tends to be 
used in the United States and the Binet system (Binet et al. 1981) is commonly used in Europe. 
Both systems look at blood count and physical examination to subset patients in groups and 
establish median times of survival. 
 
Table 1-3 Rai  and Binet B-CLL staging systems 
 
Modified from Parker and Strout (2011) .  
 
One system proposed looking at lymphadenopathy, organomegaly and cytopenias (anaemia and 
thrombocytopenia) to establish prognostic groups, stage 0 >150 months, stage I, 101 months, stage 
II, 71 months, stage III or IV, 19 months (Rai et al. 1975).The other proposed a system where 
patients are stratified in three stages looking at nodal areas and cytopenias (Binet et al. 1981). 
 
Cancer heterogeneity and B-CLL 
Cancers deriving of the same organ may be further classed in different subtypes and within these 
subtypes each cancer may contain different tumour cell populations that confer each cancer specific 
clinical characteristics such as invasive potential (Felipe De Sousa et al. 2013). Inter tumoural and 
intra tumoural heterogeneity are a challenge for successful cancer therapy. A number of factors 
(genetic, epigenetic, tumour microenvironment, origin of cancer) influence this diversity (Felipe De 
Sousa et al. 2013). Intra clonal diversity has been used to explain therapy resistance: selective 
pressure on cancer cells leads to resistant clones. Advantageous mutations- “driver” mutations- 
over “passenger” mutations alongside mutator lesions and microenvironment changes become key 
to explain clonal evolution (Greaves and Maley 2012). Passenger mutations are non function 
related somatic mutations occurring in cell division often found in cancer genomes, these mutations 
were present in ancestor cells when they acquired the driver mutations. Driver mutations grant a 
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growth advantage for the carrier cells, these cells are positively selected during the cancer evolution, 
surviving over the cells carrying passenger mutations (Stratton et al. 2009). 
 
In efforts to make records of somatic mutations in the different types of cancers databases like  
COSMIC or ICG DCC have been created. COSMIC stands for Catalogue of Somatic Mutations in 
Cancer and now it even curates mutations that offer cancers resistance to drugs (Forbes et al. 
2015). ICG DCC is the International Cancer Genome Consortium Data Coordination Centre and 
offers the opportunity to browse genes of interest or cancer types and retrieve information on 
mutation status (Zhang et al. 2011). For ZFP36L1 the web based tool shows that the gene was 
found to be mutated in malignant lymphoma and B- CLL samples from donors, the number of 
mutations and other details information may also be found in the site. A map of the gene with low, 
high and unknown mutation impact is also available, for ZFP36L1 about the same number of 
mutations are found to have a high functional impact on the protein than low impact, and about half 
that number is unknown. ZFP36 is also found mutated in malignant lymphoma and to a lesser rate 
in B-CLL. Malignant lymphoma donors also showed mutations in ZFP36L2 (ICGDCC 2016). 
 
In B-CLL the clinical heterogeneity is great and leads to variability in the response to treatments 
with patients needing clinical intervention promptly but others not requiring treatment in years or not 
at all. As its names states it is a chronic condition, prognosis depends on subtype and stage and 
although the five year survival has increased in the last three decades to eight years (Molica and 
Levato 2001) the individual survival is greatly variable, again markedly due to the disease’s 
heterogeneity. A number of markers have been found that assist in understanding the biology of B-
CLL and classifying patients in different subtypes with similar clinical course and prognosis. Overall, 
this classification of B-CLL patients in subtypes aims at enabling a successful therapy choice. In 
broad terms the major and most studied subtype is that formed by patients with mutated and 
unmutated IgHV. Cytogenetic changes have also been linked to prognosis (17p del, 13q del) 
alongside CD38 positivity. The discovery of new prognostic markers were added to the staging 
systems in use: tables 1-3 and 1-4 show Rai and Binet systems and common prognostic markers in 
B-CLL. Recently it has been proposed that genetic variability within a tumour may lead to a higher 
aggressive disease course and in B-CLL it may explain tumour progression (Ecker et al. 2015). 
Ecker et al. (2015) showed that within the more aggressive type of leukaemia, IgHV non mutated, 
there is a higher gene expression variability; and in patients with less aggressive disease course the 
variability was lower. Overall, the group led by Alfonso Valencia highlighted that the coefficient of 
variation for gene expression in B-CLL can predict its aggressiveness and this variability may be 
use to from a classifier of subtype of B-CLL patients. The IgHV unmutated subtype of B-CLL was 
also found to have more driver mutations, some of these newly identified as putative cancer genes 
(Landau et al. 2015). 
 




The table shows a list of commonly used markers, with incidence and survival time, to assess disease prognosis, CD38 
positivity is linked to a poor outcome. Table modified from Parker and Strout (2011). 
 
B-CLL prognostic markers, an overview 
 
Lymphocyte doubling time is the time needed for lymphocyte to double the number at time of 
diagnosis; less aggressive diseases are characterized by a doubling time of more than 12 months, 
median survival of 5 years (Molica and Alberti 1987, Damle et al. 2010, García-Muñoz et al. 2012) 
IgHV mutational status: mutated IgHV is linked to earlier stage disease and longer survival 
compared to unmutated IgHV ((Hamblin et al. 1999, Damle et al. 2010). ZAP70 is normally 
expressed in T cells, ZAP70 expression in B-CLL cells was found to correlate with IgHV mutational 
status and poor outcome (Rosenwald et al. 2001, Crespo et al. 2003) however, discordance 
between both factors is also found in about a quarter of patients and ZAP70 was finally established 
as an independent marker (Rassenti et al. 2004). CD38 positive clone, explained in detail later, 
suffice to say that a B cell population is assessed as CD38 positive if 20% or 30%- depending on 
the lab-of the clone expresses the cell marker. CD38 positivity is indicative of a poor prognosis 
(Hamblin et al. 2002). The majority of B-CLL patients are found to have acquired chromosomal 
abnormalities, in fact as much as 80% of them; the most common abnormality is a deletion in 13q, 
found in about 55% of patients (Döhner et al. 2000). 11q deletion is found in around 18% patients 
and is associated with other poor prognosis factors such as unmutated IgHV (Donner et al. 2000). 
Trisomy 12 is found in a slightly less proportion of patients, whilst 18% of them are found to have 
normal cytogenetics (Döhner et al. 2000) the least common is a deletion in 17p, 7% of patients, and 
is associated with unmutated IgHV and a poor prognosis (Döhner et al. 2000), the deletion seems 
to affect p53 (Zenz et al. 2010). 
 
For this cancer, as for any other cancer, the molecular mechanisms that lead these cells to behave 
in an aberrant manner are not fully understood. Although research is advancing in the discovery of 
how cells become cancerous, we are yet to understand its exact process and the need to find new 




1.3 BCL2 protein family  
 
BCL2 (B-cell lymphoma 2), encoded by the BCL2 gene, is the founding member of the cell death 
regulators “BCL2 family”. Within the family some proteins have a pro-apoptotic function (Bax, Bak, 
BAD as examples) and others, like BCL2 an anti-apoptotic effect (Thomadaki and Scorilas 2006) 
(fig 1-10). Structurally the family members have conserved domains and their presence varies 
amongst the two groups, pro -apoptotic members of the family usually lack the BH4 domain and the 
anti-apoptotic members have usually the BH1 and BH2 domains at least, but the ones similar to 
BCL2 have the four domains (Adams and Cory 1998, Thomadaki and Scorilas 2006). The BCL2 
family is divided into three subgroups: the multi domain/multi region pro-apoptotic proteins that 
directly permeabilise the mitochondrial outer membrane and the BCL2 homology domain 3 (BH3)-
only members (also pro-apoptotic) that directly or indirectly activate the pore-forming class 
members and the anti-apoptotic proteins that inhibit this process at several steps (Shamas-Din et al. 
2013). 
 
The family of proteins is generally believed to be cytoplasmic and predominantly membrane-
associated present in the outer membrane of the mitochondria, their main site of action, and the 
endoplasmic reticulum (ER). The pro survival BCL2 family members are generally found in the outer 
mitochondria membrane where they inhibit the pro-apoptotic BCL2 partners, and the pro-apoptotic 
proteins exert their activity by facilitating the permeabilisation of that membrane (Reed 2008). 
 
 
Figure 1-10 Selected proteins in the BCL2 family.  
Pro- and anti-apoptotic proteins intecations influence cell survival, the  proteins of the BCL2 family are important regulators of 
apoptosis and can act as pro apoptotic (Bax, BAD, Bak and Bok among others) or anti-apoptotic (including Bcl-2, Bcl-xL, 




BCL2’s name is linked to its discovery and role in the development of B cell lymphomas. It was first 
described in chromosomal translocations –chromosomes 14 and 18- in FLs (Tsujimoto et al. 1984, 
Cleary et al. 1986) (Bakhshi et al. 1985). The t(14;18) is seen in 85% of FLs  and 20% of diffuse B 
cell lymphomas (DLBCL), the result in the translocation is the positioning of BCL2 at chromosome 
segment 18q21 juxtaposed with the heavy chain  immunoglobulin gene leading to a deregulated 
expression of BCL2 (Vaux et al. 1988a). The description of BCL2’s anti-apoptotic and tumorigenic 
role resulted from a landmark piece of work by (Vaux et al. 1988b). Unbalanced and deregulated 
apoptosis plays a role in a number of pathologies: uncontrolled cell death is characteristic in 
diseases such as Alzheimers; whereas uncontrolled cell growth or lack of cell death determines 
cancerous processes.  
 
This commonly termed “programmed cell suicide” is driven by caspases; cysteine proteases 
caspases are sequentially activated and lead to apoptosis in two pathways. The different initiator 
caspases in either apoptotic pathways lead to end point cleavage and activation of effector 
caspases (caspases 3, 6 and 7) which in turn can cleave cellular proteins critical for cell survival 
(Adams 2003, Shi 2006).  Caspases 8 and 10 are activated after ligation of “death receptors” of the 
TNF family on the cell membrane: after a death signal, Fas associated death domain protein  
(FADD) attaches to caspase 8 and activates it, and further activate caspase  3 to lead to proteolytic 
activity, another option is that after caspase 8 attachment to FADD Bid is attached by caspase 8 
and the cleaved truncated Bid protein translocates to mitochondria and acts with pro-apoptotic 
proteins (Bax, Bak) and induce release of cytochrome C which binds to Apaf1 and leads to a 
conformational change forming the apoptosome; the apoptosome triggers activation of caspase 9  
which further activates caspase 3 , caspase 7,  caspase 6 ultimately resulting in death in the 
extrinsic apoptosis pathway (Adams 2003, Shi 2006).  The extrinsic pathway operates 
independently of p53 and immune cells like cytotoxic T cells may be involved producing ligands that 
bind to the “death receptors” and induce the cascade of events delineated above: Cytotoxic signals 
translocate BCL2 pro-apoptotic members to organelles and there they bind to the anti-apoptotic 
counterparts inhibiting their action and triggering apoptosis (Adams and Cory 2001). The intrinsic 
apoptotic pathway is induced by a number of internal stimuli; in broad terms, the intrinsic pathway is 
induced by lack of positive signals for cell survival (e.g. lack of growth factors, cytokine starvation) 
or by internal signals of accumulation of oxidative signals, misfolded proteins, endoplasmic 
reticulum stress signals, DNA damage. If the positive signals are present e.g. trophic factors, they 
bind to a trophic receptor and that binding results in phosphorylation of pro-apoptotic Bad protein, 
this phosphorylated Bad cannot bind to mitochondrial membrane bound BCL2 and Bcl-XL complex 
to inhibit their survival action. In the opposite scenario, absence of trophic factors, Bad is not 
phosphorylated and binds to BCL2/BCL2-XL inhibiting their pro survival activity, Bax, (pro-
apoptotic), is freed and permits an influx of ions and thus the release of cytochrome C into the 
cytosol, here cytochrome C binds to adaptor protein Apaf1 and pro caspase 9, forming the 
apoptosome, and containing activated caspase 9. Caspase 9 can cleave pro caspase 3 into its 
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active form and further cleaves downstream targets that lead to photolytic activity within the cells 
(targeting the nuclear lamina, the cytoskeleton etc.) if the intrinsic pathway  is triggered by DNA 
damage, p53 stimulates the transcription of pro apoptotic BCL2 proteins and are released by the 
mitochondria (Adams 2003, Shi 2006).  
 
The BCL2 family not only has residence and  direct action on the mitochondrial membrane, it also 
resides and functions on the ER, members of the three subgroups have been identified at the ER 
regulating the induction of apoptosis (Zhu et al. 1996, Germain et al. 2002, Zong et al. 2003, Chen 
et al. 2004, White et al. 2005). When apoptosis signalling is induced by ER stress, cell death also 
depends on cytochrome C release by mitochondria into the cytosol and opening of the permeability 
transition pore which leads to imbalanced mitochondrial membrane potential due to Calcium intake 
after its release into the cytosol. Once cytochrome C is released the APF1 binding step and other 
subsequent events already described take place (Samali et al. 1999, Zou et al. 1999, Acehan et al. 
2002).  
 
A number of models have been proposed to explain the anti-apoptosis mechanism of pro survival 
molecules: the sequestration model, mitochondrial integrity model, and Caspase inactivation action 
where BCL2 proteins interact with other molecules and inhibit caspases activation  (Chinnaiyan et 
al. 1997, Wu et al. 1997);  a recent review of anti-apoptotic mechanism and cell survival can be 
found in Portt et al. (2011)  where the authors describe in detail molecular mechanisms of cell 
survival in health and disease. 
 
One model explaining how BCL2 and homologs exert their pro survival functions is that the anti-
apoptotic BCL2 family members may stop the apoptosome complex from forming by sequestering 
the scaffold protein and/or by stopping apoptogenic factors from organelles such as the 
mitochondria (Cory and Adams 2002).  BCL2 and homologs may sequester the pro-apoptotic 
proteins of the family therefore stopping their cell death signalling (Yin et al. 1994).  This 
“kidnapping” takes place by binding of BH3 domain of pro-apoptotic counterparts; the BH3 α helix of 
the apoptogenic proteins can bind to a hydrophobic groove on the pro-survival proteins and 
preventing their pro cell death function (Adams and Cory 2001), concretely BAX and BAK mediated 
mitochondrial apoptosis (Emily et al. 2001). This type of anti-apoptotic pathway is the centre of 
recent approaches in cancer therapy, a number of BCL2 inhibitor therapies have been trialled, the 
bases if these therapies is that when BCL2 is antagonized by a BH3 mimetic molecule, the pro-
apoptotic molecules are released to lead to death, (this is what can occur in B-CLL). This type of 
death is based on permeabilisation of the mitochondrial outer membrane by BAX or BAK, pro-death 
BCL-2 family proteins (Vogler et al. 2009). 
 
Lack of cells death and hence oncogenesis can be the result of anti-apoptotic genes being over-
expressed whilst pro-apoptotic genes are under-expressed. Different cancers have shown BCL2 
being over expressed (Thomadaki and Scorilas 2006, Thomadaki et al. 2007), including NH 
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lymphoma (Waters et al. 2000) and B-CLL (Adachi et al. 1990). In leukaemic cells, that BCL2 over 
expression has been shown to lead to drug resistance in chemotherapy  (Miyashita and Reed 
1993). Although it is possible that in some cases, e.g. lymphomas, anti-apoptotic BCL2 over-
expression  in lymphocytes alone does not automatically lead to a oncogenesis; concomitant over-
expression of BCL2 and the myc proto-oncogene can lead to aggressive B-cell malignancies, 
lymphoma being one (Otake et al. 2007).  
 
Reviews by Reed and Pellecchia (2005) and more recent one by Zivny et al. (2010) list some of the 
advances in the knowledge of the regulation of apoptosis in cancer therapies. The review discusses 
some of the drug discovery targets identified and some of the progress to date towards translating 
the growing knowledge of these targets into new therapies for cancer and concretely leukemia. In 
both reviews, especially in the 2005 paper, the targeting of BCL2 with therapeutic potential is 
described at the level of gene expression, mRNA, protein, and endogenous activation of BCL2 
antagonists, highlighting the key role of BCL2 in the research around the control of apoptosis and 
bringing up its relevance in this research project. 
 
The 3’UTR of BCL2 mRNA is a binding site for RNA binding factors that regulate BCL2 expression 
by promoting stabilisation as in the case of HuR (Ishimaru et al. 2009) or decay of the transcript like 
AUF1 (Ishimaru et al. 2010) or Tino (Donnini et al. 2004).   
 
 
1.3.1 BCL2 and B lymphocytes: 
BCL2 is an inhibitor of apoptosis in differentiating B cells and hence it is low or absent in stages 
where cells are lost by apoptosis and highly present in stages where cells are long lived. BCL2 is 
expressed in bone marrow B cells, in pro-B cells and in mature B cells, whereas pre-B cells and 
immature B cells lack its expression (Merino et al. 1994). GC B cells express BCL2 only after 
activation by signals that prevent their entry into apoptosis (Liu et al. 1991). BCL2 expression is not 
seen in proliferating centroblasts in the dark zone and centrocytes in GC light zone, they go through 
apoptosis when their antigen affinity is lowered by hyper mutation, as opposed to the B cells in the 
mantle which do express BCL2 GC B cells, centrocytes centroblasts lack this protection against 
apoptosis by BCL2 and are programmed to die unless rescued by high affinity interaction with the 
antigen. Normal resting peripheral B lymphocytes do not express BCL2 unless they receive 
mitogenic stimulation (Graninger et al. 1987, Reed et al. 1987). 
      
1.3.2 In neoplasias the expression of BCL2 is altered: 
Normally expressed in small B cells of the mantle and marginal zone (Meda et al. 2003) (and in 
some T cells) BCL2 is over expressed in FLs with the t(14:189 translocation, present in nearly 80% 
of these (Weiss et al. 1987, Pezzella et al. 1990a, Horsman et al. 1995) and in 20% of DLBCL 
(Weiss et al. 1987)- although BCL2 over expression is also seen in lymphomas without the 
translocation-. It is common that B cells in the centre of the neoplastic follicle express BCL2 at 
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higher levels than the cells in the mantle zone, but this pattern is variable, not only due to the innate 
differences between cases of the same neoplasm but also due to the different grades or type of the 
disease, as in the case of grade III FL where BCL2 positivity is not common (Nguyen et al. 1996); 
BCL2 expression is greater in grade I and grade II types 
 
Neoplastic expression of BCL2 not only increases cell survival but also can infer resistance to 
chemotherapy induced cell death. c- Myc transcription factor is coded by c-Myc proto oncogene and 
it is at the same time a cell proliferation and apoptosis inducer (Askew et al. 1991). In B cells c-Myc 
effects proliferation (de Alboran et al. 2001).  C-Myc expression sensitises the cells to a number of 
pro-apoptotic factors thought to happen via cytochrome c release(Juin et al. 1999),  but in normal 
environment c-Myc  over expression leads to apoptosis (Evan et al. 1992) and proliferation (Evan 
and Littlewood 1993). 
 
The previously mentioned work by David L Vaux et al. in 1988 highlighted the cooperation between 
BCL2 and c-Myc promoting proliferation of pre-B cells and cell survival to immortalise pro-B cells; 
they observed how over expression of BCL2 led to neoplasia and this was synergised by c-Myc 
over expression concluding first that proliferation and survival are different pathways and are 
controlled by different signals and that inhibition of apoptosis is core in tumorigenesis. In general 
both proto oncogenes are found deregulated in lymphomas, in fact translocations of both genes 
have been reported in a number of cases which may have implications in identifying high risk 
patients  (Johnson et al. 2009). A paper published from the “The International DLBCL Rituximab-
CHOP Consortium Program” recently reported that co- expression of both proteins is linked to an 
aggressive course of the disease with an inferior prognosis for patients (Hu et al. 2013). 
 
1.3.3 BCL2 in B-CLL: 
In about 10% of B-CLLs the BCL2 gene is translocated resulting in its known increased expression 
(Schena et al. 1992) but even without that translocation B-CLL has been shown to be consistently 
dependent on BCL2 (Moore et al. 2007) protecting B-CLL cells from apoptosis in vtro and in vivo 
(Jewell et al. 1994). 
 
It is known that anti-apoptotic BCL2 is required for maintenance of leukemia (Letai et al. 2004) and 
recently, targeted BCL2 inhibition is proving effective in B-CLL (Roberts et al. 2012). Most of the 
research on the role of BCL2 in B-CLL has been done in its function of binding BH3 domain pro-
apoptotic proteins and the majority of recent cancer therapies are aimed at BH3 mimetic molecules. 
BCL2 are bound to these mimetics and pro-apoptotic molecules are released to promote B-CLL cell 
death. Patients with relapse or refractory B-CLL were treated with navitoclax, a BCL2 inhibitor, it 
selectively binds to BCL2 and BCL-xL and induces the  mitochondrial apoptotic pathway by 
avoiding BCL2 mediated sequestration and the inactivation of pro-apoptotic factors. The study 
showed that 90% of patients who had peripheral blood lymphocytosis showed a reduction of 50% 
just after day of administration of treatment; this was linked to increase apoptosis of circulating 
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leukemic cells. The disease free progression after the treatment was of 25 months. 31% of patients 
showed a partial response and nine of them did not respond to treatment. The positive outcome of 
the trial was not without side effects as patients reported thrombocytopenia, grade 4, probably 
mainly due to targeting of BCL/xL. An interesting piece of information arouse from looking for 
biomarkers responsible for the response to the drugs, and they found that levels of BCL2 were not 
altered, no correlation between BCL2 levels and response was found but the researchers 
hypothesised that the drug also targets cells expressing another pro survival factor, MCL-1 via 
displacement of its inhibitor BIM from a complex with BCL2 (Roberts et al. 2012), overall 
establishing BCL2 as a potential and valid therapeutic target in B-CLL. 
 
The BCL2 protein family not only controls mitochondrial permeabilisation during apoptosis, also 
controls cytoplasmic calcium levels (Rong and Distelhorst 2008).  If BCL2 at the mitochondria 
engages the BH3 domain of pro-apoptotic proteins and inhibits their pro cell death function, at the 
ER BCL2 modulates calcium signalling leading to proliferation and resistance to apoptosis, but here 
BCL2 acts via its BH4 domain which binds to inositol 1,4,5 triphosphate receptor (IP3R), a 
membrane glycoprotein acting as a channel. IP3R is the main intracellular Ca2+ channel with a 
diverse biological role that include apoptosis; BCL2 can dampen Ca2+ oscillations that would induce 
apoptosis. Evidence of a complex between IP3R and BCL-2 provides the connection to BCL2 and 
physiologic control of calcium levels (Palmer et al. 2004, Zhong et al. 2006). Late research has 
aimed at targeting that BH4 domain triggering apoptosis in B-CLL cells and DLBCL. Zhong and 
colleagues report on a peptide that selective targets B-CLL cells via disruption of BCL2 interaction 
with IP3R (Zhong et al. 2011). 
 
Deletion of miR15 and miR16 genes, which are responsible for encoding suppressors of BCL2, lead 
to over expression of the protein, these two genes are commonly deleted or down regulated in 
many B-CLLs. Both deletion and up regulation of expression of miR15 and miR16 are inversely 
correlated to that of BCL2, regulating BCL2 at post-transcriptional level. miR15 and miR16 have 
proven to have an antisense role to BCL2 including the induction of apoptosis by targeting BCL2 
when the miRNAs are expressed (Calin et al. 2002, Cimmino et al. 2005) one of these miRNA, miR-
16 is involved with ZFP36 in the post transcriptional control of other genes (Jing et al. 2005), as 
described in section 1.1.6 providing further ground to study the ZFP36 protein family as possible 
regulators of BCL2 expression. 
1.4 Cluster of differentiation 38, CD38   
CD38 (cluster of differentiation 38), also known as cyclic adenosine diphospate (ADP) ribose 
hydrolase, is an ectoenzyme, CD38 was discovered as part of research done on T cell surface 
molecules by Reinherz and Schlossman, giving rise to a list of novel molecules (Reinherz et al. 
1980). CD38 is a multifunctional protein, CD38 has receptor receptorial functions and enzymatic 
functions; it is a type II transmembrane glycoprotein, with an L shape form and has two domains, 
the C domain with four parallel beta sheets is the extracellular  and catalytic domain (Liu et al. 
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2005); the N terminal is formed by a number of alpha helices and two beta strands. A hinge region 
connects both domains, disulphide bonds further stabilise the structure (Lee 2006). CD38 has also 
been described in different intracellular organelles (Malavasi et al. 1994, Yamada et al. 1997, Sun 
et al. 2002), including the nucleus (Adebanjo et al. 1999, Khoo et al. 2000, Khoo and Chang 2002). 
 
Figure 1-11 Schematic structure of transmembrane proteins.  
CD38 is a type II transmembrane protein. Type I has a single transmembrane α-helix (bitopic membrane protein)  and type III 
a polytopic transmembrane β-sheet protein. Image modified from proteinchemist.com (2015)  
 
CD38 is part of a family of proteins. After CD38, CD157 was identified as a family member, they 
have sequence similarity and function analogy (Itoh et al. 1994). In murine cells CD157 expression 
is seen in synovial, vascular endothelial and follicular dendritic cells; the molecule is seen 
expressed in pre-T cells in the foetal thymus (Godfrey et al. 1993, Godfrey and Zlotnik 1993). In B 
cells it is observed in pre-B cells and circulating immature B cells that recently left the bone marrow 
(Ishihara et al. 1996). CD38 and CD157 are part of a nucleotide metabolising enzyme family with 
shared evolutionary history, other members of this family are CD26, CD39, and ADP ribosyl 
transferases (Malavasi et al. 2008). 
 
One of the first groups to highlight the possible receptor activities of CD38 even before a ligand was 
found were Mehta et al. (1996). They concluded that its enzymatic and receptor function were 
independent after observing  the effects CD38 ligation (blocking lymphopoiesis , inhibiting apoptosis 
as discussed in section “CD38 expression: B lymphocytes”) without affecting the enzymatic ability of 
the molecule. Within these observations it was also seen that CD19 is part of the receptor signalling 
cascade of CD38 in B cell precursors acting as a docking site for kinases and activating the proteins 
of this type (Kitanaka et al. 1997). It seems that the CD38 channel is autonomous from other 
surface receptors, ligation of CD38 in circulating B cells induced CD25, HLA-II and mRNA of a 
number of cytokines leading to proliferation of the cells, this effect was also seen in B blast cells, but 
Ig production was never observed (Funaro et al. 1997). Interest in CD38 signalling is especially 
relevant as it is thought to be a co-receptor that has a key role in B-CLL as it will be discussed 
further on. 
 
As an enzyme CD38 is involved in Ca2+ signalling, its enzymatic activity was first highlighted in 
research done on intracellular messengers in the Aplysia sea mollusc as a result of observing the 
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similarities between CD38 and the ADP ribosyl cyclase (ADPRC). Later the similarity  between 
human lymphocyte CD38 and Aplysia’s ADPRC was further confirmed by DNA sequence analysis 
(States et al. 1992). This observation led to increasing research over the years in ectoenzymes and 
their catabolism of nucleotides and certainly CD38 enzymatic role. The enzymatic functions of 
CD38 contribute to the array of its immunoregulatory functions. 
 
The main catalytic functions of CD38 are ADP-ribosyl cyclise and hydrolase activity: 
 
A. CD38 acts as a glycohydrolase on nicotinamide adenosine dinucleotide (NAD+) inside the cell, 
catalysing it into ADP ribose and nicotinamide, molecules that have a role in Ca2+ signalling. CD38’s 
role in calcium signalling has been widely studied, it is considered the main ADP ribosyl cyclase in 
mammals, CD38 transfers the ADP ribosyl moiety of NAD+ to different receptors (Berthelier et al. 
1998).  
 
B. The production of cyclic ADP-ribose  (cADPR, ADP-ribosyl cyclase activity) and to hydrolyse this 
cyclic metabolite into ADP-ribose (cyclic ADP-ribose hydrolase activity) (Berthelier et al. 1998). 
 
Stimuli lead to induction of cADPR activity by CD38 synthesis and hence calcium release from 
intracellular cytosolic compartments but also Ca2+ entry from the outer environment of the cell, all 
leading to a range of cellular events. Calcium mobilisation is involved in a variety of cell functions, 
cell proliferation and differentiation, neurotransmitter production, muscle function, and in lymphocyte 
activation and proliferation. A recent review of CD38’s enzymatic role can be seen in Wei et al. 
(2014). 
 
CD38 function as an enzyme has got a role in diabetes; cADPR and Ca2+ both induce insulin in cell 
free system of islet microsomes, further on using rodent studies confirmed a link between CD38 and 
diabetes, CD38 mRNA levels are reduced by 50% in islets (Takasawa et al. 1998), and genetically 
modified animals for increased or reduced expression of CD38 showed that mice over expressing 
CD38 had enhanced glucose induced insulin release whereas CD38 knockout mice had severe 
beta cell impaired function In humans nearly 18% of diabetes patients in a Japanese study were 
shown to have autoantibodies for CD38 linking this data to one of the causes of major impairment in 
glucose induced insulin (Ikehata et al. 1998). High CD38 auto autoantibodies titres were also found 





Figure 1-12 Enzymatic activities of CD38.  
NAD exists as NAD+ and NADH, NAD with a key role in energy metabolism is also involved in signal transductions. NAD+ 
has a role in redox reactions, as a donor of ADP ribosylation and as a precursor of cyclic ADPribose, both are second 
messengers that lead to the release of Calcium from intracellular compartments when stores are low in the cytosol. The top 
reaction happens in neutral pH and the bottomone in acidic pH.The chemical structure of the product in the reaction are 
shown in the figure, image modified from Malavasi et al. (2008)  
 
Before relating the relevance of CD38 in lymphocytes, and specifically in B cells and B-CLL, it is 
worth mentioning that CD38 is widely found in non-immune tissues, although the protein may 
regularly be found as a nuclear or cytoplasmic molecule, not as an ectocellular element. CD38 is 
found in brain, eye, prostate, gut, muscle, bone, kidney and other tissues, a table with further 
references found (Malavasi et al. 2008). 
 
1.4.1 CD38 and B lymphocytes 
CD38 is an important molecule in B cells; it is expressed differentially in B cell development. CD38 
is found expressed in bone marrow precursor cells, down regulated in normal mature resting B 
cells. CD38 expression in B cells seems induced when naive B cells are activated, it increases upon 
entry to the GC, it is highly expressed just before these cells go into SHM, and decreases when 
centroblast/centrocytes differentiate and finally disappear in memory cells (although not the case for 
murine memory B cells) to finally being expressed again in plasma cells (Malavasi et al. 2008). This 
expression pattern highlights the relevance and need for CD38 at different stages in B cell 
development (Malavasi et al. 1994, Funaro and Malavasi 1998). The micro-environment of the cell 
and the impact of soluble ligands for CD38 have an important role in the functions of CD38 in B 
cells. CD31 is a ligand for CD38, CD31 is a platelet adhesion molecule that by binding to CD38 
seems to control signalling to lymphocytes (Deaglio et al. 2001).  Stimulated CD38 in immature B 
cells induces apoptosis (Kumagai et al. 1995), whereas in mature B cells (and murine) inhibits 
apoptosis (Santos-Argumedo et al. 1993, Zupo et al. 1994). In the stroma supported bone marrow 
microenvironment CD38 ligation stops lymphopoiesis, it inhibits growth of immature B cell 
precursors, and this is not done by altering the enzymatic action of CD38, thus indicating a possible 
regulatory role in B cell lymphopoiesis by a CD38 ligand (Kumagai et al. 1995). Inhibition of DNA 
synthesis and induction of apoptosis is what led to blocking differentiation in B cells. In tonsillar GCs 
the opposite occurs, CD38 binding by anti-CD38 monoclonal antibodies protects GC mature B cells 
against apoptosis mediating pro-survival signal but this cross linking fails to induce proliferation 
(Zupo et al. 1994), and in mature circulating B cells ligation of CD38 does induce proliferation 
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through promoting induction of cytokines, CD25 expression and MHC-II (Funaro et al. 1997, 
Malavasi et al. 2008). 
 
1.4.2 CD38 and B-CLL: 
B cell lymphomas, myelomas and leukaemias all generally express CD38. Expression of CD38 in 
B-CLL cells seems to increase signalling via B cell receptor (BCR) (Lund et al. 1996) and regulate 
IgM and IgD induced apoptosis (Zupo et al. 2000). The interaction between the microenvironment 
and B-CLL cells seems to be important in rescuing cells from apoptosis, in this microenvironment 
CD38 is said to play a key role (Chiorazzi et al. 2005, Deaglio et al. 2006) CD38 increases cell 
survival and proliferation, the latter possibly due to interaction between CD38 and CD31 (Deaglio et 
al. 2010). 
 
The first indication of CD38 as a negative prognostic marker in B-CLL came from Damle et al. 
(1999) , they connected IgHV mutated status to CD38 expression. However,further research 
established that these two markers might be working independently and in fact CD38 itself may vary 
during the course of the disease (Hamblin et al. 2002), hence IgHV mutation and CD38 expression 
are now considered independent parameters for prognosis. The threshold at which a patient is 
considered clinically positive for CD38 is not clear (this varies from 10%, 20% to 30% of cells in the 
clone expressing CD38); an Italian group has suggested that the size of the population expressing 
CD38 is irrelevant and the mere presence of a CD38+ distinct population related to IgHV status is 
what is relevant as a prognostic tool (Ghia et al. 2003). In any case, a CD38 positive population 
identifies a poor disease prognosis notwithstanding the issue of CD38 varying expression through 
the course of the disease. Malavasi et al. (2008) have worked on the hypothesis that CD38 
expression in B-CLL has pathogenic potential and have looked at CD38 ligation effects with 
monoclonal antibodies showing that  CD38 ligation leads to proliferation and blast transformation on 
some B-CLL cells, thus ndicating that CD38 may act as a signalling receptor too (Deaglio et al. 
2003).  
 
The first suggestion of CD38 acting as BCR co-receptor came from Deaglio et al. (2003)  as they 
observed that the signalling abilities of CD38 are enhanced by IL2 acting via up regulation of CD38 
expression, and that CD31 ligand, which is expressed in stromal cells and nurse like cells, bound to 
CD38 may activate CD38 signals, furthermore the interaction between CD38/CD31 upregulates 
CD100 (a survival receptor)  that is  involved in sustaining B-CLL growth and survival (Deaglio et al. 
2005).  
 
Combined expression of CD38 and cytoplasmic kinase ZAP70, another negative prognosis marker 
(Hamblin et al. 2002),  indicates aggressive disease course. CD38 ligation is linked to activation of 
ZAP70, and a downstream survival pathway by tyrosine phosphorylation of ZAP70 in CD38/ZAP70 
positive B-CLL cells (Deaglio et al. 2007). Their association and how they interact or act as co-
receptors relaying signals is not clear. Besides B-CLL, CD38 is found in lymphoid tumours 
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(Malavasi et al. 1984), some AIDS associated lymphomas (Hoffmann et al. 2005) and many post-
transplant lymphoproliferations (Garnier et al. 2002). 
 
CD38 mRNA has an ARE in its 3’ UTR, it contains a basic AUUUA sequence flanked by uridines. 
Using bioinformatics tools to identify mRNA relevant to plasma cells, CD38’s 3’UTR ARE was 
highlighted as a possible target for the ZFP36 proteins (Nasir et al. 2012). The ARE of CD38 is a 
binding site for miRNAs and recent papers reported regulation of the CD38 mRNA in airway smooth 
muscle cells by miRNA-708 (Dileepan et al. 2014) or miR-140-3p (Jude et al. 2012b). Other RNPB 
like Hur have been examined for their binding ability to the ARE of CD38, resulting in evidence 
indication that  although HuR is able to bind to a nucleotide representing the CD38ARE, in  fact the 
induction of CD38 expression by TNF in asthmatic airway smooth muscle cells may be down to 












1.5 Aim and Objectives of the project 
 
This overall aim of this project was to investigate role of ZFP36L1 protein in human B cell functions. 
Specifically, the project focussed on investigating the role of ZFP36L1 in normal and malignant 
mature B cell populations by studying its ability to post-transcriptionally regulate BCL2 and CD38 
mRNAs. 
 
The following were objectives of the project: 
 
1. To measure levels of ZFP36L1 expressed in B cells; (A) representing different stages of B cell 
differentiation from early B progenitor to plasma cell stage. (B) A particular focus is on determining if 
there are heterogeneous levels of ZFP36L1 expression in different B-CLL populations that are 




2. To determine if the inferred BCL2, and CD38 mRNAs encoding important regulatory proteins in B 
cells, are authentic ZFP36L1 mRNA targets and whether. ZFP36L1-mediated post-transcriptional 
regulation of these mRNAs plays important roles in mediating functional effects in B cells. 
 
3. To analyse ZFP36L, BCL2 and CD38 protein expression levels in healthy lymphoid tissue and 
malignant lymphoma tissue sections by immunohistochemistry in order to see if the hypothesised 
negative regulation of BCL2 and CD38 mRNAs by ZFP36L1 is reflected in an inverse relationship in 

















































2.1 Materials and Methods 
Throughout the different experiments performed in this project a variety of reagents and protocols 
were used. The following pages provide a list of materials used It includes reagents, equipment and 
cells information. The second half of this chapter provides a description of the methods used. When 
the protocol used as recommended by the manufactures this is stated, if a change has been 
implemented this is also noted; when protocols have been designed or considerably modified for 
the purpose of the research a description of the methods is provided. Most of the trade names of 
reagents, and kits, purchased from a provider are registered trademark and must be treated as such 
even if not stated within the main text of this thesis 
 
Some key materials such as Hela cells, tissue slides and plasmids have been kindly donated by 
other researchers to whom I take this opportunity to declare my gratitude and whose names are 
mentioned .as appropriately in the text. 
2.2 Materials: 
This section lists the different materials used during the experiments performed in this project. The 
city and country of a supplier is only cited the first time 
 
PCR materials 
In all the PCR reactions performed a Biometra T Personal Cycler was used.  
Master Mix, Promega, Southampton, UK. Prod M750B 
RNAase free water, Promega, Prod P119A. 
 
Restriction enzymes 
Xba1, Promega Prod R6185 
Xho1, Promega Prod R6165 
 
DNA Ladders and Protein Markers 
DNA 1kb Ladder, Promega, Prod no. G5711 and 100bp DNA Ladder, Promega, Prod no. G2101 
were used in gel electrophoresis to estimate the size of unknown fragments of DNA in an agarose 
gel (2% or 1%). The loading dye used was 6X Blue Orange Dye from Promega, Prod no. G1881. 
To assess the molecular weight of unknown proteins the Pre-stained Protein MW Marker from 











Primers used in PCR and Sequencing 
The primers used in this project were custom made for each experiment and ordered from 
Invitrogen, Paisley, UK and Eurofins, Ebersberg, Germnay. 
 
Table 2-1 Primers.  
Primer  Sequence Company 














ZFP36L1 Reverse  5’-CTGGGAGCACTATAGTTGAGCA-3’ 
 















The plasmids used in this project are shown below; a map with their key features can be found in 
the appendix section. 
 
Table 2-2 Plasmids. 
Plasmid Company 
pGem T Easy vector Promega, Prod no.A1360 
pmirGLO Promega Prod no. E1330 
pcDNA6ZFP36L1 
pcDNA6mutZFP36L1 
Provided by Dr Christoph Moroni, University of Switzerland 
 
pcDEST26ZFP36L2 SourceBioscience (Full ORF Expression clone) 
pcSPORT 6 ZFP36 Donated by Dr Manfred Frick, Universität Ulm, Germany 









The different antibodies used in Western blots and in immunohistochemistry are listed in table 2.3. 
 




Cell Signalling, Danvers, MA, USA, Prod no. 2876 
BRF1/2 Rabbit 
Western blot 
Cell Signalling, Prod no. 2119 
TTP (ZFP36) (N-18) Goat Polyclonal IgG 
Western blot 
Santa Cruz Biotechnology, Santa Cruz, CA, USA, 
Prod no. sc-8458 
Donkey anti-rabbit-HRP Pierce Thermos Scientific, Prod.no.31458 
Donkey Anti Goat IgG HRP 
Western blot 
Promega, Prod no. V805A 
Anti-HSP90a/b (H-114) rabbit Santa Cruz Prod no. sc-7949 
Pan-Actin (DC18C11) Cell Signalling, Cat no. 8456 
CD38 FITC anti-human CD38, clone HIT2 Biolegend, London, UK, Cat no. 303503  
Rabbit anti-human ZFP36L1 lab made 
sera-9332 and pre -immunised sera as 
negative control for IHC 
The sera was lab-made produced by immunizing a 
rabbit with a synthetic peptide 
(HSGSDSPTLDNSRR) corresponding to amino acids 
313- 236 of human ZFP36L1 (J. Murphy) 
Monoclonal Mouse anti-human BCL2   DAKO Cambridgeshire, UK, Prod no. M0887 for IHC 
 
Rabbit anti-human CD38  
IHC and Western blot 
Abcam Cambridge, UK, Prod no. ab108403 
HRP Polyclonal Goat anti-mouse DAKO, Prod no. PO447 for IHC. 













A number of kits were used in this project, detailed of these are given in the following table 
 
Table 2-4 Kits 
SuperSignalWestFemto  
Used to detect chemiluminence using a UVP machine 
Pierce ThermoScientific Prod no. 34095 
Dual Luciferase Reporter Assay System Promega Prod  no. E1910 
QIAprep Spin Miniprep Kit QiAgen, Crawley, UK, Prod no. 27106 
QIAquick Gel Extraction kit (50) QIAgen Prod no. 28704 
EndoFree Plasmid Maxi Kit (10) QIAgen Prod  no.12362 
RNAeasy Mini kit QiAgen, Prod no. 74104 
Reverse Trasncriatse kit for QRTPCR QiAgen, Prod no. 205311 
Sybr Green PCR Kit QiAgen, Prod no. 204143/ 204163 
 
For SDS page and Western blot 
 
Table 2-5 Western blot materials 
Mini PROTEAN Tetra Cell Biorad Herts, UK, Prod no. 65-8000 
Mini Trans-Blot Electrophoretic Transfer Cell Biorad Prod  no.170-3930 
Mini PROTEAN TGX Precast Gels, 10%, Biorad Prod no. 456-1033 
 
Oligos 
The oligos used during the siRNA experiments were acquired from Invitrogen, details in table 2.6 
 
Table 2-6 siRNA oligos 
Stealth ZFP36L1 siRNA1 MSS236070(3-164089G05 Invitrogen 
Stealth ZFP36L1 siRNA2 MSS236071(3-164089G07 Invitrogen 




 FuGENE HD Transfection Reagent, Promega, for DNA transfection. Prod no. E231 
 Hiperfect, QIAgen, Prod no. 301704 




Cell lines used in the project so far are shown in the following table: 
 
Table 2-7 Cell lines used in the project 
Name Origin Description Source 
HeLa cells Human Human cervical epithelial cell line Dr Edward Wright, 
University of Westminster 
HEK293T cells Human Human embryonic kidney epithelial cell line Dr Marie Bijlmakers, Kings college London 
Ramos cells Human Human Burkitts B lymphoma cell line From ATCC, CatN CRL1596 
Namalwa Human Human Burkitts B Lymphoma cell line From ATCC CatN CRL1432 
NALM6 cells Human Pre-B cell line Dr Kwee Yong, University College Medical 
London 
JJN3 cells Human Myeloma cell line Dr Kwee Yong, University College Medical 
London 
KMS27 Human myeloma cell line Dr Kwee Yong, University College Medical 
London 
MM1S cells Human Myeloma cell line Dr Kwee Yong, University College Medical 
London 
KMS-28 cells Human Myeloma cell line Dr Kwee Yong, University College Medical 
London 





A combination of kits and reagents were used in the immunohistochemistry investigations, the 
details are displayed in the following table 
 
Table 2-8 Immunohistochemistry materials and reagents 
Dinitrophenol (DNP)amplification Tyramide Signal Amplification (TSA) DNP (HRP) from Perkin 




Tablets from Sigma Aldrich, Dorset, UK 
Antigen Retrieval Solutions 100mmol/L of Tris and 10mmol/L of EDTA, pH 9 and pH 6 
buffer (10mM Sodium Citrate, 0.05% Tween 20) 5 mins 
 
TN (Tris and NaCl buffer) wash 
buffer 
0.1 M of Tris HCl, 0.15 M NaCl: pH 7.5 
 
TNB (Tris NaCL blocking buffer) 0.1 M of Tris, 0.15 M of NaCl plus blocking reagent supplied by 




Tissue slides from human tonsils, reactive lymph nodes and FL were kindly donated by Dr. Anthony 
Warford (University of Westminster). Records of tissue sections are kept within the University of 
Westminster under his supervision and in accordance with the Human Tissue Act. Laica Application 
Imaging system was used to produce the histology photographs. 
2.3 Methods: 
 
Cell Culture and isolation 
All mammalian cell culture was done under a class II laminar flow hood under sterile aseptic 
conditions.  
 
For HEK29T cells Dulbecco’s Modified Eagles Medium (DMEM) with 10% foetal calf serum (FCS, 
PAA, Cat. No. A15- 102), 50 U/ml penicillin/streptomycin/glutamine (Sigma Aldrich Cat. 
No.10378016) was used. HeLa cells were maintained using this media or RPMI1640 (Sigma, Cat 
No. 12633020) 
Nalm6, JJN3, KMS27, KMS28, MM1S, RPMI-8226 and KMS-11cells (all obtained from Prof. K 
Yong, Dept. of Haematology, University College London, UK) were maintained in RPMI 1640, 10% 
FCS, 50 U/ml penicillin/streptomycin and 2 mM L-Glutamine. Blood from B-CLL patients was 
obtained from the Haematology Department, University College London under the direction of Prof. 
Amit Nathwani (Research Ethics Committee reference number, 09/H07146). B Cells were isolated 
from B-CLL patients’ blood using Histopaque (Sigma Aldrich) density gradient media; cells at 1x108 
or more were used for the production of protein lysate for Western blot analysis. Protein lysates 
were prepared using standard lysis buffer and the protein content was quantified using 
Bicinchoninic Acid Assay and results were used to determine the appropriate protein loading 
amount for SDS and Western blot analysis. 
 
Long term mammalian and bacterial cell storage 
Mammalian cells were aliquoted and stored in FCS (85%), DMSO (15%) and stored in cryo-tubes in 
liquid nitrogen after being kept overnight at -80C. 
Bacterial cells were stored in autoclaved sterilised 60% glycerol at -80C. A sterile loop was used to 
scrap the surface of the culture for recovering bacteria, the loop was then streaked onto an agar 
plate or to culture media for incubation at 37C. 
 
Cloning of putative target mRNA AREs into luciferase reporter vectors 
Human BCL2ARE sequences, wild type and mutant versions were amplified from plasmids 
PCRII/bcl-2 ARE+ and PCRII/bcl-2 mutARE  (Lapucci et al. 2002) and cloned into pmirGLO 
luciferase reporter vector (Promega) to generate pmirGLOBCL2ARE  and mutant 
pmirGLOBCL2ARE luciferase reporter vector. The amplified ARE DNA sequences  were run on an 
agarose gel (2%), bands were extracted and purified (using the appropriate Qiagen kit, listed in 
previous pages and cloned into pGem T easy vector, from Promega, adding restriction sites for 
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Xba1 and Xho1. JM 109 E. coli cells were transformed, plated out and individual colonies were 
cultured and used to prepare minipreps that were then checked for positive colonies containing the 
wild type and mutant versions of the BCL2ARE pGemT Easy constructs. After the checks were 
done the inserts were amplified by PCR and used to clone into pmirGLO luciferase reporter vector. 
The DNA sequences of the constructs were checked by DNA sequence analysis (GACT 
Sequencing services, London, UK), and are shown in the appendix section. The same protocol was 
followed for cloning of CD38 3’ UTR ARE; in this case the sequence was amplified from pmirTarget 
CD38 reporter vector (Origene cat no. SC206546) with primers designed to introduce restriction 
sites for Xho1 and Xba1. The DNA sequence of this vector construct was checked by DNA 
sequence analysis (GATC Sequencing services) and is shown in the appendix section. 
 
Recovery of plasmids that were spotted on filter paper 
The area on the filter paper was cut out and placed in an eppendorf tube with sterile water at room 
temperature. After 5 minutes incubation the tube was then centrifuged and the supernatant 
containing the diluted plasmid used for subsequent experiments.  
 
Transformation of competent JM109 E. coli cells 
The pGem T Easy protocol was followed. Competent JM109 in 50µl aliquots were purchased from 
Promega (cat. no. L2005) and used for transformation. These cells were shown to be the best 
option in the transformation experiments, the number aliquots tubes were defrosted on ice and cells 
were used to proceed with transformation. 
 
Plasmid DNA Minipreps and Maxipreps 
Qiagen kits were used for maxipreps and minipreps of plasmid DNA and, manufactures instructions 
were followed in each case. 
 
Restriction enzyme digestion 
Minipreps of plasmids were checked by enzymatic digestion using Xba1 and Xho1 restriction 
enzymes. The reaction was prepared adding 10 units of each enzyme per 1µg DNA in a total of 20µl 
reaction. The appropriate buffer from Promega was buffer D (R004A), where both enzymes work at 
100-75%. Water was added and the reaction was put in a 37oC water bath for 1h. After the hour the 
samples were run in a 2% agarose gel and viewed under UV light. 
 
Gel purification of DNA fragments 
DNA bands were extracted and DNA purified using the Qiagen kits mentioned above according to 
the manufacturer’s instructions. 
 
DNA ligation 
Ligation to pGemT Easy vector and pmirGLO were done following the protocol for pGem T Easy 
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For ligation into pmirGLO several agarose gels were run to maximise the number of DNA and 
therefore the amounts of DNA extracted, the concentration and purity of DNA was key in the 
success of ligation into pmirGLO. Vector to insert DNA ratios of 1:3 and 1:6 showed the best results. 
Ligations were, in all cases, left at 4C incubating overnight. 
 
Polymerase chain reaction (PCR) 
PCR was carried out using PCR Master Mix (Promega). 25µl reaction volume was prepared as per 
instructions: 12.5µl of Master Mix, 1µl of forward primer (10µM), and 1µl of reverse primer (10µM), 1 
µl of template DNA and 9.5µl of RNAase free water. A Biometra T Personal thermocycler was used 
to run a PCR cycling program as described here: Denature step, 95oC for 2 minutes, then 30 cycles 
of 95oC for 30sec, 50oC for 30 seconds, and 72oC for 1 minute in 30 cycles with a final extension 
step at 72oC for 5 minutes. 
 
Agarose Gel electrophoresis 
0.5% to 1% agarose gels were prepared by dissolving the appropriate amount of agarose powder 
(Invitrogen, Cat. N. 16500100) in 50ml of TBE buffer (Trizma base, 54g, Boric acid, 27.5g and 20ml 
of 0.5M EDTA in 1L of distilled water). A microwave was use to heat up the solution to dissolve the 
agarose and then cooled before adding it to a gel tray with an appropriate comb. The gels were left 
to set for 30 min to 45 mins. After setting, the DNA samples were loaded on to the gel after adding 
6X Blue Orange Dye from Promega (Prod no. G1881) to the DNA. Electrophoresis was performed 
by running gels were run at 100 volts for1 hour. The gel was then bathed in Ethidium bromide 




DNA sequencing services were GATC, London, UK and SourceBioScience, Nottingham, UK,  
sequencing services. Instructions from each company to prepare samples were followed. Samples 
were delivered to the company with appropriate primers. 
 
SDS polyacrylamide gel electrophoresis (PAGE) 
Proteins from different B cell populations were separated using SDS PAGE with precast gels from 
Bio-Rad, 10% Acrylamide, 30µl (cat. no.456-1033). 30-40µg of protein samples were loaded after 
mixing with the equivalent volume of Laemmmli buffer (Sigma) and heating the samples for 3 min at 
950C. The gels were run at 100-120v for 1 hour. 
 
Western blot analysis of protein expression 
Using a Bio-Rad SDS-Western blot tank the proteins were transferred from the gel to a 
nitrocellulose membrane (Protran). After 1h at 100v the membrane was removed from the transfer 
reaction and left in blocking buffer (5% milk powder, 0.1% Tween 20 in PBS) at 4oC overnight. The 
membrane was incubated with the primary antibody for 1h in a shaking tray at room temperature. 
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Then the membrane was washed 3 times for 5 minutes each with PBS 0.1% Tween 20. After the 
washes the membrane was incubated with the HRP conjugated secondary antibody. Finally the 
membrane was washed 3 times (5min each) with PBS 0.3% Tween 20, and another 3 times (also 5 
min each) with PBS 0.3% Tween 20. 
 
Enhanced chemiluminescent detection of protein expression on Western blots 
SuperSignal West Femto chemiluminescence substrate (Pierce Thermo Scientific) was used to 
detect the horseradish peroxidase conjugated secondary antibody bound to membranes using an 
AutoChemi System UVP tool from Bioimaging systems. The reagents and UVP Auto Chemi 
equipment alongside Labworks 4.1 software were prepared, set up and used as per their 
protocol/instructions. 
 
HEK 293T cells transfections and 3′UTR Luciferase Reporter Assays 
The HD Fugene kit and manufacturers protocol were used to carry out transfection of HEK293T 
cells with the wild type and mutant constructs of pcDNA6ZFP36L1, pcDNA6 ZFP36L2 and 
pcSPORT6-ZFP36 and the pmirGLOBCL2ARE wild type, the mutated version of the BCL2ARE and 
the pmirGLOCD382ARE. Another control, pcDNA3, the empty vector was also used in transfection 
experiments. 24 h prior to transfection 1 ml of HEK 293T cells (2×105 cells/ml) were seeded per well 
of a 12 well plate. Cells were then transfected with 100 ng of pmirGLOBCL2 3′ARE or its mutant 
version, or pmirGLOCD38 3’ARE Luciferase reporter vector along with 200 ng of human expression 
vector for each ZFP36 protein family member (pcDNA6ZFP36L1 or its zinc finger mutated version, 
pcDNA6ZFP36L2, pcSPORT6-ZFP36). An empty vector control, pcDNA3, was also transfected. 
3.3µl of Fugene was used per transfection reaction with 50 µl of serum free medium. Cells were left 
incubating at 37oC for 24h after transfection in the case of pcDNA6ZFP36L1 and 
pcDNA6ZFP36L1mut, then cell lysates were prepared by the passive lysis protocol (Promega), and 
luciferase and renilla signals measured using the Dual luciferase reporter assay system (Promega) 
on a Fluostar Optima (BMG, Labtech) plate reader. 
For ZFP36L2 and ZFP36 the cells were lysed at least 48hours after transfection. For 
pmirGLOCD382ARE experiments the optimum time for preparing cell lysates was found to be 48-72 
hours after transfection.  
 
Overexpression of ZFP36L1 in HEK293T cells  
A cDNA encoding the ZFP36L1 open reading frame was cloned into the pcDNA6 plasmid 
(pcDNA6ZFP36L1) and this or empty pcDNA3 was co-transfected with the pmirGLOBCL2ARE wild 
type or mutant version into HEK 293T cells. After 24h to 72h following transfection, cells were lysed 








A gel imaging scan and software were used to perfume densiometry analysis of Western blot 
results. The GS-800 Calibrated Densitometer from Bio-Rad was used, the software was Quality 
One, also from Bio-Rad 
 
siRNA transfection using Lipofectamine siRNAiMax 
HeLa cells were cultured in RPMI or DMEM complete media and plated in 12 wells plates or 6 wells 
plated at 1- 2x105/ml concentration reaching 80% confluency on the day of transfection. A total of 
20nM siRNA was used and the manufacturer’s instructions were followed for each transfection 
reagent tested. Incomplete media RPMI or DMEM was used to dilute transfection reagents and 
siRNAs. The transfection complex was added to the wells and they were left to incubate for 24, 48 
and 72 hours to determine the right time for harvesting cells and follow on analysis. 
 
Flow cytometry analysis of immunofluorescence stained cells  
Cell sorting and flow cytometry analysis was done using Cyan ADP Summit. Cells were incubated 
on ice with staining buffer (PBS and 0.01%FCS) and an appropriate amount of antibody was added 
and incubated as per manufactures instructions for 30 min at 40C. Cells were washed twice or three 
times in staining buffer to eliminate unbound antibody and re suspended in 0.5 ml of staining buffer 
ready to measure using a cell sorter. 
 
Statistical Analysis and Graphs 
A students T test was performed to analyse statistical significance of differences between datasets 
wherever applicable. The p values are indicated as follows: *p<0.05, **p<0.01, ***p<0.001 and 
exact values are given in legends. The statistical analysis tool in GraphPad Prism was used to 
obtain p values. The same software was used to design the graphs shown in this thesis. 
 
Immunohistochemistry 
Healthy lymphoid tissue sections were used to analyse the expression of ZFP36L1 and BCL2 and 
CD38 protein. 4 slides per case were used so each slide would be stained for either ZFP36L1 or 
BCL2 or CD38 and a fourth slide used as a negative control for ZFP36L1, which was the pre- 
immunised serum. A total of n=3 (3 individual cases) were analysed for healthy lymphoid tissue and 
also n=3 for FL. Protein concentrations of rabbit anti-huZFP36l1 and pre-immunised serum were 
calculated and staining amounts adjusted to ensure that equal concentrations of antibodies were 
used on each slide. The following dilutions were used for each antibody: ZFP36L1, 1/50, pre 
immunised serum, 1/37, BCL2 and CD38, 1/100. 
 
Tissue slides were processed for dewaxing, dehydration and clearing (Incubating the slides for 30 
minutes in at oven at 600C degrees and bathing slides for at least 3 minutes in: xylene 1, xylene 2, 
then in 99% alcohol (industrial methylated spirit was used) 99% alcohol again, then 75% alcohol 
and a second incubation in 75% alcohol, to finally wash in running tap water. Endogenous 
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Peroxidase Activity was blocked by immersing the slides in fresh made solution of 0.3% hydrogen 
peroxide (0.5 ml of 30% of H2O2 and 49.5 ml of methanol) for 10 minutes. 
 
Antigen Retrieval was performed for restoration/de-masking of epitopes by heat induced epitope 
retrieval (HIER) using a pressure cooker using the appropriate pH HIER buffer (details of buffers are 
shown in Materials section-Immunohistochemistry-. With slides for ZFP36L1 and pre-immunised 
serum staining pH9 buffer was used and pressure cooking for 10 mins was used, for BCL2 and 
CD38 pH buffer 6 was used and 5 minutes pressure cooking. Slides were cooled down in running 
water and then washed 3 times for 5 min in TN buffer (details in Materials-Immunohistochemistry-) 
 
Sections were dried around the tissue section and the area was circled with a DAKO pen. 100µl of 
prepared (diluted) primary antibody was added onto each slides fully covering each section. The 
slides were then incubated in a moist chamber overnight at 4C. All primary antibodies were 
incubated overnight. 
 
After overnight incubation the slides were washed 3 times with TN buffer for 5 minutes and 
horseradish peroxidase labelled anti-rabbit or goat secondary antibody diluted 1/100 in TN buffer 
was added and left for 30 min at room temperature in a moist chamber. Then the slides were 
washed again 3 times with TN buffer for 5 minutes. 
 
TyramideSignal Amplification detection 
Tissue sections were covered with freshly prepared DNP amplification reagent and incubate 10 min 
and then washed in TN buffer for 3 x 5 min. Slides were covered in anti-DNP-HRP diluted 1/100 in 
TNB and incubate for 30 min. slides were washed again in TN buffer for 3 x 5 min. 
 
Chromogen development  
Chromogen development was carried out using SIGMAFAST DAB with (cobalt) metal enhancer, 
Prod no. D0426, Sigma Aldrich. The solution was prepared fresh by dissolving one 
diaminobenzidene and one hydrogen peroxide tablet in 5 ml of pure water. As soon as the tablets 
fully dissolved, the sections were covered with the substrate solution and incubated for a maximum 
of 10 minutes monitoring blue - black substrate development microscopically for optimal results. 
 


















“Investigating BCL2 3’ UTR ARE mRNA as a target of the ZFP36 family of proteins”
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3.1 Introduction and background 
 
BCL2 is the founding member of the apoptosis regulator family of proteins with the same name. The 
three subgroups of the family, categorised by their structural domains, exert regulatory functions on 
apoptosis and pro-survival as described in the introduction of this thesis. BCL2 is an anti- apoptotic 
protein known to have an important role in cell survival and carcinogenesis (Adams and Cory 2007). 
Over expression of BCL2 protein is reported in many types of human cancers (Sánchez-Beato et al. 
2003). Its role in haematological malignancies is widely studied and it is known to play a major part 
in B-CLL. A hallmark of malignant, mostly non-dividing, B-CLL cells is the over expression of the 
anti-apoptotic protein BCL2 (Vaux et al. 1988b, Dyer et al. 1994, Kitada et al. 1998, Letai et al. 
2004, Adams and Cory 2007, Moore et al. 2007, Otake et al. 2007, Majid et al. 2008). The 
discovery of BCL2 was linked to the finding of a translocation in FLs, t(14;18) leaving the BCL2 
gene under the control of the Ig heavy chain (IgH) promoter and resulting in over transcription by 
the 4 enhancers in the 3’ end of the IgH gene. The outcome is an overproduction of anti-apoptotic 
BCL2 (Tsujimoto et al. 1984, Tsujimoto et al. 1985a, Heckman et al. 2003). However, in most 
malignancies the t(14;18) translocation is not present, including  B-CLL where only 5% of cases 
show that juxtaposition of genes (Adachi et al. 1990), and hence BCL2 over production which drives 
the accumulation of mature leukaemic lymphocytes (Majid et al. 2008) is not down to that genetic 
re-arrangement, it must rather be as a result of deregulation at another level, be it transcriptional 
(Young and Korsmeyer 1993, Alkayed et al. 2001) or post-transcriptional (Dyer et al. 1994, Harigai 
et al. 1996, Sherrill et al. 2004).  
 
Clarifying transcriptional and post-transcriptional mechanisms in the control of BCL2 protein levels 
in B cell malignancies, with or lacking t(14;18)(q32;q21), can have therapeutic implications. The 
BCL2 family and namely BCL2 protein is a main target in cancer therapy (thor Straten and 
Andersen 2010). In recent times manipulation of BCL2 family members’ function and levels has 
been the focus of new drugs developed with varying success, recent reviews can be found in (Kang 
and Reynolds 2009, Thomas et al. 2013, Vogler 2014). BCL2 functions through heterodimerization 
with pro-apoptotic members of the BCL2 family to prevent mitochondrial pore formation and prevent 
cytochrome C release and initiation of apoptosis. Many of the new drugs act on the BCL2 protein: 
inhibitors called BH3 mimetics are small peptides that inhibit the function of BH3 BCL2 members, 
including BCL2 itself, by binding to their BH3 groove which in turns blocks heterodimerization and 
inhibits protein activity (Besbes et al. 2015). There are also attempts to develop a BH3 profiling tool 
to use as a biomarker to predict response to the BH3 mimetics and identify resistance mechanisms 
to new agents being studied in B-CLL (Davids et al. 2013). 
 
The 3’UTR of BCL2 mRNA has a 107 nucleotide ARE, it contains a type II ARE with a series of 
AUUUA repeats, it includes a series of pentamers near a nonamer (Schiavone et al. 2000) and it 
serves as a regulatory sequence for the mRNA transcript. Several AUBPs are known to bind to the 
ARE and thus post-transcriptional ARE led regulation of BCL2 expression requires analysis of its 
AUBPs; the complexity of the regulatory network is even more intricate since affinity for AREs may 
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change due to post-translational modifications (Ishimaru et al. 2010). TINO and AUF1 destabilise 
the BCL2 transcript while Nucleolin stabilises it (Donnini et al. 2001, Lapucci et al. 2002, Ishimaru et 
al. 2009, Ishimaru et al. 2010). TINO interacts with BCL2 mRNA (Donnini et al. 2004), this protein 
was initially seen to degrade a chimeric reporter construct containing the BCL2 ARE. AUF1 
(Lapucci et al. 2002, Ishimaru et al. 2010), Mex3D (Tino)(Donnini et al. 2004) are other AUBPs 
have been shown to mediate BCL2 mRNA in vtro downregulation, other proteins like HuR promote 
stabilisation of mRNA (Ghosh et al. 2009, Ishimaru et al. 2009). AUF1 was one of the first AUBPs 
researched in relation to BCL2 and it was shown that this protein bound in vtro and in vivo to the 
BCL2 ARE (Lapucci et al. 2002).  HuR, another AUBP, also was shown to have a role in BCL2 
mRNA regulation via its ARE; downregulation of HuR reduced endogenous BCL2 levels but the 
opposite was seen for ectopic BCL2 (Ghisolfi et al. 2009, Ishimaru et al. 2009), but besides this, 
BCL2 itself was seen to overcome the activity of HuR and hence take the lead role in the regulation 
of its own mRNA in a dose-dependent manner (Ghisolfi et al. 2009). Other groups have reported on 
the role of Nucleolin (Ishimaru et al. 2010). Nucleolin has been shown to bind to murine Bcl2 mRNA 
increasing its half-life (Ishimaru et al. 2010).  Over expression of nuecleolin and altered localisation 
leads to augmented BCL2 mRNA stability in B-CLL cells (Otake et al. 2007), EBP1 has been shown 
to destabilise the transcripts in vtro using a chimeric construct in HL-60 leukaemic cells (Bose et al. 
2006).  
 
As already introduced, the ARE motif is also a regulatory site for miRNAs, miR16 and miR15 induce 
apoptosis by targeting BCL2, they are able to recognise and bind to its 3’UTR ARE mRNA 
(Cimmino et al. 2005). In B-CLL up regulation of BCL2 is thought to be due to deletion or 
downregulation of miR16 and miR15 which are found deleted in the majority of B-CLLs (about 70%) 
(Calin et al. 2002). The level of  miR15a/16-1 and BCL2 expression were found inversely correlated 
in B-CLL where increased BCL2 relates to down regulated miR16 (Cimmino et al. 2005). This 
miRNA regulation of BCL2 brings up a link to the ZFP36 proteins as this family of proteins has been 
reported to be involved in miR16 function (Jing et al. 2005). The prototype, ZFP36 protein, and 
miR16 are needed to recognise and bind to ARE in TNF 3’ UTR: mRNA decay mediated by the 
ARE in 3’UTRs of unstable mRNAs is dependent on the presence of miR16 and requires ZFP36’s 
presence, the binding of ZFP36 is not directly to miR16, rather via ZFP36 association with 
Ago/eiF2C family members so a complex with miR16 is formed for the targeting of the ARE (Jing et 
al. 2005). 
 
The ARE of BCL2 mRNA is a class II ARE, a type of ARE that ZFP36L1, ZFP36L2 and ZFP36 are 
able to bind to via their tandem ZFD to promote transcript degradation (Lai et al. 2000). Using a 
gene expression microarray dataset of 206 cell line, representing cell types of diverse histological 
origin, Bioinformatics research identified possible mRNA targets for the ZFP36 protein family. One 
of the possible targets identified was  BCL2 mRNA as a candidate for ZFP36L1 and ZFP36 
(Zekavati et al. 2014). Another group also reported BCL2 mRNA as a candidate for ZFP36L2 
(Hudson et al. 2004). In particular for ZFP36L1, induction of apoptosis had already been reported in 
cell lines such as Ramos (Burkitts lymphoma cells) (Ning et al. 1996, Johnson et al. 2000, Johnson 
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and Blackwell 2002), and an interaction with BCL2 ARE had also been shown in REMSA assays 
(Zekavati 2009, Zekavati et al. 2014). 
 
 
Figure 3-1 BCL2 mRNA identified as a target for ZFP36 proteins.  
Network diagram showing bioinformatic interactions established using  reverse engineering gene regulatory network for the 
ZFP36 family. BCL2 appears as a possible target for ZFP36L1. AImage adapted from Zekavati et al. (2014)  
 
The post-transcriptional regulation (or rather deregulation) of BCL2 mRNA could be key in the 
oncogenic role of the protein (Capaccioli et al. 1996, Bevilacqua et al. 2003, Capaccioli 2015). 
Understanding the interaction between ZFP36L1, and the other ZFP36 family members, and BCL2 
mRNA could provide important information of ZFP36L1’s role in cell fate regulation. The research 
reported in this chapter is especially relevant to this topic and adds further evidence to the 
complicated regulatory network of BCL2.  
                  
In order to assess the relationship between ZFP36 proteins, especially ZFP36L1 and BCL2, two 
strategies were followed; part of the investigation was done at mRNA level, and a second part was 
done at ZFP36L1 and BCL2 at protein level. The latter looked at BCL2 and ZFP36 proteins by 
Western blot analysis of primary leukaemic cells, and cell lines representing B cell development 
stages (see chapter 6) Immunohistochemistry analysis of ZFP36L1 and BCL2 in healthy tonsil 
tissue and FL tissue was also done and these findings are described in chapter 5. 
 
This results described in this chapter show the experimental data from analysing the direct 
interaction of ZFP36L1, ZFP36L2 and ZFP36 to the 3’ UTR ARE of BCL2 mRNA by using a 3’UTR 
dual luciferase reporter assay (DLR assay). The following was analysed: 
 
 If the members of the ZFP36 protein family were able to bind to the 3’UTR containing the ARE 
region of BCL2 mRNA and induce its degradation. 
 If the ARE core sequence was key for recognition, binding and degradation of the 3’ UTR. 
 If the binding to the 3’ UTR UTR ARE via ZFP36L1’s dependent on the integrity of the ZFD. 
 
The 3’UTR DLR assay has high sensitivity and its dual reporter quality allows data to be normalised 
to successful transfection and cell viability. The DLR assay uses the different biochemical 
luminescence properties of  luciferase proteins from firefly (Photinus pyralis) and sea pansy (Renilla 
reniformis) (Sherf et al. 1996).  Firefly luminescence occurs due to an oxidative reaction, and no 
posttranslational processing is needed, nor is it needed for Renilla’s luminescence. Different 
substrates are used in each case (oxigen and coelenterazine respectively), this avoids cross 
activation permitting distinguishable luminescence signals from each gene which are sequentially 
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measured. The pmirGLO dual reporter vector allows for the insertion of a sequence of interest, in 
this case a 3’UTR ARE, downstream of the luciferase stop codon. Firefly luciferase is the primary 
reporter gene, to monitor mRNA stability, and renilla luciferase acts as control, luminescence 
readings from this gene are used for normalisation for transfection efficiency and cell viability. A 
reduction in firefly luciferase luminescence indicates binding to the cloned sequence of the RNA 
binding protein that has interacted with the 3’ UTR sequence and therefore caused a reduction in 
firefly expression (vector map provided by Promega can be seen in appendix). 
 
3’ UTR luciferase reporter assays have previously been successfully used to analyse the 
relationship between another putative target, also part of the ARACNe list of possible mRNA targets 
of the ZFP36 family: BLIMP1 (Nasir et. 2012). BLIMP1 is an important and key transcriptional 
repressor, it has been identified (with other factors such as Bach2) to form an important regulatory 
network for the terminal differentiation of B cells to plasma cells (Igarashi et al. 2007). The 
luciferase assay has also been used as part of the research done to validate targets like Stat5b. 
(Vignudelli et al. 2010) demonstrated that ZFP36L1 and also ZFP36 are able to directly bind the 3′ 
UTR of Stat5b mRNA, and thereby triggering its degradation. A luciferase assay was also used for 
investigating ZFP36L1 and ZFP36L2 interaction with the 3’UTR of MAPK mRNA, binding of the 
ZFP36 proteins degraded the MAPK 3’UTR mediated reduced luciferase activity (Lin et al. 2012). 
(Adachi et al. 2014) used a luciferase reporter assay to validate LDLR mRNA as a target for ZFP36 
proteins. 
 
In the present study the interaction between ZFP36 proteins and BCL2 3’UTR ARE and its possible 
degradation effect was investigated. HEK293T cells were transfected with the following constructs 
following the experimental outline detailed below:   
 
Table 3-1 BCL2 3’UTR ARE luciferase assay experimental layout.  
ZFP36L1 vs BCL2 3’UTR ARE ZFP36L2 vs BCL2 3’UTR ARE ZFP36 vs BCL2 3’UTR ARE 
wtZFP36Ll1  vs wtBCL2 ARE 
                     vs mut BCL2 ARE 
wtZFP36L2  vs wtBCL2 ARE 
                    vs mut BCL2 ARE 
wtZFP36 vs wtBCL2 ARE 
                vs mut BCL2 ARE 
muZFP36Ll1 vs wtBCL2 ARE 
                      vs mut BCL2 ARE 
  
Empty vector vs wtBCL2 ARE 
                       vs mut BCL2 ARE 
Empty vector vs wtBCL2 ARE 
                       vs mut BCL2 ARE 
Empty vector vs wtBCL2 ARE 
                       vs mut BCL2 ARE 
Untransfected cells Untransfected cells Untransfected cells 
For ZFP36L1 the mutation consisted in a single nucleotide change within its ZFD; for BCL2 ARE the mutation consists in a 
deletion of a core AU sequence, figure 3-4, Transfection combinations were performed in a minimum of n=3 independent 
experiments. Cells were transfected with 100 ng of pmirGLOBCL2 ARE luciferase reporter vector, or its mutant version, and 
with 200 ng of human ZFP36L1 expression vector (pcDNA6ZFP36L1) or ZFP36L1 with a zinc finger domain mutation 
(mutZFP36L1) or empty vector (pcDNA3). pcDNA6.ZFP36L2 or pcSPORT 6.1 ZFP36 were also transfected using 200ng of 




Since ZFP36 proteins are reported to recognise and bind to 3’UTRs of mRNAs via their ZFD, in this 
study, a mutated ZFP36L1 variant was used, the mutation consist of a single nucleotide 
modification within the ZFD that leads to an aminoacid change. A mutated BCL2 ARE was also 
used where the core AU rich sequence was deleted (Lapucci et al. 2002). These mutated 
constructs would provide information regarding the specificity of the interaction between ZFP36 
family protein ZFDs and AREs and the importance of their integrity.  
 
In order to perform the 3’ UTR DLR assays, human BCL2 ARE sequences from plasmids 
PCRII/BCL2ARE+ and PCRII/BCL2 mutARE (Lapucci et al. 2002) were cloned into the pmirGLO 
luciferase reporter vector.  Wild type and mutated versions of BCL2 3’ UTR ARE were amplified 
using primers to insert restriction sites for Xho1and Xba1, the products were then cloned into the 
dual reporter vector pmirGLO. Once successful cloning was confirmed in pmirGLO by PCR, 
restriction enzyme analysis and DNA sequencing the assay was performed. HEK293Tcells were 
used for transfection experiments as these cells are commonly known for easy culture and 
transfection. Importantly this cell line does not express ZFP36 proteins and neither expresses 
BCL2. The strategy, results and their discussion are described in the following pages. 
 
3.2 Validation of BCL2 ARE as a target for the ZFP36 protein family using a  3’ UTR dual 
luciferase reporter assay 
3. 2. 1 Cloning of the BCL2 3’ UTR ARE into dual reporter vector, pmirGLO 
 
In efforts to determine whether BCL2 mRNA is a direct target for ZFP36L1 protein, we cloned a 
BCL2 ARE wild type, identified in these set of experiments as (+), and a mutant BCL2 ARE into the 
pmirGLO luciferase reporter vector (Lapucci et al. 2002). 
3. 2.1.1. Polymerase Chain Reaction (PCR) and restriction enzyme analysis 
In order to confirm the success of cloning different tests were carried out: restriction enzyme 
digestion of plasmid minipreps (fig. 3-2) and PCR analysis (fig. 3-3). 
 
Figure 3-2 A and B show bands corresponding to the right size AREs for BCL2ARE “+” (396bp) and 
its mutant version (289bp) released from the pmirGLO vector after enzyme restriction; this 
confirmed the cloning of the inserts in the vector. Figure 3-3 shows amplicons of the right size again 
for both wild-type and mutant AREs showing PCR amplification of the inserts was successful and 










                  A                                                                          B 
 
Figure 3-2 Analysing the cloning of BCL2 3’UTR ARE into pmirGLO vector.  
Restriction enzyme digestion of pmirGLO vector after cloning of BCL2 AREs (A) Gel shows in both lanes linearised pmirGLO 
from one colony and digested product BCL2 ARE mutant after restriction digestion with Xho1 and Xba1, the band correspond 
to the right size for BCL2 ARE mut. The second gel (B) shows BCL2 ARE insert of correct size also after digestion of 















Figure 3-3 PCR analysis to detect cloned BCL2 3’UTR ARE in pmirGLO vector.  
PCR of pmirGLO AREs constructs to detect inserts cloned into of pmirGLO. The figure shows agarose gel with correct size 
PCR amplified bands for BCL2 ARE mut -Lane1- and BCL2 ARE+ -Lane 2- amplified from pmirGLO plasmid minipreps. 
Clones were selected from colonies on LB agar plates. The same colonies were minipreped and digested with Xho1 and 
Xba1 obtaining restriction products shown in figure 3-2. 
 
3. 2.1.2 DNA Sequencing results to confirm the correct DNA sequence of clones used in 
these studies. 
Clones for both the wild-type and mutant BCL2 AREs were DNA sequenced using appropriate 
primers. The ZFP36L1 insert in pcDNA6ZFP36L1 and its zinc finger mutant version 
(pcDNA6ZFP36L1 mut) were also DNA sequenced. DNA sequencing results confirmed the right 
DNA sequences and expected mutations for BCL2 ARE and ZFP36L1 constructs were all correct. 




BCL2 ARE wild type and its mutant version were successfully cloned into pmirGLO, a luciferase 
reporter vector. The success of cloning was assessed in different ways; minipreps of 
pmirGLOBCL2ARE and mutant BCL2 ARE were tested using Xba1 and Xho1 restriction enzymes- 
whose recognition sites had previously been introduced designing the appropriate primers and 
amplifying the ARE from a stock plasmid by PCR-. This restriction reaction gave bands of the right 
size for both AREs (wild type BCL2ARE -396bp- and mutant BCL2ARE -289bp-) and for the 
linearised vector, pmirGLO vector (7350bp). The same miniprep plasmids were used in a PCR 
using primers to amplify these inserts, gel electrophoresis after PCR showed amplicons of the right 
sizes for both BCL2 ARE sequences. These constructs were transfected into HEK293T cells 
alongside pcDNA6ZFP36L1 and its mutant version.  
 
3.2.2 Over expression of ZFP36L1 and effect on HEK293T endogenous BCL2 expression 
BCL2 ARE constructs were transfected along with pcDNA6ZFP36L1 into HEK293T cells. Western 
blot analysis was carried out to confirm over expression of ZFP36L1, samples transfected with the 
plasmid containing the gene showed the right size bands for the ZFP36L1 protein (fig. 3-4.A). 
 
  
                           A                                                                                B 
 
Figure 3-4 Western blot analysis of over expression of ZFP36L1 in HEK293T cells  
(A) Western blot showing bands for over-expression of ZFP36L1 in HEK293T cells transfected with pcDNA6ZFP36L1 and its 
mutant; controls used were untransfected cells and pcDNA3 empty vector  transfected cells.  Anti-ZFP36L1/2 antibody was 
used to probe the membranes. (B) Blot showing very faint bands for endogenous expression of BCL2 in all HEK293T cells 
(transfected with pcDNA6ZFP36L1 and controls) Anti-BCL2 antibody was used to detect the 26KDa protein. Anti-HSP90 
antibody was used to detect the constitutively expressed protein HSP90 as a loading control. 
 
Western blots of lysates from the transfected HEK293T cells confirmed over-expression of 
ZFP36L1 (fig. 3-4 A), bands for ZFP36L1 were detected in samples transfected with wild type 
ZFP36L1 construct and for its mutant ZF version. 
 
HEK293T cells are reported to express low/ no BCL2 (HPA, Cell Atlas CAB000003) but the 
expression profile of cell lines may vary and since Western blot analysis had to be done to assess 
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the over expression of ZFP36L1, BCL2 expression was also tested. BCL2 bands were very faint or 
not detected in all samples either transfected HEK293T cells with pcDNA6ZFP36L1 or controls (fig. 
3-4B). The very low amounts of BCL2 detected made it difficult to assess if a decrease in 
endogenous BCL2 in these cells had taken place due to over-expression of ZFP36L1. For the 
luciferase assay, these results support the use of HEK293T cells in the experimental model since 
they do not express BCL2 and have very low/absent expression of ZFP36L1. 
 
Once it was confirmed that endogenous BCL2 and ZFP36L1 were not expressed or were very 
faintly expressed in HEK293T cells, and that cells transfected with the ZFP36L1 vector over-
expressed the protein, transfection of HEK29Tcells with the different combinations of plasmids as 
laid out in table 3-1 was carried out. For further details and reagents used in the transfection please 
refer to Materials and Methods chapter. 
 
 
3. 2.3 ZFP36 protein family targeting BCL2 ARE 
3. 2.3.1 ZFP36L1 and BCL2 3’UTR ARE luciferase assay results 
HEK293T cells were transfected with pmirGLOBCL2ARE, pcDNA6ZFP36L1, and mutant versions 
for both (mutations as described in figure 3- 5). pcDNA3 empty vector was also transfected as a 
control empty vector. After 24 hours cells were harvested and luminescence for firefly and renilla 
measured with a FluostarOptima plate reader. Luciferase to renilla ratios were calculated and 














Figure 3-5 ZFP36L1 binds and degrades BCL2 ARE 3’UTR.  
Figures showing ratios of luciferase/renilla readings from FluoStar Optima. (A) HEK293T cells were transfected with 
pcDNA6ZFP36L1 and pmirGLOBCL2 ARE or a mutant version, BCL2AREmut, which lacks the core ARE region in the 
middle of its sequence.  This vector acts  as a control for specificity of recognition and binding of ZFP36L1 to the BCL2 ARE .  
(B)  HEK293T cells transfected with either empty pcDNA3, pcDN6ZFP36L1, mutant pcDNA6ZFP36L1 along with 
pmirGLOBCL2ARE.  The mutant version of pcDN6ZFP36L1 with a modification in the zinc finger region was used to test the 
role of ZFP36L1 intact zinc finger domains in recognition and binding to the BCL2 ARE. Mean and standard error shown for 
three independent experiments (n=3) in both A and B.  T-test was used to determine the significance of the difference 




Figure 3-5A shows a decrease in luciferase activity in HEK293T cells transfected with the wild type 
ZFP36L1 and wild type BCL2 ARE compared to those where a mutated version of the ARE was 
used. Reduced firefly lucifersa expression indicates binding of ZFP36L1 to the cloned target 
sequence, the wild type BCL2 ARE. The lack of an effect of ZFP36L1 on mut BCL2 ARE showed 
that the core ARE sequence was required for ZFP36L1 binding and degradation of the BCL2 ARE. 
Figure 3-5 B. shows that the level of luciferase activity was lower in cells transfected with both wild 
type constructs (pmirGLOBCL2ARE and pcDNA6ZFP36L1) compared to the level seen in cells 
transfected with a mutated ZFP36L1 (zinc finger domain mutation) and to that of empty vector 
(pcDNA3) transfected cells. These results indicated that ZFP36L1 mediates degradation of the 3’ 
UTR ARE of BCL2 and that for this effect functional ZFP36L1 zinc finger domains are needed. 
These results were statistically significant. 
 
3.2.3.2 ZFP36L2 / ZFP36 and BCL2 3’ UTR ARE luciferase assay results 
The members of the ZFP36 family may differ in their functions and may possibly recognise and 
post-transcriptionally regulate different mRNAs. In order to gather further information to characterise 
the targets recognised by each of the proteins this study it was also tested if ZFP36L2 and ZFP36 
abound and led to degradation of BCL2 3’ UTR ARE. 













Figure 3-6 ZFP36L2 and ZFP36 also target BCL2 3’ UTR ARE.   
The ratios of firefly luciferase/renilla readings from FluoStar Optima are shown.  HEK293T cells were transfected with 
pcSPORT6ZFP36 (A) and pDEST26ZFP36L2 (B) and pmirGLOBCL2 ARE or the mutant version –BCL2AREmut which lacks 
the core ARE  acting as a control for specificity of recognition and binding of the ZFP36 proteins. HEK293T cells were also 
transfected with empty pcDNA3 and pmirGLOBCL2ARE as a control. Mean and standard error shown for three independent 
experiments (n=3) in both A and B.. A T-test was used to determine the significance of the difference between the means as 
shown; A:  **P values= 0.0084 and 0.0024 respectively;    B: ***P=0.0003; *P=0.02 
 
The BCL2 ARE was further tested as a possible target for the other two human family members, 
ZFP6L2 and ZFP36, using the 3’ UTR DLR assay. The same BCL2 3’ UTR ARE constructs were 
used, wild type and mutant versions. HEK293T cells were transfected and samples were read 48 
hours for ZFP36L2 and 72 hours later in the case of ZFP36, as these times were assessed as the 
optimal ones for each set of experiments. The Material and Methods followed were those described 
for ZFP36L1. It is worth highlighting that due to the consistent results obtained from ZFP36L1 on 
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BCL2 3 ‘UTR ARE these constructs were deemed a good positive control for transfection and 
luciferase assay and were hence also transfected in these experiments (data not shown) 
 
Luciferase assay results indicated binding of both proteins, ZFP36L2 and ZFP36, to the wild type 
BCL2 3’UTR but not the mutant BCL2 3’ UTR ARE version lacking the core AU rich sequence; the 
firefly to renilla luminescence ratios for each of the ZFP36 and ZFP36L2 proteins with wild type 
BCL2 3’ UTR ARE showed very significant decreased levels compared to empty vector and the 
mutated BCL2 ARE (fig. 3-6).   
 
3. 3 Discussion 
Results from 3’UTR DLR assay showing a decrease in luciferase luminescence readings for the 
wild type ZFP36L1 and wild type BCL2 mRNA indicated that ZFP36L1 recognised and bound to 
BCL2 ARE. Following mutant ZFP36L1 transfection luciferase to renilla ratio readings were similar 
to those from pcDNA3 empty vector transfected cells, indicating recognition of BCL2 ARE had been 
inhibited by the mutation introduced in one if its ZFD -a single nucleotide mutation, a Cysteine to 
Arginine change (Lai et al. 1999; Stoecklin et al. 2002). These results further support the role of the 
integrity of the ZFDs in this protein’s function as a post-transcriptional regulator. These findings are 
in line with previous work indicating the importance of the integrity of the zinc finger domains in the 
post-transcriptional roles of the ZFP36 proteins (Lai et al. 1999, Lai et al. 2002, Stoecklin et al. 
2002, Fabian et al. 2013, Lai et al. 2014). The luciferase assay results also further support the 
hypothesis that the ARE sequence is the specific binding site for this protein. Binding by ZFP36L1 
took place to the non-mutated BCL2 ARE and did not happen with the mutated version of the BCL2 
ARE where a section of the core AU-rich region sequence is missing. ZFP36L2 and ZFP36 did not 
bind the mutated BCL2 ARE either, but did so in the case of the wild type BCL2 ARE.  
 
These results from the 3’UTR luciferase reporter assays extend previous that showed an interaction 
between ZFP36L1 protein and BCL2 mRNA ARE using RNA electrophoretic mobility shift assays 
(REMSA) (Zekavati, 2009). REMSA results showed the protein and the target formed a complex; 
ZFP36L1 interacted with the ARE of BCL2 mRNA but not if the core AU-rich sequence of the BCL2 
ARE was deleted. These experiments already highlighted the AU rich region of the ARE as the 
binding site (Zekavati, 2009; Zekavati et al. 2014).  
 
The core AU rich region of the sequence of BCL2 ARE was needed for the ZFP36 proteins to bind 
the BCL2 ARE. AREs are present in about 5-8% of human mRNAs; AREs serve as regulatory 
sequences of mRNA transcripts by means of RNA binding factors (AUBPs or miRNAs), that 
determine the fate of the transcript affecting stability, localization and translation (Bakheet et al. 
2001). An early paper was the starting point for looking at the ARE of BCL2 as a regulatory 
sequence in charge of its own downregulation (Schiavone et al. 2000). The group showed that the 
destabilisation of BCL2 and subsequent downregulation during apoptosis was linked to its own ARE 
in the 3’UTR of the mRNA transcript. The BCL2 ARE also serves as a binding site for stabilising 
factors, overexpression of  Nucleolin in B-CLL cells induces stabilisation of murine Bcl2 mRNA 
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(Otake et al. 2007) . Recently it has been reported that deletion of AU-rich elements within the Bcl2 
3'UTR reduces protein expression and B cell survival in vivo (Díaz-Muñoz et al. 2015). This study 
demonstrates that the binding of RBPs to the Bcl2 3’UTR ARE is directly linked to the stabilization 
of the its mRNA and regulates BCL2 protein expression with functional consequences for B cell 
maintenance (Díaz-Muñoz et al. 2015). The results described in this paper further support the 
conclusion that the ARE in BCL2 3’UTR is an essential factor in the regulation of the protein and 
that perhaps a major part of this regulation is done via that ARE by virtue of AU binding factors, 
such as the ZFP36 protein famiily.  
 
There is much still to find out in regards to establishing the targets that each protein of the family 
binds to and regulates. A recent paper studying structural characteristics of ZFP36 pointed at 
features in each ZFP36 protein that confer specific modes of interacting with RNA (Lai et al. 2014), 
this would explain part of the diversity  in the targets the each ZFP36 protein may bind to. However, 
the ZFP36 proteins do also share some mRNA targets. TNFα is one of the most researched targets 
for the ZFP36 family and it indeed a target shared by all three ZFP36 family proteins (Carballo et al. 
1998, Lai et al. 1999, Lai et al. 2000). It was also reported that different members of ZFP36 family 
can act redundantly as co-over-expression of ZFP36L1 and ZFP36 mediated a cumulative effect on 
Stat5b down-regulation (Vignudelli et al. 2010). Vignudelli et al. 2010, showed the protein negatively 
regulates inmature red blood cells differentiation by binding to the 3′ UTR of Stat5b encoding 
mRNA. But not only ZFP36L1, also ZFP36 was shown to directly bind the Stat5b 3′ UTR and trigger 
its degradation. More recent evidence from Adachi et al. 2014 also reported on an mRNA target that 
was shared between ZFP36L1 and ZFP36L2 (LDLR mRNA, encoding a lipoprotein). Taken 
together, the evidence is consistent with the ZFP36 family proteins may target overlapping mRNA. 
 
For ZFP36 other research further supports the results reported in this chapter: ZFP36 bound in vtro 
to BCL2 mRNA as shown by UV Cross-Linking assays RNA and Immunoprecipitation Assay 
(Bevilacqua et al. 2007) and more recent literature has provided more evidence for this  interaction 
and its functional consequences. BCL2 expression in cancer cells provides resistance to 
chemotherapy drugs like Cisplatin. Head and neck cancer cells with resistance to Cisplatin had high 
levels of BCL2 and low levels of ZFP36 and the opposite was seen in Cisplatin sensitive cells (Park 
et al. 2014). siRNA inhibition of ZFP36 led to higher BCL2 levels and lower sensitivity to Cisplatin, 
but if ZFP36 was over expressed BCL2 levels decreased. ZFP36 was therefore linked to 
downregulate  BCL2 expression in response to Cisplatin (Park et al. 2014). The interaction between 
ZFP36 and the BCL2 3’UTR ARE evidenced from the DLR assay results in this thesis may be 
providing part of the missing link between ZFP36 and BCL2. 
 
The same group reporting that ZFP36 is needed for Cisplatin sensitivity had already published in a 
previous paper that ZFP36L1 was also required for the chemotherapy action of Cisplatin also in 
human head and neck squamous cell carcinoma cell lines  (Lee et al. 2005). Using cDNA 
microarrays they found that ZFP36L1 was highly expressed in cells sensitive to Cisplatin. 
Furthermore inhibiting ZFP36L1 led to a decrease in the Cisplatin-sensitivity whereas over 
expression of the protein increased it. Elevated expression of ZFP36L1 decreased the expression 
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level of enhanced green fluorescent protein  linked to a 3'  UTR ARE of cIAP2 mRNA . In short, they 
demonstrated that ZFP36L1 expression enhanced Cisplatin sensitivity by reducing the levels of 
apoptosis protein-2 (cIAP2), another anti-apoptotic regulator (Lee et al. 2005).  
 
The presence of ZFP36L1 is also needed for the action of another cancer drugs, a monoclonal 
antibody; Rituximab is used in breast cancer treatment and is the standard of care for patients with 
B cell NHL. Rituximab mediates cytotoxicity of CD20 positive B cells, it also sensitises B cell NHL to 
cytotoxic chemotherapy and has direct apoptotic and anti-proliferative effects (Stolz et al. 2008). 
ZFP36L1 is needed for induction of apoptosis in B-CLL cells in the presence of Rituximab (Baou et 
al. 2009b) although the molecular target/s that would lead to  mediate the pro- apoptotic effect of 
Rituximab by ZFP36L1 are not known, however there is a group reporting that the monoclonal 
antibody  down regulates BCL2 in AIDS derived lymphoma cells (Alas et al. 2002). In  previous 
research, Rituximab treatment showed selective down-regulation of the BCL2 protein in B cell NHL 
cell lines, and  induced sensitivity to chemotherapy drugs through down-regulation of anti- apoptotic 
IL-10 (Alas et al. 2001), which in turn happens to be an mRNA target for ZFP36 (Stoecklin et al. 
2008, Tudor et al. 2009, Gaba et al. 2012). 
 
The 3’UTR luciferase reporter assay results described for the three human ZFP36 family members, 
and especially for ZFP36L1, indicate a direct interaction with BCL2 ARE, suggesting that ZFP36 
protein may lead to the degradation of BCL2 mRNA. These results may add further light to explain 
the mechanism of apoptosis induction in cells mediated by ZFP36 family proteins  (Ning et al. 1996; 
Johnson et al. 2000; Baou et al. 2009). 
3.4 Conclusion 
There are important implications in elucidating the complex mechanism by which anti-apoptotic 
proteins like BCL2 are regulated. The level of BCL2 is determined by transcriptional and post-
transcriptional mechanisms. In this chapter, evidence has been presented on the three members of 
the ZFP36 family of post-transcriptional regulator proteins and their ability to mediate BCL2 mRNA 
destabilisation and decay via their highly conserved zinc-finger domains and through binding to the 
AU- rich core sequence of the BCL2 ARE. 
 
Some of this work was incorporated in a paper where other experimental data further supported the 
hypothesis that BCL2 mRNA is a target for ZFP36L1 (Zekavati et al. 2014).  ZFP36L2 and ZFP36 
were also seen to bind and degrade the BCL2 ARE indicating they may also post-transcriptionally 
regulate BCL2 at the mRNA level. None of the ZFP36 family proteins bound to a mutated version of 
the BCL2 ARE lacking a core AU rich sequence in this in vtro experiments. Recent in vivo evidence 
from other researchers further supports the AUBP binding site on BCL2 as the ARE (Díaz-Muñoz et 
al. 2015). These results presented here may assist in explaining the role of ZFP36L1 and other 










































4.1 Introduction   
The overall aim of the PhD research project was to investigate two of the putative mRNA targets 
identified for the ZFP36 family of proteins; BCL2 has already been introduced in chapter 3. Aiming 
to expand the research on the list of candidate mRNAs for the ZFP36 protein family and confirm 
them as authentic targets or discount them, the second 3’ UTR ARE chosen for analysis was that of 
CD38 mRNA, which is the focus of this chapter. Both targets, BCL2 and CD38 are of special 
relevance for B cells and B cell malignancies, and notably for B-CLL.  
 
CD38 is a molecule with a role in signalling and cell adhesion, a transmembrane protein essential 
for the regulation of intracellular Calcium. In B cells its expression is developmentally regulated, with 
high levels of CD38 expression found in plasma cells. CD38 is used as a marker for human 
leukaemias and myelomas. In B-CLL it is involved in its pathogenesis and outcome, its expression 
signifies a poor prognosis. In the last few years research has placed CD38 as part of a network 
signalling for growth and survival in B-CLL cells, facts that lead to considering CD38 as a potential  
therapeutic  target  in B cell malignancies (Deaglio et al. 2008, Malavasi et al. 2008).  
 
Previous in silico analysis to find putative targets for the ZFP36 family resulted in a list of potential 
targets for ZFP36L1 (Nasir et al. 2012). The analysis using the ARACNe algorithm (Margolin et al. 
2006, Basso et al. 2010) looked for candidate mRNA targets in mature B cells related to 
plasmacytoid differentiation. A gene regulatory network was reconstructed based on microarray 
datasets terminating in a list that included targets significantly up regulated in plasma cells and 23 
candidate target mRNAs were identified such as GAS6 (growth arrest) and GFI1 (transcriptional 
repression). Importantly, the list also included BLIMP1-plasmacytoid differentiator, SEL1L- a key ER 
protein- and CD38 mRNA (Nasir et al. 2012).  All these possible mRNA targets  contain canonical 3′ 
ARE elements that are targeted by the ZFP36 protein family (Baou et al. 2009a). BLIMP1 was 
confirmed as a mRNA target for ZFP36L1 in that same study (Nasir et al. 2012). 
 
Computational analysis of the 3'UTR of CD38 gene revealed the presence of an ARE sequences 
located within the last 400-bp region of the 3’UTR. The human CD38 3’ UTR has a copy of the DNA 
motif UUAUUUAU that can also be found in the 3'UTR of some inflammatory mediators such as 
GMC-SF and TNFα, examples which are in turn confirmed targets for some or all the ZFP36 family 
members (Carballo et al. 1998, Carballo et al. 2000, Lai et al. 2000).   
 
This chapter reports on experimental work that examined whether CD38 mRNA is a target for 
ZFP36L1, it also includes data obtained for ZFP36L2 and ZFP36. Two strategies were followed, 
one consisted in directly testing if each ZFP36 protein interacted, bound to the CD38 3’ UTR ARE 
using a dual luciferase reporter assay (DLR assay). The DLR assay and the rationale for its choice 
have already been introduced in chapter 3; suffice to add that luciferase reporter assays in relation 
to CD38 have already been used to determine RNA binding factors recognising and degrading 
CD38 mRNA, examples are miR-140-3p binding to the CD38 3' UTR (Jude et al. 2012b) and 
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miR108 (Dileepan et al. 2014). The second strategy aimed to manipulate expression levels of 
ZFP36L1 by down regulating it and to analyse correlated changes in CD38 expression with the 
hypothesis being that if ZFP36L1 regulates CD38 expression down regulation of ZFP36L1 protein 
will lead to increased CD38 levels. To further research the relationship between ZFP36L1 and 
CD38, immunohistochemistry (IHC) analysis of lymphoid tissue and FL was also performed, this 
constitutes the content of chapter 5 where the results from these analyses are reported.  
 
4.2 Validation of CD38 3’UTR ARE as a target for the ZFP36 protein family using a 3’ UTR 
dual reporter luciferase assay 
 
The strategy chosen to investigate CD38 3’UTR ARE as a target for the ZFP36 proteins aimed at 
obtaining evidence for the ZFP36 protein family directly interacting, binding and leading to the 
degradation of the 3’UTR ARE of CD38 mRNA. For ZFP36L1 a mutated version of the protein was 
used to test the role of the integrity of the zinc finger domains (ZFD) in binding to the ARE.  
A DLR assay was performed after cloning the 3’UTR ARE of CD38 mRNA into the dual reporter 
vector, pmirGLO. This experiment required the cloning steps seen for BCL2 3’UTR ARE in chapter 
3 in order to insert the CD38 3’ UTR ARE sequence downstream of the firefly luciferase reporter 
gene in the plasmid. This construct was transfected into HEK293T cells, chosen here again for 
similar reasons as in the case of the BCL2 3’ UTR ARE investigation: HEK293T cells are easy to 
culture, to transfect and do not constitutively express ZFP36 proteins nor CD38. On this occasion 
the layout of the experiments was: 
 
Table 4-1 CD38 3’UTR ARE luciferase assay experimental layout: 
ZFP36L1 vs CD38 3’ UTR ARE ZFP36L2 vs CD38 3’ UTR ARE ZFP36 vs CD38 3’ UTR ARE 
wtZFP36L1  vs  CD38 3’ UTR ARE 
 
wtZFP36L2  vs CD38 3’ UTR ARE 
 
wtZFP36 vs CD38 3’ UTR ARE 
 
muZFP36L1 vs CD38 3’ UTR ARE 
 
  
Empty vector vs CD38 3’ UTR ARE 
 
Empty vector vs CD38 3’ UTR ARE 
 
Empty vector vs CD38 3’ UTR ARE 
 
Untransfected cells Untransfected cells Untransfected cells 
Independent experiments were minimum of 3, n=3. ZFP36L1 vs wt BCL2 3’UTR ARE was used as a positive control on 
initial experiments. This experiment would test if the ZFP36 proteins were able to recognise, bind and degrade the CD38 
mRNA 3’ UTR.  
 
Analysis to confirm over expression of ZFP36L1 in HEK293T transfected cells is reported in chapter 







4.2.1 Cloning of CD38 3’ UTR ARE into dual reporter vector, pmirGLO 
pmirGLO vector is a plasmid with a reporter gene, luciferase and a control gene, renilla, the 
transfection of this vector alongside human ZFP36 proteins expression vectors in HEK293T cells 
would result in two types of readings:  luminescence signals given by the luciferase gene (reporter 
gene) and another luminescence signal for the renilla gene. The renilla gene serves as a control for 
transfection and cell variability, renilla’s luminescence serves as a normaliser for the resulting data. 
For further details and discussion regarding this choice of assay please see the information in the 
introduction to Chapter 3. 
 
Briefly, human CD38 3’ UTR ARE sequence was amplified from pmirTarget (Origene), using 
designed primers to insert restrictions sites for XhoI and Xba1 enzymes for cloning into pGEMT 
easy vector and pmirGLO vector.  The target sequence, CD38 3’UTR ARE, was cloned 
downstream the luciferase gene in the dual reporter pmirGLO plasmid. To assess the success of 
the cloning, polymerase chain reaction, restriction enzyme digestion analysis and DNA sequencing 
were performed.  
4.2.1.1 Polymerase chain reaction analysis and restriction enzyme analysis 
PCR analysis to determine if the CD38 3’ UTR ARE had been successfully cloned onto pmirRGLO 
showed amplicons of the expected size for the product, 493bp (fig. 4-1). For PCR cycle settings 
please see Materials and Methods. The presence of amplicons for the target insert in tests samples 
and not in controls indicates that the primers were able to amplify the right insert since the size of 
the bands correspond to that of the CD38 3’UTR. 
 
                                 A                                                                               B                   
                                           
Figure 4-1 CD38 3’UTR PCR products amplified from pmirGLO.  
A. Agarose gel showing PCR products and various negative controls (no DNA) and using different non-specific primers, a 
band for CD38 3’ UTR ARE was amplified from a miniprep of a colony culture after transformation with pmirGLOCD38ARE.  
B. PCR products from amplifying CD38 from 2 colonies after transformation with pmirGLOCD38 construct  correct size 




The analysis performed by PCR using primers to amplify CD38 3’UTR ARE, indicated that the 
sequence was cloned onto pmirGLO vector. As controls different non-specific primers were used 
and also samples where no DNA was added were run. Primers for CD38 3’UTR were those 
designed for the amplification of the target sequence from pmirTarget, and to add restriction sites 
for Xho1 and Xba1. Restriction enzyme analysis of pmirGLOCD38ARE was attempted but bands 
were very faint and not easily visualised. Restriction enzyme analysis would have shown a band for 
the right size of the UTR, around 500bp, confirming an insert of the right size was released from the 
pmirGLO cloned vector. 
 
4.2.1.2 DNA sequencing to confirm cloning of CD38 3’ UTR ARE into pmirGLO 
PCR analysis indicated that the right size of insert had been cloned into the pmirGLO vector and in 
the right direction, however, DNA sequencing was carried out to ensure that the correct DNA 
sequence for the 3’ UTR ARE of CD38 had been cloned. A clone for pmirGLOCD38ARE was DNA 
sequenced using appropriate primers for the human CD38 3’ UTR ARE (see Materials and 
Methods). Sequencing results confirmed that CD38 3’UTR was cloned onto pmirGLO vector. 
Sequencing results and ARE motif are shown in the appendix. 
 
4.2.2 ZFP36 protein family targeting CD38 ARE- Dual luciferase reporter assay results 
Once data confirmed cloning of the CD38 3’UTR ARE onto pmirGLO vector HEK293T cells were 
transfected with the constructs as laid out in table 4-1. 
 
Cells were transfected with 100 ng of pmirGLOCD38ARE luciferase reporter vector and with 200 ng 
of human ZFP36L1 expression vector (pcDNA6ZFP36L1) or ZFP36L1 with a zinc finger domain 
mutation (mutZFP36L1), pDEST26.ZFP36L2 or pcSPORT6ZFP36 or empty vector (pcDNA3) using 
Fugene (Promega). 
 
Luminescence measures were taken in a plate reader 48-72 h later using a DLR assay system and 
a FluoStar Optima plate reader- details in Materials and Methods-. Data was analysed and plotted 
as a bar chart as seen in figure 4-2. A Student T- test was also performed to evaluate statistical 
significance:   


















Figure 4-2 ZFP36L1 mediates degradation of CD38 3’UTR ARE and ZFP36L2 and ZFP36 also target CD38 3’ UTR ARE 
for degradation. 
A. HEK293T cells were transfected with pcDNAZFP36L1 or its mutant version and pmirGLOCD38ARE; mutant ZFP36L1 has 
a nucleotide modification that leads to an amino acid change in its ZFD. The firefly luciferase/renilla luminescence readings 
compared to empty vector pcDNA3, showed that wild type ZFP36L1 led to the degradation of the CD38 ARE; zinc finger 
mutant ZFP36L1 did not bind and degrade CD38 3’ UTR ARE.  Mean ± SEM shown for independent experiments (n=3). T-
test determined the significance of the difference between the means (empty vector control Vs. sample; mutant control Vs. 
sample), T Test::***P value =0.0006 and 0.00058 respectively.  B. HEK293T cells were transfected with ZFP36L2 and ZFP36 
and pmirGLOCD38ARE. HEK 293T cells were also transfected with empty pcDNA3 and pmirGLOCD38ARE as control. 
Figure shows ratios of firefly luciferase/renilla luminescence readings from FluoStar Optima. Luc/renilla ratios of ZFP36L2 
and ZFP36 compared to empty vector pcDNA3 indicated that both proteins also lead to the degradation of CD38 3’ UTR 
ARE. Luminescence readings for untransfected samples not shown. T-test determined the significance of the difference 
between the means,  Mean ± SEM shown for three independent experiments (n=3). B:**P value =0.009 and 0.0088 
respectively. 
 
The luminescence readings normalised to the control renilla gene’s readings showed a very 
significant decrease in luciferase/renilla ratio indicating ZFP36L1 bound to the CD38 3’ UTR ARE 
(fig. 4-2A). Higher luciferase/renilla luminescence ratio indicated that the mutated version of the 
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protein, with a change in an amino acid in the zinc finger region, did not lead to the protein 
interacting with CD38 3’ UTR and readings were very similar to pcDNA3 empty vector control (fig. 
4-2A). Luciferase/renilla ratio luminescence readings were also significantly reduced in the case of 
ZFP36L2 and ZFP36 compared to empty vector controls, indicating that each of these ZFP36 family 
proteins had also bound to the 3’ UTR ARE of CD38. 
 
In all cases luc/renilla ratios were significantly lower in the tests samples compared to those from an 
empty plasmid control (fig. 4-2B) and the individual results from each independent experiment did 
not vary much from one and another as shown by the errors bars indicating SEM. 
 
4.3  Down regulation of ZFP36L1 and effect on CD38 level of expression  
 
This second strategy in the investigation to research CD38 mRNA as a target for ZFP36L1 tested if 
the interaction of CD38 3’ UTR observed in the DLR assay experiments would also lead to changes 
at the level of CD38 protein expression in situations where ZFP36L1 expression levels were 
manipulated. Other studies have already reported on the manipulation of ZFP36 proteins for 
research of target mRNA validation (Jalonen et al. 2006a, Baou et al. 2009b, Lin et al. 2012, Nasir 
et al. 2012, Adachi et al. 2014). The working hypothesis was that if ZFP36L1 targets CD38 mRNA, 
and hence controls CD38 gene expression post transcriptionally, knocking down the expression of 
ZFP36L1 protein would lead to increase CD38 levels. 
 
The objectives of this part of the project were: to manipulate the expression of ZFP36L1 by down 
regulation with siRNAs in an appropriate cell model, and measuring levels of CD38 protein to 
analyse if they were affected by this down regulation and the direction of this effect. Down 
regulating ZFP36L1 would require several siRNAs and their validation as effective in knocking down 
ZFP36L1 protein levels. This part of the project would also involve the detection of CD38 
expression by flow cytometry on live cells and Western blot analysis of ZFP36L1 and CD38 protein 
levels in cells lysates.  
 
RNA interference is a highly conserved mechanism in multicellular organisms. RNA 
oligonucleotides of about 20-23 in length regulate gene specific silencing via RISC. Briefly, long 
double stranded RNAs are cut into smaller double stranded strands by the enzyme Dicer; these 
shorter dsRNAs about 21-24 nucleotides long are called small or short interfering RNAs (siRNAs) 
and are incorporated into the RISC a multimeric protein that will be led by one of the strands of the 
siRNA to a complementary RNA sequence in the target mRNA; after binding to the transcript it is 
spliced, cleaved and translation has been inhibited (Kurreck 2006). RNAi has long been a research 
tool in laboratories; it is a commonly used technique to identify gene functions. In the case of 
siRNAs, these small oligos function by incorporating a sequence specific strand onto the RISC, in 
this way, a gene can be targeted and silenced and the effects of this silencing studied. If a given 
protein is thought to be a regulatory factor on the synthesis of a second protein the siRNA model 
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may be used to assess that relationship by means of silencing the regulatory protein and observing 
the effect on the target protein. 
 
A key part in this experimental work was choosing an appropriate cell model: 
Ideally the knockdown experiment would have been performed in primary leukaemic cells choosing 
patients with some expression of CD38 and where ZFP36L1 would have also been confirmed as 
expressed (e.g. by Western blot analysis). A B-CLL patient is classed as positive for CD38 when 
flow cytometry analysis shows CD38 is detected in 20% of malignant cells (or 30% at times, it will 
depend on the health authority of the territory and the clinical guidance issued to this respect) of the 
cell population (Dürig et al. 2002); this experiment was attempted. Spanish groups had reported 
successful transfection of B-CLL cells using Hiperfect (Redondo-Muñoz et al. 2010, Ugarte-Berzal 
et al. 2012),  other groups using Lipofectamine (Baou et al. 2009b), but the notorious difficulty of 
transfecting primary cells and optimising the experimental conditions for this objective was leading 
to contradictory results in the present project and no consistent data was produced that could allow 
to move this approach forward. Electroporation was not available to be used and due to the time 
limits of this project a second strategy was attempted. This second approach consisted in using B 
cell lines which were reported positive for CD38 expression and confirmed  from tests in the 
laboratory by using Western blot analysis and immunofluorescence and flow cytometry. H929 
myeloma cells proved a good cell line for this purpose, but again, these cells as suspension cells, 
proved a challenged for reliable transfection. 
 
Finally, a cell line model that would be easy to transfect and that would have detectable expression 
levels of ZFP36L1 and CD38 was sought. HeLa cells were confirmed to express CD38 despite 
contradicting literature, and also were shown to express ZFP36L1 and ZFP36L2; in fact HeLa cells 
have previously been used to study CD38 (Numata et al. 2012) and the same cells have also been 
used  to knockdown the expression of ZFP36L1 and ZFP36L2  (Adachi et al. 2014). Nevertheless, 
considering the contradictory reports on the literature regarding CD38 expression in HeLa cells a 
number of key authors who work on CD38 and, or in HeLa were contacted, advice was requested 
from experts in CD38 like Prof. Malavasi (University of Torino Medical School, Torino, Italy) and 
Prof Okada (Graduate University for Advanced Studies, Kanagawa, Japan), before moving ahead.  
HeLa cells were kindly donated by Dr E. Wright at the University of Westminster and tests were run 
to confirm CD38 expression and also ZFP36L1 expression using Western blot analysis. The HeLa 
cells to be used in these experiments were confirmed to constitutively express ZFP36L1 and CD38. 
They were therefore found to be a suitable model to perform the knockdown experiments and 
analyse the effect on CD38 expression of down regulating ZFP36L1. 
 
The cells were transfected with 3 different siRNAs targeting ZFP36L1 expression (please refer to 
Materials and Methods) and appropriate controls (Scramble RNA, untransfected cells); knockdown 
efficiency for each siRNA (referred to as siRNA1, siRNA2 and siRNA3 from this point on) was 
assessed using Western blot analysis, and effects on CD38 expression was analysed by 




4. 3.1 Western blot analysis of down regulation of ZFP36L1 by siRNAs 
This part of the project aimed at analysing the effectiveness of 3 different siRNAs and different 
transfection reagents to down regulate the expression of ZFP36L1 in HeLa cells.  
Briefly, HeLa cells were plated and transfected following manufacturer’s instructions for each 
transfection reagent tested (only Lipofectamine RNAiMax –LifeTechnologies- and Hiperfect- 
Qiagen- results are shown here). Three siRNAs targeting different parts of the ZFP36L1 gene were 
tested (from Life Technologies). A final concentration of 20nM siRNA was transfected into HeLa 
cells in exponential growth. Cell harvest time was estimated as optimal 48-72 hours after 
transfection.  
 
One problem encountered was obtaining enough lysate from an optimised numbers of cells in order 
to detect expression of CD38. This was solved by plating HeLa cells in 12 wells plates and 
transfecting a number of wells and/or using 6 wells plate. Another factor that shows to be important 
in order to be able to assess an effect on CD38 was the time of incubation until harvesting the cells. 
Once the optimal time to harvest the cells was assessed, siRNA transfected HeLa cells were 
prepared for flow cytometry and cells lysate for Western blot analysis, for methods please refer to 
Chapter 2. 
 
Western blots were performed to confirm the down regulation of ZFP36L1 by the siRNAs.  Figure 4-
3 shows ZFP36L1 expression levels in HeLa cells transfected with siRNAs: siRNA1 and siRNA2; 
Scramble siRNA, and in untransfected HeLa cells using two different reagents: Lipofectamine 
RNAiMAX and Hiperfect. 
 
Figure 4-3 ZFP36L1 knockdown in HeLa cells analysed by Western blot.  
Western blot analysis of ZFP36L1 expression to assess knockdown efficiency for two different siRNAs and two different 
transfection reagents.  siRNA1 is more efficient in knocking down ZFP36L1 expression than siRNA2 and compared to 
controls, scramble RNA and untransfected cells.  Of the 2 reagents, Lipofectamine RNAiMAX seems to be the best as a 
transfection reagent as shown by stronger band intensity and levels of ZFP36L1 knockdown. Transfections were done in 
HeLa cells which express ZFP36L1, and CD38, and serve as a good model for this experiment. Cells transfected were lysed 
in NP40 buffer and processed for Western blot analysis. Anti-human ZFP36L1/ZFP36L2 antibody was used and the blot was 




Western blot analysis of ZFP36L1 expression knockdown efficiency for two different siRNAs and 
two different transfection reagents showed that, with both transfection reagents used, siRNA1 was 
more efficient in knocking down ZFP36L1 expression than siRNA2 but siRNA2 still was able to 
reduce ZFP36L1 expression levels considerably. Down regulation was seen with both reagents 
used (Lipofectamine RNAiMAx and Hiperfect) and in both cases the same pattern of down 
regulation was observed for each siRNA, higher down regulation in siRNA1 than in siRNA2 
transfected cells. Expression of ZFP36L2 was unaffected. For scramble RNA (control RNAi) and the 
untransfected HeLa cells the level of expression of ZFP36L1 was roughly equivalent and higher 
than those of the siRNA transfected samples. 
 
4.3.2 Analysis of CD38 expression after ZFP36L1 down regulation 
This was investigated using two different experimental strategies: A. Immunofluorescence and flow 
cytometry of cells and B. Western blot analysis of cell lysates. 
 
The previous pages described how successful down regulation of ZFP36L1 was confirmed in HeLa 
cells using ZFP36L1 specific siRNAs. For the same cells the levels of CD38 expression was 
analysed by immunofluorescence and flow cytometry and also by Western blot analysis. Harvested 
cells were stained with FITC labelled anti-human CD38 antibody; fluorescence levels of all samples 
were read using a flow cytometer (CyAn ADP Analyzer, from Beckman Coulter). For detailed 
description of this experiment and reagents please see Materials and Methods. Cell samples where 
flow cytometry analysis had shown a histogram shift in fluorescence intensity indicating an increase 
in CD38 expression were lysed and used for Western blot analysis alongside controls. 
A. Flow cytometry analysis of CD38 levels in ZFP36L1 knockdown HeLa cells 
CD38 is an ectoenzyme, the molecule is a cell membrane protein and its expression can be easily 
analysed by flow cytometry. In flow cytometry the cells are stained with a fluorescently labelled 
antibody and the fluorescence signal is detected following excitation with a laser. The cells are 
initially distributed in a density plot by size and granularity and an area can be chosen (gating) to 
further analyse fluorescence in a histogram plot. This approach was chosen to analyse, in HeLa 
cells, the expression of CD38 in siRNA transfected cells, scramble siRNA transfected cells and 
untransfected cells. Testing the hypothesis that ZFP36L1 targets and degrades CD38 mRNA, the 
samples where ZFP36L1 is down regulated would show an increase in CD38 fluorescence 
indicating higher CD38 expression compared to controls if the hypothesis were correct. 
 
After siRNA transfection and knockdown of ZFP36L1 expression, HeLa cells were prepared for flow 
cytometry analysis of CD38. The cells were stained with FITC labelled anti-human CD38 antibody; 
in each experiment the density plot was gated where the largest population of cells was 
concentrated, considering size and granularity to gate for live cells. Where possible samples were 
run so that a similar number of cells would be counted within the area originally gated and so a 
similar number of cells would therefore be compared. Figure 4-4 shows a representative density 
plot with gating where the populations of cells is denser; figure 4-5 shows histograms comparing 
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CD38  fluorescence signals for the 3 different siRNAs, scramble transfected cells and untransfected 
HeLa cells.  
 
 
Figure 4-4 siRNA transfected HeLa cells density plot.  
Representative density plot with gated area for analysis. Gates were chosen in control samples and placed where the 
population of cells was densest so the largest number of cells could be compare across samples. Size (FS LIN) and 
granularity (SS LOG) were considered in order to gate so live cells would be placed within the area. Samples were run trying 
to achieve an equal number of cells within the original gate so an even number of cells will be compared across samples. 
 
 
Figure 4-5 CD38 fluorescence histogram in ZFP36L1 down regulated HeLa cell samples and controls.  
Overlay log fluorescence intensity histogram with siRNA transfected samples and controls with gated cell area for % of cells 
and MFI analysis. Red: Scramble; Green=siRNA1, Blue= siRNA2, Yellow=siRNA3. A shift in fluorescence towards the right 
was observed in all siRNA transfected samples with down regulated ZFP36L1, that shift indicated an increase in CD38 




Flow cytometry analysis of HeLa cells transfected with the 3 different siRNAs showed that all siRNA 
transfected cells resulted in a shift in the histogram curve for CD38 fluorescence, the shift is 
indicative of increased CD38 levels compared to controls. This was true for the three siRNA 
transfected samples silencing ZFP36L1 but with different degrees of CD38 detection for each 
siRNA. There was a clear difference observed in the case of siRNA1, which is also the siRNA 
leading to the highest ZFP36L1 knockdown and transfection of cells with siRNAi1 led to the highest 
increase in CD38 expression.  
 
Table 4- 2 Percentage of CD38 positive cells in R2 gate (as shown in Fig 4-5) in different experiments 










56.58 23.12 27.68 23.07 
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37.23 40.21 36.69 
Data shaded blue was analysed for statistical significance. 
 
Paired T Test analysis of  siRNA1 and Scramble RNA transfected cells produced a value of 
P=0.014 showing  a statistical difference in the % positive CD38 cells in siRNA1 transfected vs 
scramble siRNA transfected cells (Table 4-2). 
 
Figure 4-6 shows normalised mean CD38 fluorescence levels for siRNA transfected samples. CD38 
mean fluorescence from samples with down regulation of ZFP36L1 were increased compared to 
scramble transfected cells where no down regulation of ZFP36L1 was seen: 
 
 
Figure 4-6 CD38 Mean fluorescence intensity ratios normalised to scramble transfected cell mean fluorescence 
intensity levels. 
CD38 mean fluorescence intensity in samples where ZFP36L1 had been down regulated by each siRNA relative to CD38 
fluorescence detected in scramble RNA transfected samples where ZFP36L1 had not been knocked down.   n=5 for siRNA1; 




Normalised mean fluorescence intensity for each set of transfected cell samples, showed that 
siRNA1 transfected cells, where down regulation of ZFP36L1 was most effective, led to an increase 
in CD38 fluorescence levels compared to scramble transfected cells (fig. 4-6). 
 
To summarise, flow cytometry analysis of CD38 expression in HeLa cells transfected with the 3 
different siRNAs against ZFP36L1 indicated that for the siRNA that had shown the most efficient 
ZFP36L1 knock down by Western blot, siRNA1, CD38 levels increased the most compared to the 
scramble controls where no down regulation of ZFP36L1 occurred. SiRNA2 lead to the second 
largest increase in CD38 levels which also correlated to its effects down regulating ZFP36L1 less 
efficiently than siRNA1. siRNA3 transfected cells showed the least increase in CD38 levels. The 
results from flow cytometry analysis for CD38 levels inversely correlate to level of decrease in 
ZFP36L1 expression and are consistent with the ZFP36L1 knock down levels seen by Western blot 
figure 4-3. 
B. Western blot analysis of CD38 expression in down regulated ZFP36L1 samples  
To further assess the possible increases in CD38 levels detected by immunofluorescence and flow 
cytometry following ZFP36L1 down regulation, cell lysates of siRNA transfected HeLa cells used in 
the previous set of experiments, were used in Western blotting to detect CD38 expression levels 
(these same samples were used to assess ZFP36L1 knockdown by Western blots in figure 4-3). On 
this occasion samples were Western blotted for CD38 analysis, -the results are shown using 
Lipofectamine RNAiMax transfected cell lysates-. 
 
Figure 4-7 Western blot analysis of CD38 expression in ZFP36L1 down regulated HeLa cells.  
Figure shows bands detected for CD38 in samples where ZFP36L1 had been down regulated (siRNA1 and siRNA2) and 





Western blot analysis of CD38 expression showed bands for CD38 in all samples, with the highest 
expression corresponding to samples where siRNA1 had been used to knockdown ZFP36L1 
protein levels leading to the highest down regulation of ZFP36L1. The band detected for CD38 in 
the samples transfected with siRNA2 was not of an intensity or size that could determine an 
increase in CD38 as it should be expected from the results obtained by the flow cytometry analysis, 
these bands were measured in order to semi quantitate the blot results and further analyse 
expression levels. 
C. Semi-quantitative analysis of expression bands detected for ZFP36L1 knockdown and 
CD38 
The bands detected by Western blot analysis to confirm down regulation of ZFP36L1 and increased 
expression of CD38 (fig. 4-7) were semi quantified using GS-800 Calibrated Densitometer from Bio-







































































Figure 4-8 ZFP36L1 bands intensity normalised to HSP90 and CD38 bands intensity normalised to HSP90 levels. 
A. The intensity of the bands for siRNA1 downregulated ZFP36L1 was  60% less to that of scramble transfected samples; 
intensity of band for  ZFP36L1 knock down using siRNA2 was of 30% less to scramble samples confirming a considerable 
level of downregulation of the protein. .B. CD38 bands intensity normalised to HSP90. Intensity levels normalised to HSP90 
indicated that CD38 expression increased, CD38 bands in the samples with highest ZFP36L1 downregulation were 20 to 
30%  increased  in intensity compared to scramble siRNA transfected cells with no ZFP36L1 downregulation. The increase in 





Semi quantitative analysis of protein bands detected in blots confirmed that the highest knockdown 
of ZFP36L1 is achieved with siRNA1 which corresponds to the highest incresed in CD38 expression.  
Normalisation of protein expression to HSP90 levels for ZFP36L1 downregulated samples showed 
that siRNA1 was able to knockdown the expression of the ZFP36L1 protein to half the level than 
that found in siRNA2 transfected cells (fig. 4-8). For siRNA2 transfected samples the intensity 
values normalised to HSP90 expression determined that CD38 expression was higher than in 
scramble or untransfected but the increase was minimal. 
4.4  Discussion. 
The luminescence readings from the DLR assay showed a very significant decrease in 
luciferase/renilla ratios indicating ZFP36L1 interacted with CD38 ARE (fig. 4-2A) and suggesting it 
may mediate CD38 mRNA degradation. Readings from the samples transfected with the mutated 
version of ZFP36L1 showed increased luminescence (fig. 4-2A); the CD38 ARE was not targeted 
by the mutated version of ZFP36L1 with a zinc finger base pair modification leading to an amino 
acid change, indicating that intact zinc fingers motifs are required for ZFP36L1 targeting the CD38 
ARE. 
 
This result is in line with previous evidence shown in this thesis for BCL2, and in the REMSA 
assays (Zekavati 2009, Zekavati et al. 2014) already discussed in chapter 3 for BCL2. The same 
ZFP36L1 mutant construct was also used to study ZFP36L1 interaction with BLIMP1, in a luciferase 
assay where they also tested the functionality of the ZFD showing that the target ARE was not 
bound by the altered ZFD protein (Nasir et al. 2012). The interaction between the proteins and the 
ARE does take place via the protein’s ZFD and functional ZFDs are required for the degradation of 
the mRNA 3’ UTR ARE.  
 
A mutated version of CD38 ARE was not available for use in this study, however, research looking 
at the post transcriptional regulation of CD38 provides information not only on other factors that bind 
to its 3’ UTR but also on the specificity of that ARE for that interaction. A 2014 paper showed that 
CD38 mRNA is negatively regulated via its ARE by miR709 and reports on findings validating the 
binding of miR-708 to the 3’ UTR of CD38 (Dileepan et al. 2014). The study used a mutated version 
of the UTR target sequence, this mutant hindered, reversed the inhibitory effect of miRN-708 on 
luciferase activity, and this observation led to confirming the specificity of its target binding at the 3’ 
UTR ARE of CD38.   
 
The interaction between CD38 and ZFP36 proteins has been suggested by other authors looking to 
determine the ARE relevance in the regulation of this protein. CD38 ARE is not a binding site for 
HuR, over expression of HuR in airway cells did not alter its mRNA decay (Jude et al. 2010). In a 
subsequent review by the same author he proposed that other RNA binding proteins like ZFP36 
may have a counteracting role in TNFα induced CD38 expression (Jude et al. 2012a). The 
regulatory web of CD38 expression might involve the ZFP36 family in two ways,  by direct 
regulation via its ARE and by regulation of TNFα in a dual pathway; TNFα is itself a confirmed 
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target for the three ZFP36 proteins and, on the other hand, it also regulates CD38 post 
transcriptionally, TNFα regulation by another miRNA, miR140-3p, induces CD38 expression (Jude 
et al. 2012b).  
 
The DLR assay provided evidence indicating that the other ZFP36 family members also recognise 
CD38 ARE (fig. 4-2B) but for these proteins no further investigations were pursued. These results 
are in agreement with what was obtained for BCL2 and with other research showing the proteins 
might share some targets. In previous work it has been confirmed that the 3 ZFP36 family proteins 
bound and degraded the mRNAs of not only TNFα (as already mentioned in chapter 3) but also 
GMCSF, or IL3 (Carballo et al. 1998, Carballo et al. 2000, Stoecklin et al. 2000, Lai and Blackshear 
2001, Stoecklin et al. 2002). More recently, ZFP36L1 and ZFP36L2 were shown to bind to the 
3’UTR of MAPK mRNA and downregulate its 3’UTR mediated luciferase activity (Lin et al. 
2012).The redundancy in their role as post transcriptional regulators proposed by Vignudelly et al. 
2010 has been discussed in chapter 3.  
 
Manipulation of gene expression via RNA interference or over expression has also been a key 
strategy in the quest to elucidate gene function in general, and concretely to validate putative 
targets for this family of proteins. Past and recent groups have demonstrated by RNAi the role of 
ZFP36 proteins in mRNA regulation; double siRNA-mediated knockdown  of  ZFP36L1 and 
ZFP36L2 has been used previously showing that  silencing of the proteins could efficiently be 
achieved in HeLa cells (Adachi et al. 2014) and provided supporting evidence to the experimental 
strategy followed in this thesis . The Adachi group used antisense nucleotides against ZFP36L1 and 
ZFP36L2 to investigate the relationship between these proteins and LDLR. They demonstrated that 
downregulation of ZFP36L1 and ZFP36L2 resulted in up regulation of LDLR mRNA and LDLR 
protein, they used a luciferase reporter assay, cloning the 3’UTR of LDLR mRNA, and finally 
assessed knockdown efficiency by QRTPCR and Western blot analysis. 
 
The same siRNAs used to knockdown ZFP36L1 expression in this thesis were used in previous 
studies (Zekavati et al. 2014); of the 3 siRNAs tested, siRNA1, and siRNA2 yielded the most 
efficient knockdown (no Western blot data is shown for siRNA3). Knockdown for ZFP36L1 
expression was optimally achieved by siRNA1; siRNA2 knockdown was less efficient compared to 
siRNA1 but still achieved a high downregulation of ZFP36L1, and the same result was seen when 
either reagent, LipofectamineRNAiMax or Hiperfect, was used. For scramble RNA (control RNAi) 
and the untransfected HeLa cells, the expression of ZFP36L1 was evident and higher than that 
observed in the siRNA transfected samples. The different knockdown efficiency between siRNA1 
and siRNA2 may be down to the fact that these siRNAs target different exons in the ZFP36L1 gene; 
however, this was not further investigated. 
 
Efficiency and specificity in downregulation are important assessments for RNA interference, a 
problem that might be encountered is “off target “effects (Jackson et al. 2003). The off target effects 
arise from the sense strand of siRNAs having homology to a non-target gene which is incorporated 
to the RISC; an unwanted gene is in consequence silenced which can interfere the interpretation of 
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results. Unwanted silencing effects on ZFP36L2 and/or ZFP36 could influence CD38; these proteins 
were also shown to interact with the 3’UTR ARE of CD38 mRNA in the DLR assay. Off targets 
effects may happen even between sequences of low homology since only a small region of base 
pairing is required and not only genes from a homologous family but other genes can be affected by 
the siRNA oligos. Considering that avoiding all off targets effects is pretty much impossible, different 
methods and techniques have been developed to reduce them. The siRNAS used in the present 
study were designed to not recognise sequences in ZFP36L2 and ZFP36 transcripts; expression of 
ZFP36L2 was unaffected, as seen in figure 4-3, which provides evidence to confirm that siRNA1 
and siRNA2 acted with specificity for silencing ZFP36L1.   
 
Advanced specificity alignment of Stealth siRNA (“Life technologies”), the type used in these 
experiments, limits potential for off-target effects. In classic siRNAs both strands could enter the 
RNAi pathway but the siRNA used for these experiments are modified so only the antisense strand 
is able to enter the silencing pathway, get incorporated into the RISC and engage in the 
interference and knockdown of gene expression, hence limiting very much the off target events. 
This modification  to stop the sense strand producing off target effects is done on the most modern 
siRNAs (Chang et al. 2012).  The Stealth siRNAs used in the CD38 investigation are also more 
stable with a longer half-life. Their stability is an advantage for the study of some targets as in the 
case of CD38, where in order to observe an effect due to knockdown of the regulator protein 
(ZFP36L1) incubation of the cells had to be longer than the usual 24-48h. 
 
Within the efforts to ensure that the phenotype observed in the siRNA experiments described in this 
chapter is reliable, controls were put in place, such as a scramble version of siRNA and the use of 
different siRNAs to target ZFP36L1. A strategy to ensure specificity in RNAi experiments and that 
knockdown of a gene leading to a phenotype is not due to off target effects consists in using 
multiple siRNAs to the same target. The basis of this is that their off-target effects will be different 
but their effect on the target mRNA would be expected to be the same, and so an important 
requirement to validate the specificity of a knockdown experiment would be confirming the observed 
phenotype with more than just one siRNA which would target different regions (Cullen 2006). The 
standard rule is to use at least two siRNAs, Western blot data is shown in figure 4-3 for two siRNAs 
confirming downregulation of ZFP36L1. Downregulation by siRNA1 and siRNA2 was observed even 
when using two different transfection reagents, furthermore the downregulation reproduced the 
pattern of reduction in ZFP36L1 for each siRNA (highest downregulation by siRNAi1, followed by 
siRNA2) further confirming the reproducibility of the results. 
 
These results or rather these differences in the level of downregulation of the protein by each siRNA 
were later observed to be consistent with the results obtained by flow cytometry analysis of CD38 
expression. Overall, analysis of flow cytometry results indicated that different levels of 
downregulation of ZFP36L1 inversely correlated to different levels of increased CD38. Flow 
cytometry analysis of HeLa cells transfected with each siRNA showed a shift in the histogram curve 
for CD38 fluorescence indicating increased levels of CD38 compared to controls (fig. 4-6). Cells 
transfected with siRNA1, where the level of ZFP36L1 had been downregulated the most, showed 
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the biggest increase in CD38 fluorescence compared to scramble RNA samples (fig. 4-6). siRNA2 
led to the second largest increase in CD38 levels which also correlated to its effect downregulating 
ZFP36L1 less efficiently than siRNA1. The third siRNA tested, siRNA3 was not as efficient in 
leading to an increase in CD38 mean fluorescence. Further analysis of siRNA transfected cells for 
CD38 levels showed that there were differences between % CD38 positive cells compared to 
scramble controls in all siRNA transfected cells, for siRNA1 transfected cells showed that there was 
also a strong statistical difference in the % of CD38 positive CD38 compared to scramble siRNA 
transfections (table 4-2). 
 
Densitometry analysis of ZFP36L1 and CD38 bands (fig. 4-7 and 4-8) resulted in data showing that 
ZFP36L1 band intensity was about 60% lower than in scramble RNAi control, and that for those 
samples CD38  band intensity increased 20-30%;  for siRNA2, these numbers were 30% reduction 
in ZFP36L1 band intensity and 2.5% CD38 intensity increase. Although no further comment may be 
made on this analysis since it was performed just once, the intensity levels would seem to indicate 
that siRNA1 downregulated ZFP36L1 double than siRNA2 and although siRNA2 achieved a less 
efficient downregulation of the protein it still knocked down ZFP36L1 considerably; the correlated 
level of CD38 in siRNA2 samples was lower than that seen in samples with the highest ZFP36L1 
knockdown (fig. 4-8 A and B). From the data obtained, and within the limits imposed by 
densitometry measures,  a question may be made to the possibility that  perhaps  a certain level of 
ZFP36L1 downregulation is needed for a considerable and clearly detectable increase in CD38 
expression to be measurable.  
 
Lastly, a comment on data shown for untransfected cells: the blots show how the lysate of these 
cells gave CD38 bands that do not match that of scramble transfected cells (fig. 4-7 and 4-8) 
although flow cytometry has shown a more similar result when untransfected and scramble are 
compared. Scramble siRNAs activate the RNAi machinery in order to determine baseline reference 
for the effect of the siRNAs  When it comes to comparing results it must be taken into account that 
siRNA transfected samples and scramble siRNA transfected samples are more equally treated as 
both have had the same transfection reagent and equal amounts of RNA added, and that is not the 
case for untransfected cells. It is also known that transfection may cause the cells to stress, may be 
immunogenic or the transfection reagent may cause toxicity (O’Keefe 2013). There is one last 
possible explanation for the stronger CD38 band detected in the scramble siRNA transfected 
samples and that would be a partially complementarity of the scramble oligo with the ZFP36L1, 
however the protein levels do not seem downregulated. Off target effects of the control siRNA are 
also a possibility, but, as already discussed, these oligoes are new generation siRNAs and have 
been validated to avoid secondary effects. Therefore the seemingly augment expression of CD38 in 
samples transfected with scramble siRNA are most possibly down to the manipulation, reagent and 
transfection process (O’Keefe 2013). To further assess this possibility more than one scramble 
siRNA could be used in future experiments, also other transfection reagents and even a different 
cell line could be used. Measuring mRNA levels would also assist in evaluating any effect of 
scramble siRNA on either protein studied. In addition, the difference observed between Western 
blot and flow cytometry results may also be due to the sensitivity of the methods and complexity -of 
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blotting in this case-, but also due to the different independent samples analysed; where Western 
blot analysis just done once, flow cytometry analysis was performed in at least n>5 samples, 
making the latter results more reliable 
 
It is impossible to quantify the direct relationship between level of downregulation of ZFP36L1 and 
up regulation of CD38 by the experiments shown here alone, although flow cytometry is more 
sensitive and can often have a better quantitation range. Western blot is, at most, a semi-
quantitative method, measuring a protein relative to total protein from cell lysates where variations 
in loading and transfer rates between samples in the lanes influence the detection of the proteins in 
the membrane  (Dragowska et al. 2000).  Because of these variables other methods such as 
QRTPCR might be also useful to help quantitate down regulation/or up regulation of a gene. 
However, Western blot analysis with controlled and normalised results provides, like in this case, 
evidence of increase or decrease expression and a trend. Some argue that analysing knockdown 
and up regulation at the protein level by Western blot rather than solely by QRTPCR is a more 
reliable way to assess downregulation, especially in mammalian cells because only part of 
mammalian RISCs are capable of performing siRNA-directed RNA cleavage, for the rest the 
expression is suppressed by actually interfering with protein synthesis, if knockdown is only 
analysed by measuring RNA levels (be it  by quantitative PCR or northern blotting) it can 
overestimate knockdown for long-lived proteins, as it is the case of CD38,  or underestimate 
knockdown caused by contributions of non-catalytic RISCs (Chang et al. 2012). Hence analysis of 
downregulation of ZFP36L1 (and later expression of CD38) by Western blot serves in this project as 
an appropriate method demonstrating that ZFP36L1 expression had been downregulated by 2 
different siRNAs, and CD38 had increased in the same samples. 
 
CD38 is a plasma cell marker and its regulation by ZFP36L1 may fit with a role for the ZFP36L1 
protein in mature/plasma B cells. Other researchers (Wegmüller et al. 2007, Vignudelli et al. 2010) 
had already reported a role for ZFP36L1 in the negative regulation of cell differentiation; when the 
protein was downregulated by shRNAs cardiomyogenesis was enhanced (Wegmüller et al. 2007); 
and targeting of Stat5b mRNA by the protein negatively regulates erythroid differentiation  
(Vignudelli et al. 2010).  Results from this chapter provide further information on the regulatory 
framework of plasmacytoid differentiation by ZFP36L1, they fit into the work done indicating that 
ZFP36L1 may function as a negative regulator of plasma cell differentiation 
 
BLIMP1 contains several pentameric AUUUA motifs (Nasir 2012), just like CD38, and its validation 
as  target for ZFP36L1 (Nasir et al. 2012) provided evidence of ZFP36L1 being implicated in B cell 
lymphopoiesis by negatively regulating the mature B cell to plasma cell stage. B cell line models 
and murine primary B cells showed ZFP36L1 expression but it was not detected in plasma cells 
(Nasir et al. 2012). ZFP36L1 knockdown experiments using shRNA led to enhanced cytokine-
induced plasma cell differentiation but enforced expression of ZFP36L1 in the murine BCL1 cell line 
showed blocked cytokine-induced plasma cell differentiation (Nasir et al. 2012). The BLIMP1 study 
used a similar experimental strategy to that described here for CD38. Their gene expression 
manipulation results also show a similar pattern to those described in this chapter. They also used a 
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luciferase reporter assay to confirm ZFP36L1 bound to BLIMP1 3’UTR, silencing of ZFP36L1 
resulted a significant increase in levels of blimp1 mRNA, that increase was smaller with another 
shRNA, and those results translated to Western blot analyses with highest ZFP36L1 knockdown 
cells expressing higher levels of BLIMP1 protein compared to control cells (Nasir et al. 2012). 
 
The relevance of ZFP36 proteins regulating CD38 may be extended to mature B cell malignancies 
where several reports show that ZFP36 genes are altered in MM by being either deleted or mutated 
(Davies et al. 2003, Chapman et al. 2011). Deletions in a regulatory intron of ZFP36L1 have been 
found in a significant minority of primary MM cases, a malignancy classically CD38 positive 
(Chapman et al. 2011); the functional relevance of this finding is not yet known but results from this 
chapter could be relevant in this regard. The mRNA degradation machinery seems also to be 
impaired in myeloma by loss of exosome function, the exosome is one of the components involved 
in the ZFP36 led degradation pathway (Chen et al. 2001), that impairment may be as a result of 
another mutated gene found in 11% of myeloma cases studied, Rrp44 gene (encoding exosome 
component 11), which is mutated within its coding region (Chapman et al. 2011).  
 
In an earlier paper, clinical data, cytogenetics and microarray expression analysis to compare 
healthy versus malignant gene expression in monoclonal gammopathy of unknown significance 
(MGUS) and MM were used to develop molecular profiles associated with plasma cell malignancy. 
The resulting transcriptome model evidenced genes differentially expressed between plasma cells 
from healthy donors and individuals with MGUS or MM. Post-transcriptional regulatory proteins 
shown to be downregulated included members of the zinc finger family, namely ZFP36L1 and 
ZFP36 (Davies et al. 2003). On the other hand, in MM a number of suspected and confirmed 
targets for ZFP36 proteins are up regulated and involved in developing and sustaining cell 
malignancy, e.g. TNFα, GMCSF and IL6   supporting the growth and survival of MM cells both by 
stimulating proliferation and inhibiting apoptosis (Hussein 2002) 
4.5 Conclusion 
 
The DLR assays showed that CD38 3’ UTR ARE is bound by ZFP36L1 via its ZFDs, ZFP36L2 and 
ZFP36 results also indicated they interacted with the CD38 3’ UTR ARE. Downregulation of 
ZFP36L1 by siRNAs correlated to increased CD38 expression, further providing evidence to 
establish a post transcriptional regulatory role of ZFP36L1 over CD38 mRNA. In order to improve 
these experiments a siRNA phenotype rescue could be performed, and also measurements of 
mRNA levels by QRTPCR could be studied.  
 
The findings could also be extended by performing ZFP36L1 knockdown in primary B cells, such as 
B-CLL cells or human tonsil B cells. Mutant versions of the ARE for CD38 and ZFD mutant versions 
of ZFP36L2 and ZFP36 could also be used in other luciferase assays to extend the studies 
presented here. The expression of these other two ZFP36 family proteins could also be 
manipulated to assess any changes in CD38 expression and QRTPCR measurements taken 
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5.1 Introduction  
 
This part of the thesis describes IHC experiments in healthy lymphoid tissue (tonsil and lymph 
nodes sections) and FL to test for patterns of expression of ZFP36L1 in relation to the putative 
targets under study. Based on the results described in previous chapters, the hypothesis behind this 
set of experiments was that positive and high levels of ZFP36L1 expression in cells may be 
associated with absent/low levels of BCL2 and CD38. These experiments would add another 
dimension to this project since they look at protein expression at tissue level. In IHC analysis 
antibodies bind to antigen in a specific manner and provide spatial localisation, also giving 
information of particular cells and proteins.  
 
Tonsils are defined as accumulations or mass of lymphoid tissue located in the upper respiratory 
and gastrointestinal tract. Lymph nodes are small, bean shaped structures and part of the lymphatic 
system distributed around the body. They serve as a filtering point of the lymph fluid brought in by 
lymphatic vessels. Their structure is formed by cortical and medullary regions, and like tonsils they 
have primary follicles (lymphoid follicles without a GC) and secondary follicles (lymphoid follicles 
with a GC).  
 
Whilst lymph nodes are distributed throughout the body, tonsils are present in the aerodigestive 
tract. Pharyngeal tonsils situated at the roof of the nasopharynx, tubal tonsils posterior to the 
opening of the Eustachian tube in the ear, palatine tonsils in the oropharynx, and lingual tonsils on 
the posterior tongue constitute the Waldeyers ring, protecting the entry to the respiratory systems; it 
is a ring of lymphoid tissue involved in the production of immunoglobulins and the development of 
both B cells and T cells. Tonsils are part of mucosa associated lymphoid tissue (Kenna et al. 2009). 
Palatine tonsils are covered by stratified squamous epithelium that invaginates to form blind ended 
tunnel like structures, these are networks of branched crypts, allowing for a larger internal surface 
area and hence, increased contact between the lymphoid tissue resident immune cells and 
environmental influences; the crypts serve as a first contact to pathogen entry route. The tonsils are 
formed by four lymphoid compartments: reticular crypt epithelium, the extra follicular area, the 
mantle zones of lymphoid follicles, and the follicular GCs. In tonsils, foreign particulate or bacteria 
may enter the crypts and pass to the follicles (transcytosis) by the epithelial cells within the crypt 
lining starting an immune response. The GC may be polarised  with cells forming two zones, a light 
zone (with centrocytes, CCs) nearer the antigen entry site and a dark zone (proliferating 
centroblasts, CBs), that will move to the light zone away from the site of antigen entry at the 
epithelial surface; a mantle of cells also forms surrounding the GC (Knowles 2001, Natkunam 
2007); in the case of the lymph node polarisation can also be seen in the GC but the antigen entry 
happens from the lymph fluid via lymph vessels (Janeway et al. 2001). 
 
Tonsil and lymph nodes contain B cells that represent different stages of B cell differentiation that 
include GC B cells, and memory and plasma B cells. The primary follicle mostly contains mature 
naive B-cells, that upon activation of resident T cells, will develop into a GC formed by those B cells 
undergoing clonal expansion, B-cell receptor affinity maturation, positive selection of B cells 
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according to receptor affinity for antigen and differentiation to B memory cells and plasma cells 
(Brandtzaeg et al. 2003), Therefore, tonsil and lymph node sections can be very helpful for this 
study since they house different B cell populations.  
 
GC formation, independently of whether it is in tonsillar tissue or lymph nodes, starts with IgM+IgD+ 
naive B cells receiving stimulatory signals from helper cells, they are activated by antigen receptor 
stimulation and B cells transform into CBs and start to proliferate, they form the dark zone of the 
GC. SHM inducing single nucleotide changes in the IgV regions takes place modifying the antibody 
affinity to the antigen and the cells become CCs, forming the light zone of the GC. As CCs the B 
cells now go through clonal selection based on the ability of their antibodies to recognise the 
antigen held on follicular dendritic cells and at this stage many CBs undergo apoptosis so the 
highest antibody affinity containing CCs survive. Those CCs with the highest affinity antibody are 
selected for survival and eventually differentiate into plasma cells or memory cells. Some CCs also 
change IgM and IgD to other Ig isotypes through class-switching using somatic DNA recombination 
and generating different effector antibodies. Those high-affinity antibody containing memory B cells 
leaving the GC will be long lived cells and are able to rapidly differentiate into Ig-secreting cells 
upon secondary immune responses (Klein et al. 2003). 
 
GC B cells are involved in the pathogenesis of many types of human B cell malignancies, including 
DLBCL, FL, and Burkitt Lymphoma  (Stevenson et al. 1998, Epstein et al. 1999). The counterpart to 
healthy tonsil tissue and healthy lymph nodes is here represented by FL  tissue, viewed as a GC–
derived neoplasm  (Leich et al. 2009). Lymphomas are subdivided depending on the type of cells 
that are involved; they are mainly categorised as HL and non-HLs and in IHC analysis this division 
is made based on the presence of Reed Steinberg cells. The symptoms tend to be similar for both 
categories of diseases, tiredness, fever, night sweats, itchiness, and at times swelling in key nodal 
areas. Under the category of non-HL there are B and T cells lymphomas, with B cell lymphomas 
making 85% of cases  (Dotan et al. 2010, Mitchell et al. 2012). B cell lymphomas of high grade 
include Burkitt or DLBCL. FL is the second most frequent non-HL in the Western world and is 
usually an indolent disease with a 7 to 12 median survival. It affects older adults, has no cure and 
can transform into an aggressive version of the disease (Pulte et al. 2013). FL is considered a low-
grade neoplasm but within FL the histologic grading can be from I to III. At grade II the disease 
starts to show similarities with DLBCL although cytogenetic characteristics differ (no BCL2 
translocation). Grading of FL is recommended to be done based on the counting methods by Mann 
and Berard as per World Health Organisation 2008 guidance and classification system  (Harris 
2008, Pileri et al. 2008)  where FL cases can be defined to be in one of the 3 stages depending on 
number of CBs/high power field (Jaffe 2009); details of this grading system alongside Ann Arbor 
staging  system can be found in appendix. Grade 3 is divided into 3A and 3B after observing CCs 
(3A) or solid sheets or entire follicles made of CBs (3B) (Jaffe 2009). The staging is based on 
morphological features so IHC analysis is at the core of the assessment. Whereas in many cases 
the indolent nature of the disease permits patients to live without the need for drug treatments, 
patients with grade III FL, behaving like or transforming into DLBCL, are usually treated (Ott and 
Rosenwald 2008). Treatment will depend on assessment of each patient and may include 
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radiotherapy, chemotherapy, monoclonal antibody therapy, e.g. Rituximab (Doss et al. 2012), and 
even surgery. Immunohistologic markers typically used in the assessment of FL are CD10, BCL6 
and BCL2 (Fouad-Younes et al. 2010). BCL2 is typically found in the GC-like structure at the centre 
of the follicle.   
 
In a neoplastic follicle components of a normal reactive GC can be found, CCs and CBs are present 
but in abnormal ratios; the degree to which the follicle structure is maintained varies and the 
follicular pattern can be lost towards a diffuse form although some partial follicle structure might still 
be identified (Ott and Rosenwald 2008).  Histologically, FL can present different structural patterns 
that range from complete effacing of the normal follicle structure to partial conservation of 
some typical features, it can consist of sheets of lymphoid cells arranged either diffusely or in a 
follicular formation although either way no real GC formation is present besides these cell 
aggregates resembling lymphoid follicles (Fouad-Younes et al. 2010). The more aggressive 
versions are characterised by diffuse lymphomas where the pattern taken by the cells does not 
show a follicle structure formation, or follicle aggregation,  uniform sheets of neoplastic lymphocytes 
are present instead of the histologic features of a normal lymph node (Elmore 2006). In FL with 
some conserved structure neoplastic cells aggregate into follicles, irregular, larger and more 
variable in size than normal follicles presents an intermediate stage in the disease; it is also 
possible to find partial  FL involvement where some GCs show non malignant characteristics and 
others do display FL features (Armitage et al. 2009, Ioachim and Medeiros 2009, Jegalian et al. 
2011) 
 
Therefore due to its pathogenicity FL can be said to biologically represent the neoplastic version of 
a normal GC (Ott and Rosenwald 2008). It is also interesting because of some of its molecular 
clinical characteristics, especially considering one of the proteins researched in this thesis, BCL2.  
BCL2 expression in FL is well characterised and has a particular profile: about 90-95% of FL have 
BCL2 expression, it is known to be found inside the GC/follicle cells as opposed to non-malignant 
GC cells which do not express BCL2. In normal tissue BCL2 is detectable in mantle zone cells and 
outside the GC. Another protein, CD38 is not a marker that is used in FL, but this malignancy would 
still provide a good model for the aims of the present study. CD38 is a marker for plasma cells, and 
some of these may be found in GC/follicles in cells undergoing plasmacytoid differentiation. 
 
Based on the hypothesis outlined in the first paragraph of this text, this part of the project looked at 
the relationship between expression of ZFP36L1 and BCL2 and CD38 expression in healthy 
lymphoid tissue and also in  malignant lymphoid tissue. The experiment would potentially provide 
important information regarding the regulation of BCL2 and CD38 expression in relation to 
ZFP36L1. ZFP36L1 expression has only been reported upon once, in normal tonsils (Nasir et al. 
2012), and never in malignant tissue. CD38 is a well characterised protein but the information 
available regarding its expression in lymphoma is also limited. 
 
A custom antibody against human ZFP36L1 was produced by immunising rabbits with a synthetic 
peptide (J.M. Unpublished) was used (see Materials and Methods section for full description), 
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alongside pre-immunisation serum as negative control, (the same batch was used thoughout the 
experiments, number annotated in materials list, to avoid variablity).  
  
Anti-BCL2 and anti-CD38 antibodies were purchased (see Materials and Methods section for full 
details). Human tonsil, lymph node and FL slides were kindly donated by Dr Anthony Warford 
(Department of Biomedical Sciences, University of Westminster). Handling of slides and their 
storage was done in accordance with the Human Tissue Act, 2004. All slides were paraffin sections. 
For further information on methodology please refer to Materials and Methods (chapter 2). Three 
cases (n=3) of non-malignant lymphoid tissue and three cases (n=3) of FL were analysed, four 
slides of each case were used for each antibody and in all cases the slides were consecutive cuts. 
 
In all the experiments, reported here, one antibody known to be positive for each tissue was used 
as positive control, this was either BCL2 or CD38 as appropriate. Advice throughout the IHC 
process and on interpretation of results was sought from Dr Anthony Warford, a senior pathologist. 
The focus of this analysis was to assess if cells expressing ZFP36L1 are also positive for BCL2 or 
CD38; the positive staining is reported here in a range of 0 to 3: 0 = no staining, 1 = scant/ faint 
staining, 2 = moderate staining and 3 = abundant/strong staining. Scoring was assessed by Dr 

























5.2 Immunohistochemistry analysis of expression of ZFP36L1 and BCL2  
in healthy tonsil tissue and lymph node tissue and  in FL 
 
5.2.1 Immunohistochemistry analysis of ZFP36L1 and BCL2 in normal tonsil tissue. 
Tonsil and lymph node tissue slides were stained with ZFP36L1, pre immunised serum and anti-
BCL2 antibodies using appropriate antigen retrieval methods and Tyramide Signal Amplification, 
results representative of n=3 are shown below. Detailed methods and list of materials can be found 
in chapter 2. 
 
A 





Figure 5-1 ZFP36L1 expression in human tonsils sections. 
Human tonsil sections stained with pre immunisation serum (left) as control, and lab made anti human ZFP36L1 raised in 
rabbit (right) using equal concentrations of antiserum. A. Area shown: GC with nearby crypt. A.Images taken at x10, showing 
several GCs and crypt. B.Images show enlarged GC in the mid region to appreciate pattern and difference in the staining. 
Slightly intense staining is detected in the lower part of the GC in left and right images, with slightly stronger stain in the right 
figure- could be due to possible concentration of ZFP36L1 expressing cells within the dark zone of the GC  .A.and B. images 
are from the same case but representative of n=3. M=mantle; G= GC; C=Crypt. 
 
Healthy tonsil tissue was stained using the lab made anti-ZFP36L1 and pre-immunised serum after 
calculating and equalising protein concentrations of the two different antiserums. The GCs were 
                         Pre- immunisation serum                                                                               anti-ZFP36L1 




clearly defined and identified with surrounding mantle zone. The area shown in figure 5-1 shows a 
GC with nearby crypt and some polarisation, typical of normal GCs and not distinguishable in 
malignant tissue. Results showed that there was weak to moderate positive staining in GCs for 
ZFP36L1; the staining was cytoplasmic. High background was observed for anti-ZFP36L1 
antiserum and control serum which was not optimal for the assessment of staining but a closer 
photograph of the signal aided in further confirming a difference between pre immunised serum and 
anti-ZFP36L1 antiserum staining. Interestingly, close assessment of the staining indicated the 
possibility of a definition of a dark zone and light zone and it appeared that ZFP36L1 expression 






























Figure 5-2 BCL2 expression in human tonsil sections. 
Human tonsil tissue stained with anti BCL2 antibody, left. The same case shown for ZFP36L1 staining in figure 5-1 is shown 
here for BCL2 staining. A. Image  taken at x10 showing several GCs and crypt. B. enlarge area of central GC to show detail 
of cells stained by anti-BCL2 antibody; detail image of staining for BCL2  in germinal centre where only a few cells are 
positive for BCL2, indicated with arrows.  Staining is strong in the mantle and cytoplasmic. Representative of n=3. M= 











                            
Figure 5-3 ZFP36L1 and BCL2 expression in human tonsils. 
A and B. Comparing staining locations of BCL2 and ZFP36L1 expression in human tonsil sections; expression from 
consecutive cut slides of the same area and case. X10  Both antibodies showed cytoplasmic staining; representative of n=3 
 
BCL2 staining showed the protein was moderately to strongly detected in mantle zone B cells, 
BCL2 was not seen at large in GC cells (fig. 5-2). Only a few cells (fig. 5-2B, indicated by arrows) 
stained for BCL2 within the GC as opposed to ZFP36L1, which showed a great many cells within 
the GC do express the ZFP36L1 protein. 
 
A summary of IHC results on healthy tonsil tissue is shown in table 5-1. BCL2 and ZFP36L1 
detected in cells in spatially different locations, BCL2 not seen in GC and ZFP36L1 signals 
indicated cells within the GC did express the protein.  
 
Table 5-1 Immunohistochemistry results for ZFP36L1 and BCL2: 
Antibody Cells stained Staining * Comments 
Anti-ZFP36L1 GC 
1-2 weak to 
moderate 
 
High background, but shows stronger signal in GC, in 
agreement with Nasir et al. 2012. 
 




2-3 moderate to 
strong Consistent with literature; low/not detected in GCs 
*Staining classified as 1- weak, 2-moderate, 3-strong 


















IHC analysis of ZFP36L1 expression showed positive detection of the protein in GCs, where BCL2 
is low/not expressed. BCL2 was, as expected, not present in the majority of normal GC cells, 
whereas its detection is observed in the mantle zone and interfollicular areas; the results shown 
above are supported by the literature and by what is known about BCL2 function as a pro-survival 
protein, B cells undergoing SHM and affinity maturation die within the GC unless rescued by 
survival signals and are then primed by BCL2 for survival. 
 
In samples stained for ZFP36L1 a high background was observed in the sections stained with the 
negative control antiserum and anti-ZFP36 antiserum, most likely due to the unprocessed and 
unfiltered state of these antiserums, which had not been purified. After obtaining these results 
consideration was done as to purifying both, control serum and anti-ZFP36L1 antiserum, however 
the relatively small amounts available for the present study did not allow for this possibility. A close 
examination of the staining results indicated the presence of ZFP36L1 stained cells was observed 
in the GC cells. This is in agreement with a previous report where the same anti-ZFP36L1 lab made 
antiserum was used, and localisation of ZFP36L1 expression in GCs was observed (Nasir et al. 
2012).   
 
Overall, when staining results of both proteins were looked at and compared, results indicated that 
ZFP36L1 was present in the GC, whereas BCL2 was only detected in very few cells within the GC. 
 
5.2.2 Immunohistochemistry analysis of ZFP36L1 and BCL2 in FL  
FL slides were stained with anti ZFP36L1 antibody and pre-immunised serum, and BCL2 antibody. 















Figure 5-4 ZFP36L1 in FL sections 
Case 2;  FL with progressive effacing of follicle centre structure although some conservation can be seen with concentration 
of cells. Image shows ZFP36L1 staining in cells in 3 neoplastic follicles. A. taken at x10, B. 3 areas selected for amplification 
to show detail of staining, are shown here demonstrate difference in the FC border. C. the other 2 selected areas, left image 
shows positive staining within FC cells compared to right image of staining outside the FC (right), arrows  in the right boxed 
image indicate some strong positivity for ZFP36L1 comparable to inside the FC. There is also background staining due to the 
unpurified nature of the antibody. FC= follicle centre. Case shown is the same as in the images that will be presented further 






FL slides stained with anti-ZFP36L1 showed that the protein was detected in cells forming the 
misshaped follicles characteristic of FL although cells stained with the antibody can be also be seen 
outside the follicle centres too (C, bottom right). Generally stronger staining was observed in the 
follicle areas although maximum staining is moderate. Within the FC cells are not as clearly defined 
as in normal tissue but some cells can be seen with darker stain for ZFP36L1 (arrow, figure C, left 
The detection of ZFP36L1 does not seem to change in relation to non-malignant tissue and remains 
largely present within the centre of follicles –GC in non-neoplastic cases-. Overall the high 
background signal made difficult the assessments but overall results would indicate that follicle 
centre cells expressed ZFP36L1 protein. 
 
The same cases using consecutive tissue slides were stained with anti-BCL2 antibody, however on 
this occasion no results were obtained, the antibody did not produce any staining. These runs on FL 
tissues were done over a year after the images shown in the previous section; the most likely 
reason for the antibody failing to provide a signal was thought to be its expired date and/or storage. 
These samples were processed at the same times as other samples e.g. anti-CD38 stained 
samples, which gave positive results and effectively worked as a positive control.  
 
The literature has a large number of papers and images where BCL2 is reported to be detected in 
follicle centres cells in FL. A number of images are given here from different sources, duly 
referenced, in order to facilitate the discussion further on. BCL2 staining distinguishes non -
malignant reactive follicles from FL, IHC analysis of its expression can be used to differentiate FL 
from e.g. follicular hyperplasia although for a clinical diagnosis of FL other markers must be 
analysed. BCL2 is an anti-apoptotic protein, a pro-survival inner mitochondrial membrane protein 
and the BCL2 gene is translocated in most cases of FL from chromosome 18 to chromosome 14 
placing the expression of the BCL2 protein under the control of the promoter and enhancers of the 
IgH chain gene leading to over expression of BCL2. The highest percentage of cases showing a 
translocation of BCL2 are seen in grade I and II FL but it may also be present in grade III FL, and 
furthermore  increased over-expression of BCL2 may be observed even when that translocation is 
not present (Ott and Rosenwald 2008). 
 
 
Figure 5-5. Reference image for BCL2 staining in FL 
Image modified from (Natkunam 2007) to demonstrate typical staining pattern for BCL2 in FL cells; it shows how BCL2 
expressing cells are detected in the GC on the right image of FL. BCL2 protein was detected by using an IHC technique that 
produces a brown stain. In reactive follicles BCL2 is present in mantle zone cells but not follicular centre B cells. Left image 





Figure 5-6 Reference image of follicular and inter follicular BCL2 staining in FL 
Typical BCL2 staining pattern in FL . Left follicular pattern, middle and right show  inter follicular pattern, adapted from  
(Fouad-Younes et al. 2010). For this FL case the structure of the follicle centres is still fairly preserved. 
 
 
Figure 5-7 Reference image of FL stained for BCL2, 
Follicle centres show cells strongly positive for BCL2. In this case some follicles  do not have BCL2 positive cells or the 
population is sparse, the FL partially involves the follicle. From (Fletcher 2007). Extensive research reports BCL2 detected in 
follicle centres in FL., as opposed to BCL2 expressing cells in healthy tonsils and lymph nodes (fig. 5-1.B) but FL may show 
only partial involvement of the lymph node  and therefore some follicle centres may have less BCL2 expressing cells. 
 
 
Figure 5-8 Reference image of FL follicle centres strongly positive for BCL2 
The follicles have partially lost their normal structure and cells are strongly positive for BCL2. Adapted from (Fletcher 2007), 
as opposed to non-malignant follicles where in GCs  BCL2 is restricted to the mantle and to portions of the light zone 
implicated in the selection and maintenance of plasma cells and memory B cells. Some positivity for BCL2 in normal GC is 














Table 5-2 shows a summary of IHC data of FL samples stained for ZFP36L1 and BCL2. 
 
Table 5-2 ZFP36L1 and BCL2 staining in FL: 
Antibody Cells positive Staining* Comments 
Anti-ZFP36L1 Follicle centre cells          2 
 
High background, but shows stronger signal in 
neoplastic follicle- never reported before. 
Pre-immunised serum   
 
High background 
BCL2 Follicle centre cells          3 
 
As per literature- references stated after each image 
shown 
*Staining classified as 1- weak, 2-moderate, 3-strong 
 
BCL2 immunostaining shows that BCL2 is expressed mainly in the neoplastic follicle centres 
although may be found in inter follicular neoplastic B cells. ZFP36L1 is detected also in the 
neoplastic centre cells. Abnormal follicles show no apoptosis, positive for BCL2, no phagocytosis 
and no/ reduced mitotic features and lack a well defined mantle, as it can be seen in the 
representative images from diverse sources. Although BCL2 is found in cells within the neoplastic 
follicle centres, some centres may not have cells expressing the protein if the FL involvement is 
partial (illustrated in fig. 5-7); the detection can be moderate to strong, depending on the stage of 
the FL. 
 
5.3  Immunohistochemical analysis of ZFP36L1 and CD38 expression in normal tonsil tissue 
and lymph node and FL 
 
IHC analysis of ZFP36L1 and CD38 expression in healthy tonsil and lymphoma sections was 
performed to further assess the relationship between both proteins and analyse if there is an 
inverse relationship between them, in terms of their levels of expression, at tissue level. 
 
FL samples had been used to study the expression of ZFP36L1 and BCL2 as described at the 
beginning of this chapter and IHC analysis of the second putative ZFP36L1 target studied in this 
project, the CD38 mRNA, may also provide useful information. Since CD38 is a well characterised 
plasma cells marker in normal lymphoid tissue, and although CD38 is not a marker commonly 
studied in FL, it may still present an interesting scenario for the aim of these experiments. Some 
plasmacytic differentiation can be seen in a number of FLs. For example, within the mophological 
variations of FL a small number of  follicle centre cell lymphomas show plasma cell differentiation  
with either intra or inter follicular monoclonal plasma cells (Gradowski et al. 2010). 
 
In order to assess the expression of ZFP36L1 and CD38 in B cells, normal lymphoid tissue was 
used for IHC analysis as described in materials and methods (chapter 2). The same analysis was 
later performed on FL sections. To compare CD38 expression with that of ZFP36L1 the results 




5.3.1 Immunohistochemistry analysis of ZFP36L1 and CD38 in healthy tonsillar tissue. 
 
 
Figure 5-9 Detail of CD38 staining in human tonsils GCs 
GCs of normal tonsils stained with anti CD38. Left, image is at x40. Right:, part of GC enlarged shows cell membrane 
staining of CD38 positive cells. The images shown are representative of analysis carried out on three separate cases (n=3). 
M=mantle; G= GC.  
 
 
Figure 5-10 CD38 staining and ZFP36L1 on human tonsils 
GCs of tonsil stained with anti-CD38 antibody some cells in the GC stained for CD38, but stronger staining is shown outside 
the GC. The majority of CD38 positive cells appear in the subepithelial region. There are few CD38 positive cells with 
moderate staining in GC and M. Right, same area stained with anti-ZFP36L1 antibody, cells positive for ZFP36L1 are seen 
mainly in GC, Only a few cells may be considered to show overlapping expression for both proteins inside the GC but due to 
the dense staining of ZFP36L1 this is difficult to assess. Magnification is at x10. G= GC; M= mantle zone. 
 
CD38 and ZFP36L1 were detected in cells generally in spatially different locations, a few CD38 
stained cells in GC, with moderate staining whereas ZFP36L1 was detected mainly within GC cells; 










Table 5-3 Immunohistochemistry summary results ZFP36L1 and CD38: 
Antibody Cells positive Staining* Comments 
Anti-ZFP36L1 GC 1-2 weak to moderate 
 
High background, but shows stronger signal in 
GC, in agreement with Nasir et al. 2012 




Mainly outside of 
GC; and at lower 
level GC 
Overall stain is weak in 
GC cells, where a few 
cells show level 2 
staining. 
Larger number of cells 
outside GC and M with 
level 3 staining 
Membrane staining 
Localisation and type of staining is consistent 
with literature. 
* Staining classified as 1- weak, 2-moderate, 3-strong 
 
CD38 was mainly detected in cells outside the GC and outside the mantle zone with stronger 
staining than cells in those found within GC, here a few cells resulted positive for CD38 with 
moderate staining as it can be seen in figure 5-9 and 5-10. 
 
Compared to GCs stained for ZFP36L1, figure 5-10 images showed that where CD38 is highly 
detected, outside GC and mantle zone, in the sub epithelial region, no clear or obvious staining for 
ZFP36L1 was detected there. In the GC, staining for CD38 is mostly weak or moderate and there 
are also a few cells with high level CD38 staining. In contrast, ZFP36L1 expression is mainly 
located in GC cells. CD38 membranous staining is clearly seen in figure 5-9. 
 



























Figure 5-11 FL tissue stained with CD38,  
FL tissue stained for CD38, magnification at x10. With areas selected and enlarged. FL case showing little conservation of 
normal follicle centre features and showing progressive sheet appearance of neoplastic cells. For CD38,  it showed 
moderate to strong staining within the centre cells, and some staining seen outside the partially effaced follicle centres. 
Arrows show single cells positive for CD38 with strong membrane staining observed in scattered plasma cells.  Intrafollicular 
plasmacytoid differentiation is characteristic of high grade FL (Gradowski et al. 2010). Top and right boxes show detail of 
CD38 positive cells in progressively effacing follicle centres 
 
A summary of staining results for ZFP36L1 and CD38 in FL are shown in table 5-4 
 
Table 5-4 ZFP36L1 and CD382 staining in FL 
Antibody Cells positive Staining* Comments 
Anti-ZFP36L1 Follicle centre cells 1 to 2 low/weak 
 
High background, but shows stronger signal 
in GC, consistent with Nasir et al. 2012 





cells, some outside 
the centres 
Strong staining 
observed in scattered 
plasma cells-C. 
In the follicle centre 
staining is moderate 




FL may show some plasmacytoid 
differentiation, and CD38 would detect 
plasma like cells, hence plasma cells 
outside follicle provide the strongest 
positivity for this marker 







5.4.1 Analysis of ZFP36L1 and BCL2 expression  
Results from IHC have indicated that ZFP36L1 is detected in GC cells in normal lymphoid tissue, 
and in FL it is found in follicular centre cells. In normal tissue there may be indication that ZFP36L1 
could be able to differentiate the light and dark zones within the GC. In the GC naive B cells get 
activated and start proliferating rapidly, clonal expansion of these CBs within the dark zone takes 
place and during this stage SHM occurs leading to modified antigen receptors. Differentiated into 
CCs in the light zone these cells are not as active and not proliferating; CCs are selected based on 
the binding affinity to the given antigen and the remaining cells will die by apoptosis (Klein and 
Dalla-Favera 2008). The increased proliferating rate within the dark zone may explain the darker 
stain observed for ZFP36L1, indicating a higher expression of the protein consistent with the cycling 
state of these cells. There is rapid interchange of CCs and CBs between the zones to the point of 
these cells being considered transient states of a same development step and that are very much 
indistinguishable in their morphology with much overlap in their gene expression, although they do 
have differences in action, chemokine, proliferation and DNA damage genes (Bannard et al. 2013). 
This opens a route to perhaps further study of ZFP36L1 detection in these different B cells (CBs 
and CCs) in different locations within the GC. 
 
As widely reported in the literature BCL2 is also seen in the follicle centres of FL, as opposed to 
non-malignant tissue where GC cells generally do not express the protein (fig. 5-2). In normal 
lymphoid tissue, e.g. tonsils, as depicted in figure 5-1 BCL2 is observed in cells within the mantle 
zone, no BCL2 or low levels of BCL2 expressed in isolated cells within the GC are detected: in 
normal tissue BCL2 is needed to maintain selected B cells that will move on to performing a normal 
function in immune responses, it develops its anti-apoptotic role in resting B cells of the mantle zone 
and post follicular B cells resulting in long-lived memory cells and plasma cells, but in the GC, cells 
do not have BCL2 expression and go through apoptosis unless selection for survival takes place by 
antigen specificity. 
 
The opposite scenario is seen in malignancy, as represented in figures 5-5, 5-6, 5-7 and 5-8. BCL2 
is a key marker to differentiate a neoplastic follicle from a non-malignant hyperactive one; its 
detection distinguishes follicular hyperplasia or a reactive lymph node from FL (Knowles 2001) 
(although sometimes BCL2 T cell positivity within GC may be observed, which complicates 
diagnosis, a pan T cell marker may be used in these cases (Knowles 2001)). About 80-90% of FL 
cases have a BCL2 translocation - t(14;18)(q32;q21)-, more common in  low grade FL (Bakhshi et 
al. 1985, Tsujimoto et al. 1985b). The translocation leads to over expression of the BCL2 protein 
and these FL show reduced mitotic features and a mantle cell layer definition loss. In FL without the 
translocation, BCL2 may be over expressed by other genetic aberrations (Ott and Rosenwald 2008, 
Wahlin et al. 2012). The over expression of BCL2 leads to an accumulation of B cells in the GC 
“falsely” rescued from apoptosis, on top of the BCL2 translocation their increased life span also 
means an opportunity for other genetic changes to take place that accompany the formation of FL 
(Ott and Rosenwald 2008), in fact, some argue that the mere presence of that translocation is not 
111 
 
sufficient for the development of the malignancy but other added genetics hits accompany the 
neoplasia. Other secondary chromosomal aberrations happen in FL, and the accumulations of 
these and greater complexity are features of higher grade FL (Yunis et al. 1987, Ott et al. 2002). 
One of these secondary translocation involves another oncogene: Myc, a t(8;14)/MYC (De Jong et 
al. 1988) that is usually linked to a Burkitt like appearance; in these cases diagnosis can be done by 
observing the morphology and additional detection of the BCL2 translocation (Ott and Rosenwald 
2008). 
  
The altered regulation of BCL2, and even the t(14;18)(q32;q21), is also present in other B cell 
malignancies: in about 10-40% of DLBCLs (Gascoyne et al. 1997) and even in a small number B-
CLL cases (Elyamany et al. 2014). But even if the translocation in present B-CLL may still show an 
increase in BCL2  expression (Dyer et al. 1994, Majid et al. 2008). 
 
With regard to ZFP36L1 detection, the antibody raised in rabbit had already been used in the only 
report to date showing IHC data of ZFP36L1 in lymphoid tissue (Nasir et al. 2012). Nasir et al. 2012 
reported that they mainly found the protein within cells of the GC in normal lymphoid tissue. The 
results of n=3 non-malignant sections reported in this chapter are consistent with their findings as 
besides a high background a structural delineation of the GC with signs of an increased signal from 
within their cells was observed (fig. 5-1). In the FL cases stained for ZFP36L1 it was seen that the 
protein continued to be detected in the follicle centres, now neoplastic GCs, its expression was, 
therefore, concurrent with that of BCL2.  
 
The results of ZFP36L1 detection in FL within the follicle centre would not necessarily oppose the 
hypothesis of ZFP36L1 as a negative regulator of BCL2 expression. One possibility is that ZFP36L1 
expression has not changed- or not changed compared to the increase in BCL2 expression- but 
certainly BCL2 levels have increased abnormally be it because of the presence of that translocation 
that  leads to the juxtaposition of BCL2 gene  with enhancer sequences of the IgH gene promoter 
region, or by other mechanisms in the small number of FL cases without that translocations, but 
where the over expression is at equivalent level to cases with the cytogenetic abnormality (Pezzella 
et al. 1990b). The result is an augmented, out of control over production of BCL2 in cells where no 
change in ZFP36L1 expression has occurred, therefore a normally expressed protein (ZFP36L1) – 
or perhaps even a down regulated or mutated non-functional ZFP36L1- would not be able to down 
regulate the abnormally produced BCL2 at least not to the same level that would be seen in normal 
cells, especially if other pathways that may interact and assist ZFP36L1 in the targeting and down 
regulation of BCL2 may also be altered.  This possibility is only a hypothesis to explain the results 
obtained in FL and would need of course further research, starting from ensuring that ZFP36L1 
itself is or is not abnormally produced in FL. There are reports that indicate that in some cancers the 
level of ZFP36L1 is down regulated or even mutated (Davies et al. 2003, Chapman et al. 2011). In 
general other tests could be done to improve and further investigate the findings reported here such 
as enhanced IHC with a purified antibody for ZFP36L1, comparing mRNA levels of normal and 




FL can present itself in a range of forms, from low grade to high grade, its presentation can be 
morphologically different; as seen, structurally, the neoplasia can show complete effacing of follicle 
centre structure or misshaped follicles but where centres can be clearly seen. Partial involvement of 
FL (fig. 5-7) may show only some neoplastic follicles and others with normal phenotype; in fact the 
partial nodal involvement by a FL can be missed if neoplastic follicles constitute a smaller proportion 
of all follicles. As represented in figure 5-7 (Fletcher 2007), it is possible to see BCL2 expression 
within the follicle centres in a varying degree within the same case of FL. It would have been 
interesting to stain one case of partial involvement of FL for ZFP36L1 to observe if those centres 
lacking, or with small number, of BCL2 expressing cells also showed staining for ZFP36L1 and to 
what level. 
 
Having discussed the above, based on the differential staining pattern for each antibody, there are 
indications in the results from this set of analyses to support the hypothesis of ZFP36L1 targeting 
the pro-survival BCL2 mRNA. BCL2 in normal GC would not be detected within the GC since B 
cells there are going through apoptosis unless rescued by a survival signal after SHM and affinity 
maturation. After this rescue, BCL2 expression would prime the selected cells for survival so they 
can carry out their immune effector functions. If ZFP36L1 negatively regulated BCL2, it is 
reasonable to deduce that both proteins would not be highly expressed together in the same cells at 
the same time unless some normal regulatory mechanism has gone wrong as it happens in the 
development of FL.  
 
The IHC evidence gained in the experiments and discussed in this chapter provides further 
information on the relationship between ZFP36L1 and BCL2 closer to in vivo expectations. These 
IHC results, especially in the case of non-malignant  tissue, showing  ZFP36L1 expressed in GCs 
where BCL2 is very lowly/not  expressed, must be considered alongside the luciferase assay results 
discussed in chapter 3 which showed the interaction of the ZFP36 proteins, specially ZFP36L1 with 
the BCL2 3’UTR ARE. In addition, further evidence from RNA electrophoretic mobility shift assays, 
provided in Zekavati et al. 2014 and also the evidence recently published on the role of the ARE in 
the regulation of BCL2 from in vivo studies (Díaz-Muñoz et al. 2015)  must also be taken into 
account. Taken together, accumulating evidence strengthen a working model that is consistent with 
ZFP36L1 targeting BCL2 mRNA in vivo. 
 
5.4.2  Analysis of expression of ZFP36L1 and CD38  
The GC is a complex formation with diverse cell populations; the expression patterns of cell 
markers, as in this case CD38, is connected to the diversity and the biology of the B cells in the 
follicles. GC formation is the result of antigenic stimulation of B cells; B cells cycle through the GC, 
and a small percentage survive to become plasma cells or memory B cells. Naive B cells residing in 
primary follicles start proliferating after stimulation forming GCs; within the GC a light zone 
populated with CCs, and a dark zone, populated with CBs that are highly proliferative and may 
undergo SHM, can be observed. These two zones are not distinguishable in neoplasms. Around the 
dark/light zones naive resting B cells that are not proliferating are pushed outwards and form the 
mantle area (may be considered an extension of the primary follicle). Once selection and maturation 
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of CB has happened the B cells leave the GC as plasma or memory cells. And thus, peripheral B 
cells can be divided into into naive, GC, memory, and plasma cell populations and in consequence 
a number of subpopulations of B cells can be found in, and, around a GC with different phenotypes 
determined, or rather, explained by the biology of the GC; in the case of CD38 the marker is 
reportedly expressed by GC B cells, plasma cells (and immature B, pre-B cells). Mantle zone, naive 
B cells are recognised as IgD+IgM+CD38− /resting small B cells; the GC starts with the clonal 
expansion of a few antigen-specific founder B cells, these are IgD+IgM+CD38+ (and low levels of 
BCL2); GC cells are IgD−CD38+ CBs and CCs; plasmablasts (IgD−CD38++ ), these are early plasma 
cells that will leave the secondary lymphoid organ and migrate to the bone marrow or inflamed 
tissues and memory cells  are IgD−CD38low  (Lebecque et al. 1997). 
 
Considering the above, overall, CD38 detection results observed in figures 5- 10 are the expected 
results for B cells in GCs: positive for a number of cells within the GC with weak/moderate staining, 
CD38 positivity is stronger and in increased number of cells outside the GC, in plasma cells, or 
rather plasmablasts. Plasmablasts have transformed from naive mature B cells into a GC B cell and 
finally into a terminally differentiated B cell. The weak staining cells in the GC may be those that 
after, antigen capture via BCR-and Th interaction, have the B cells phenotype IgD+ and low/no 
CD38 which further develop into IgD− and CD38+ GC founder B cells (Pascual et al. 1994). 
 
As seen also in figure 5-9 CD38 positivity was strongest outside the GC cells and the mantle zone; 
the literature reports widely that although within the B cell follicles, CD38 is present on GC B 
cells, and not expressed by mantle  B lymphocytes, committed plasma cells express higher levels of 
CD38 in the GC, in fact it is reported as the strongest positivity in the B cell compartment (Mehta et 
al. 1996, Funaro et al. 1997, Oliver et al. 1997, Funaro and Malavasi 1998, Mehta and Malavasi 
2000, Malavasi et al. 2008).   
 
The CD38 pattern of expression is useful in delineating B cell subsets and in understanding the 
signalling events involved in the development of these B cells (Oliver et al. 1997) but previous 
studies had defined tonsil B cell subsets by their expression of IgD and CD38 as “ yes or no” 
category  (Berek et al. 1991) (Choi 1997), however, the CD38 positive cells have also clear 
differences in CD38  expression levels that allow for other sub-classifications; other studies extend  
the “yes/no” classification  by demonstrating that CD38+ tonsillar B cells can be divided into novel 
populations of CD38low and CD38intermediate cells by flow cytometry (Grammer et al. 1999), and 
therefore showing a lower level of staining within the GC cells compared to those outside. This is 
demonstrated in figure 5-9 consistent with the grading in CD38 expression which is probably 
highest in terminally differentiated plasma cells. Further studies showed that plasma cell 
differentiation can be dissected in distinct, developmental stages of CD38 low and CD38 high 
positive cells, including a CD38 low plasma cell precursor population present in tonsillar GCs (Arce 
et al. 2004). This supports the idea that IgG expressing cells upregulate CD38 as time passes and 
cells grow/differentiate, but that initial IgG producing cells express no or low CD38. Tissue sections 
in their study provided a similar result to the result shown in this chapter; cells containing high 
quantities of IgG in their membrane and expressing only little CD38 are located in tonsillar follicles. 
114 
 
In contrast, CD38 high IgG-containing plasma cells are mainly present outside the follicular areas. 
The group established that during their course of differentiation, CD38 low plasma cell precursors 
possibly leave the follicles and increase the expression of CD38, also supported by other studies 
(Fairfax et al. 2008, Oracki et al. 2010). 
 
So, overall, CD38 expression is detected in cells within the GC, but at weak/moderate level and 
number and is highly expressed, or highest expressed in plasma cells outside the GC and mantle 
zone. The highest CD38 surface density among human cells is found in pathological terminally 
differentiated plasma cells and their healthy version (Malavasi et al. 2008) which is also seen in 
figure 5-11. 
 
When compared to the detection of ZFP36L1 (fig.5-1 and 5-2, left), it is seen that, besides the 
background and the difficulty in assessing cell staining, it would seem that ZFP36L1 protein is 
mainly detected within the GC cells, here it would coincide with some cells expressing CD38 but 
further comments on this cannot be done due to the quality of the staining; what seems fair to 
conclude is that where CD38 expression is highest expressed ZFP36L1 is lowest/not detected: 
outside the mantle, within interfollicular space by plasmablasts (fig. 5-9 and 5-10) and that also the 
opposite is  true, where ZFP36L1 is highest detected (in GC, fig. 5-1) CD38 is lowest. This would 
actually be consistent with evidence of other ZFP36L1 mRNA targets associated with plasma cells. 
Previous chapters and specially chapter 4 have already discussed the evidence of ZFP36L1 
targeting BLIMP1 as reported by Nasit et al. 2012 (Nasir et al. 2012). Suffice to highlight in this 
chapter that BLIMP1 is a protein strongly linked to inducing plasmacytoid differentiation (Shaffer et 
al. 2002). The regulator/target relationship between ZFP36L1 and BLIMP1 shown in Nasir et al. 
2012 would suggest that in plasma cells, BLIMP1 (and CD38) would be detected but ZFP36L1, as 
their negative regulatory protein, would not be present or it will be present at low levels. Evidence 
on early plasma cell commitment within the GC, shows CD38 positive cells/ IgG early secreting 
cells are committed to plasma cell differentiation in accord with the observation of BLIMP1 being 
expressed in about of 4–15% of GC B cells (Arce et al. 2004). In fact, and perhaps not surprisingly, 
BLIMP1 revealed a similar staining pattern to that of CD38 with some positive staining within GC 
cells and most staining in number and intensity in cells outside the GC near the epithelium (Arce et 
al. 2004). In tonsils, BLIMP1 protein is strongly expressed by plasma cells present in GCs, although 
staining is scattered, and is also seen in sub epithelial areas (Garcia et al. 2006). It is worth 
commenting that in B cell lines blots (fig. 6-1, chapter 6) ZFP36L1 was not detected in mature, 
plasma cells of MM further supporting the hypothesis that this protein is not expressed or very lowly 
expressed in plasma cells. Other regulators of differentiation are also found in GC and have a link to 
ZFP36L1. Certain cytokines are found in GCs that function to modulate cell differentiation, growth 
and signalling. A number of cytokines, already reported as mRNA targets for ZFP36L1, were 
detected outside the GC cells or reported as very lowly expressed within GC cells. These include 
GMCSF which is only produced by mantle zone cells and not within the GC cells (Pistoia and 
Corcione 1995),  TNFα, IL-6 or IL-10, IL2, are synthesized by both B cells in the GC and mantle 
zone, but at different levels with low/no detection within the GC cells (Butch et al. 1993, Toellner et 
al. 1995, Lisignoli et al. 1998). Another reported mRNA target for ZFP36L1, cIAP2 is detected in 
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plasma cells in reactive lymph nodes and bone marrow plasma cells (Jourdan et al. 2009), whereas 
in FL its expression is observed in most cases (Akyurek et al. 2006).   
 
Whilst CD38 was detected in plasma cells and in the GC cells, in the case of FL, the phenotype 
only partially seemed to resemble its non-malignant counterpart. CD38 was found in the neoplastic 
follicle centres (fig. 5- 11), The staining in cells within the neoplastic centres indicated a denser 
population of cells expressing CD38 compared to a normal non-malignant GCs, this indicate a 
higher concentration of CD38 expressing cells. CD38 is not a marker for FL as BCL2 is, and its 
expression is rarely studied but some authors have suggested its analysis can distinguish between 
follicular hyperplasia and FL (Mantei and Wood 2009) by determining the positivity and abundance 
of CD38 cells in the malignant follicle.  
 
The results observed in figure 5-11 are consistent with the results shown in one of the few reports 
found demonstrating CD38 expressed by the neoplastic follicles in all cases studied and it was 
down regulated in the interfollicular B-cell component in the vast majority of cases (Dogan et al. 
1998).  The results reported in this chapter are consistent with this description, and overall are 
markedly opposed to the phenotype found in normal tonsil tissue, where the highest CD38 detection 
is found in the interfollicular regions, outside the GC and mantle zone (fig. 5-9). 
 
An important point must be highlighted, the phenotype of cells described against their location in FL 
cases is difficult to assess, since the various morphologies that it can present may impact the 
description of where in the tissue cells are found. In low grade FL GCs may be completely effaced 
and sheets of neoplastic cells can replace the non-malignant structure in the follicle, there are cases 
with partial involvement of FL,  and also abnormal GC structures These are only examples of the 
morphological variety that may be found and hence, the results from the present study could be 
extended by analysing a more extensive number of cases for each grade of FL. 
 
5.5  Conclusions 
 
IHC analysis of non-malignant lymphoid tissue has shown that the presence of BCL2 and ZFP36L1 
is in different locations, ZFP36L1 mainly in GC, BCL2 in mantle zone and interfollicular areas. For 
CD38, its expression is dectected in GC cells but not as high as in cells outside the GC, where the 
highest staining is observed in most likely plasma cells. 
 
For BCL2 and CD38 there is a bulk of literature confirming these findings, but this is the first time 
that ZFP36L1 expression has been analysed so extensively in normal lymphoid tissue and also in 
malignant sections (other than results reported by Nasir et al. 2012 on normal tonsil sections, in the 
supplemetray information of their paper). 
 
BCL2 is an anti-apoptotic protein that would not be detected in the majority of GCs cells which 
undergo apoptosis if not clonally selected; CD38 is highest expressed in plasma cells largely 




For the purpose of this research, the relationship between BCL2 and ZFP36L1 seems 
straightforward since in non-malignant tissue results show that where one protein is found the other 
is not, or at most that in cells where the highest expression of one is detected the other protein does 
not provide a signal. This inverse relationship would support the hypothesis of a negative regulatory 
role of ZFP36L1 on BCL2 expression. 
. 
For CD38, the literature reports GC cells as positive, however, the level of positivity varies, within 
different sub-populations of GC B cells, which would be consistent with findings reflected in figure 5- 
9 and table 5-4. The data shows the detection of CD38 within the GC at a lower level of intensity to 
that of cells outside the GC (likely plasma/plasmablasts that have left the GC). The existing 
literature shows a grading in the expression level of CD38 in lymphoid cells positive for this marker 
and confirms that the highest expression is seen in plasma cells and not the GC (Grammer et al. 
1999, Arce et al. 2004). All these considerations would not contradict the idea of a negative 
regulatory role of ZFP36L1 on CD38, however, further investigations should be made to elucidate 
the relationship between ZFP36L1 and CD38 expression. Particularly helpful, would be a single cell 
analysis examining individual cells within lymphoid tissue for their expression of both these proteins. 
 
ZFP36L1 detection within GC cells is consistent with a role for the protein as a negative regulator of 
its two proposed mRNA targets studied in this chapter, BCL2 and CD38. The ZFP36L1 protein has 
been reported to be a key regulator of differentiation (Vignudelli et al. 2010, Nasir et al. 2012) and 
differentiation is a key feature within the GC, as GC B cells develop into plasma B cells or memory 
cells.  As seen, the expression of other reported ZFP36L1 targets that modulate differentiation, 
growth and siganlling -BLIMP1 (Nasir et al. 2012), GMCSF (Pistoia and Corcione 1995)TNFα, 
interleukin 6 (IL-6) or IL-10, IL2(Butch et al. 1993, Toellner et al. 1995, Lisignoli et al. 1998)  
cIAP2(Jourdan et al. 2009, Akyurek et al. 2006)- may well also be found in highest levels in cells 
where ZFP36L1 expression is lowest although this was not further investigated in the present study 
and remains to be determined.  
 
It is worth mentioning that some of the positive cells detected by the antibodies used could be from 
T cells producing the target epitope proteins. In this regard, GCs primarily consist of B cells along 
with a small number of T cells (5 to 10%) and follicular dendritic cells (FDC) (< or = 1%) (Butch et al. 
1993). 
 
Finally, the results shown in this chapter for BCL2 and CD38 expression in relation to ZFP36L1 
expression in lymphoid tissue, must also be taken into account alongside the luciferase assay 
results described in chapter 3 and 4, that provided evidence of a direct interaction and functional 
interaction of ZFP36L1 protein with BCL2 and CD38 mRNA 3’UTRs leading to their degradation. 




















“Analysis of ZFP36 family protein, BCL2 and CD38 protein expression in B cell lines and 

























This chapter focuses on the analysis of ZFP36 proteins expessed in different B cell populations. It 
aimed at identifying how the ZFP36 proteins were expressed in cell lines representing B cell stages 
and in primary cells of B-CLL origin. The analysis of protein expression was done by Western blot. 
In some blots levels of expression of BCL2 were also analysed in order to assess the relationship 
between ZFP36L1 and BCL2. CD38 expression were also measured in a smaller sample of B-CLL 
cells.  
6.2  Western blot analysis of ZFP36L1 protein expression in different B cell lines  
 
6.2.1 Cell lines representing different stages of B cell development  
SDS PAGE and Western blot analysis were performed on lysates from different B cell lines 
representing various stages of B cell development. Antibodies for ZFP36L1/ ZFP36L2 and BCL2 
were used to detect protein expression. Bands were seen for ZFP36L2 and BCL2 but no bands 
were detected for ZFP36L1 (fig. 6- 1). ZFP36L2 showed different levels of expression amongst the 
B cell lines; all myeloma cell lines showed bands for ZFP36L2 except in the case of MM1S. At 
increased exposure MM1S presented only a faint band for the protein (fig. 6-1C). The expression 
levels were observed to be diverse amongst the ZFP36L2 expressing cells. Of the two lymphoma 
cell lines analysed, Ramos showed a ZFP36L2 band at different exposure levels, but in the 
Namalwa cells a band was only seen after increased exposure indicating low level expression. The 
same pattern was seen with pre-B-cell cell line Nalm 6 where a ZFP36L2 band was observed after 
increasing exposure time. BCL2 bands were clearly detected in all the cell lines tested, however the 
strength of the bands was slightly variable indicating that for BCL2, expression levels were 
generally low and showed some heterogeneity. Table 6-1 shows a summary of Western blot protein 



























Figure 6-1 Western blot analysis of ZFP36L1 and ZFP36L2 expression  
Western blot analysis of ZFP36L1 (40KDa) and ZFP36L2 (60KDa) and BCL2 (26KDa) in various cell lines representing 
different B cell development stages. BCL2 and ZFP36L2 were detected with anti-BCL2 and anti-ZFP36L1/2 antibodies, 
bands were seen for ZFP36L2 and BCL2, No signal was detected in any blot for ZFP36L1. ZFP36L2 and BCL2 showed 
heterogeneity in their expression patterns and levels. Loading control was carried out by probing with anti- Actin antibody 




6.3  Western blot analysis of ZFP36 protein family expression and BCL2 expression in 
primary B-Chronic Lymphocytic Leukaemia cells 
 
Western blot analysis of ZFP36L1 expression in B-CLL cell populations indicated mostly low levels 
of ZFP36L1 (40kD) expression but there was some heterogeneity in levels of ZFP36L1 expression 
in different B-CLL populations (fig. 6-2). In contrast, the higher molecular weight protein ZFP36L2 
(60kD) was not at all or barely expressed (fig. 6-2). BCL2 expression was also detected for the 
same samples, its expression was heterogeneous with different levels of BCL2 expression in the 
various B-CLL populations. Anti-ZFP36 antibody was also used to analyse expression of ZFP36 in 
B-CLL cells and homogeneous bands were present in all the samples tested (fig. 6-2). Table 6-2 
shows bands detected and expression levels for ZFP36L1/L2 and BCL2 in the different B-CLL 
tested. 















Figure 6-2 Western blot analysis of ZFP36, ZFP36L1, ZFP36L2 and BCL2 expression in B-CLL cells.  
A.B.C Show Western blots resulsts for ZFP36L1 and ZFP36L2 alongside BCL2. D. Shows different B-CLL cells probed for 
ZFP36L1 and ZFP36L2; the same cells, and 2 other populations are shown in another blot probed for ZFP36 and BCL2 in 
figure E.  F Shows membranes probed with anti-ZFP36L1/ZFP36L2, anti-BCL2 and anti-ZFP36. Results showed 
heterogeneity in the expression of the proteins, especially for ZFP36L1.  ZFP36 was expressed at low to medium levels in 
the different B-CLL populations. ZFP36 was observed to be the only ZFP36 family member to be expressed homogeneously 
in all B-CLL populations. An antibody able to detect both proteins, ZFP36L1 and ZFP36L2 was used. Anti-HSP90 antibody 





Table 6-1  A summary record of relative levels of expression of different proteins in different cell lines 
Cells ZFP36L2  ZFP36L1  BCL2  
Nalm 6,  
pre-B cell 
* 0 * 
Ramos, 
lymphoma 
** 0 ** 
Namalwa, 
lymphoma 
* 0 * 
JJN3, myeloma *** 0 ** 
MM1S, 
myeloma 
* 0 * 
RPMI8226, 
myeloma 
*** 0 * 
KMS28, 
myeloma 
** 0 * 
KMS27, 
myeloma 







Table 6-2  A summary record of relative levels of expression of different proteins in different B-CLL populations. 
B-CLL 
population ZFP36L1 ZFP36L2 BCL2 ZFP36 
CLL1/5/11 *** 0/* ** ** 
CLL2 ** * **  ND 
CLL3 0 0 **  ND 
CLL4/14 * 0/* ** ** 
CLL6 0 0/* * ND  
CLL7 0 0/* * ND  
CLL8 * 0/* * ND  
CLL9/12 0 0/* * ** 
CLL10 **/*** 0 *** ** 
CLL13 ** 0 * ** 
CLL15 */** 0 ** ** 
CLL16 ** 0 *** ** 
CLL17 *** 0 ** ** 
CLL18 ** 0 * ** 
 
0 = Band not detected 
* = Faint band/Low expression 
** = Medium band/ Medium expression 






population ZFP36L1 ZFP36L2 BCL2 ZFP36 
CLL19 * 0 ** ** 
CLL20 */** 0 ** ** 
CLL21 0 0 * ** 
CLL22 **/*** 0 * ** 
CLL23 ** * ** ND 
CLL24 0 0 ** ND 
CLL25 * O ** ND 
CLL26 * * * ND 
CLL27 ** 0 ** ND 
CLL28 ** 0 * ND 
CLL29 * * * ND 
CLL30 *** * * ND 





6.4. Western blot analysis of ZFP36L1 and CD38 expression in B cell chronic lymphocytic 
leukemia cells 
 
B-CLL cells were used to analyse the expression pattern of CD38. The total number of B-CLL 
populations used was smaller than those used to study ZFP36 proteins and BCL2, this was due to 
the reducing umber of samples available in the last 18 months and the lack of time at the end of the 
project. Here a Western blot is shown for different B-CLL cells populations demonstrating that the 
pattern of expression of CD38 in these primary cells does not seem to directly correlate with the 
expression of ZFP36L1, a similar result to that seen in the analysis of BCL2 expression in relation to 
ZFP36L1. 
 
0 = Band not detected  ND=Not done 
* = Faint band/Low expression 
** = Medium band/ Medium expression 





Figure 6- 3 Western blot analysis of CD38, ZFP36L1, ZFP36L2 and BCL2 expression in different B-CLL populations.  
Results indicate a heterogeneous expression pattern amongst the different B-CLL populations, analysis of ZFP36L1 
expression indicated that high expression levels of the protein correlated with different expression levels of CD38 or even no 
expression (CLL30, CLL28, CLL27). In samples where no ZFP36L1 was detected or was detected at low levels, CD38 
expression also varied (CLL23, CLL15/2 and CLL26, CLL25). These results are similar to those observed after the analysis 
of BCL2 expression in relation to ZFP36L1 in previous sections, figures 6-1 and 6-2. 
 
The number of samples used in these blots was very small, just eight BCLL cells populations were 
tested , and this is one limitation that must be considered in this analysis, a larger set of samples 
could be tested to further confirm the results observed in the Western blot shown in figure 6-3 
These results are consistent with the pattern of expression  found during the analysis of BCL2 
expression in relation to ZFP36L1, that a number of samples with similar expressions levels of 
ZFP36L1 showed  varying degrees of CD38 expression.  Clinical data available for the patients 
samples was not complete, but some extra information was gathered by flow 
cytometry/immunofluorescence analysis of CD38 performed by Nadeeka Rajakaruna (PhD student 
at the University of Westminster ) who has kindly agreed referring to her data in this thesis. Flow 
cytometry analysis of CLL30 indicated mean fluorescence intensity of CD38 at 98.78% 
corresponding to the largest CD38 band in figure 6-3. The other samples analysed in the blot show 
different expression levels for CD38 alongside a heterogeneous expression pattern of ZFP36L1 in 
the same samples; CLL30 and CLL28 are positive for ZFP36L1 and CD38 but the level of CD38 is 
different between the two populations of cells whereas CLL27 has a high level of ZFP36L1 but not 
detectable levels of CD38. The remaining samples still have detectable levels of CD38 but low/no 




In summary, analysis of ZFP36L1/ZFP36L2 and CD38 expression revealed heterogeneity in the 
pattern of expression of the proteins. Samples with no or low ZFP36L1 showed positivity for CD38 
at low to high levels or even no positivity at all. This pattern of expression seems similar to what 
was observed for BCL2, where no direct relationship is observed-inverse or proportional- between 
ZFP36L1 and CD38 expression in B-CLL cells.  
6.5 Clinical data 
An attempt was made to analyse clinical data provided for each B-CLL sample in order to assess if 
the ZFP36 family protein expression pattern observed related to clinical features that could explain 
the results obtained. The clinical data available included information on: cytogenetics, IgHV 
mutation, CD38 positivity but for any given sample not all this information was completed so a 
complete analysis was not possible. 
 
Table 6-3: Western blot analysis summary  data from all proteins  analysed and comparison with clinical data 
obtained for all B-CLL samples: 
B-CLL 
population ZFP36L1 ZFP36L2 BCL2 ZFP36 CD38 IgHV Zap70 CD38 Cytogenetics YD 
CD38 
pos %  
CLL1/5/11 *** 0/* ** **   unm   pos   2003 nm 
CLL2 ** * **   **       11q     
CLL3 0 0 **     unm       2011   
CLL4/14 * 0/* ** **               
CLL6 0 0/* *                 
CLL7 0 0/* *     mut     13q 1999 20.1 
CLL8 * 0/* *         neg   2001   
CLL9/12 0 0/* * **         17q   7.7 
CLL10 **/*** 0 *** **         17q   6.36 
CLL13 ** 0 * **         Yes(1and2) 1998   
CLL15 */** 0 ** **   unm   neg   2007 95.8X 
CLL16 ** 0 *** **   unm   pos   2005   
CLL17 *** 0 ** **   mut pos pos   2007   
CLL18 ** 0 * **   mut   neg   2004 22.4 
CLL19 * 0 ** **               
CLL20 */** 0 ** **         17p 13q 2012   
CLL21 0 0 * **   unm   pos gain 12 2011   
CLL22 **/*** 0 * **         13q 2011 nm 
CLL23 ** * **   *           36.65 
CLL24 0 0 **   0 mut   neg     nm 
CLL25 * o/* **   **             
CLL26 * * *   *           47.28 
CLL27 ** 0 **   0           4.25 
CLL28 ** 0 *   ** mut   neg 13q   97.06X 
CLL29 * * *             2009 9.39 
CLL30 *** */** *   ***           98.78 
CLL31 ** 0 ** **           1996 86.6 
0= no detection or very faint band detected; Blank spaces: no info provided, or no tests done ; YD=Year diagnosis  
Boxes blue: Blot results; Boxes green: clinical data provided by UCLH London hemato-oncology clinic  Boxes pink: CD38 % 
of cells positive lab measured, % data measured by University of Westminster PhD student  Nadeeka Rajakaruna nm=not 
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measured, no % given. The two samples marked with an X are queried samples, the clinical data says these are negative for 
CD38 but the data provided by immunofluorescence analysis performed by Nadeeka Rajakaruna) gave a large positive, this 
may be due to measuring CD38 at a different time, it is know that CD38 positivity may varied throughout the disease course. 
 
Further analysis of clinical data and protein expression results could not be pursued due  to 
incomplete information.  Data on percentage of positive cells for CD38 produced by Nadeeka 
Rajakaruna was requested in the hope that this could provide some more information but this 
attempt was also unsuccessful as data was available only for a small number of samples, however 
it was noticed that data from Western blots and flow cytometry analysis were highly consistent for 
those samples that were tested for CD38 expression by these methods.  
The seemingly contradiction between clinical data stating CD38 negative status for CLL28 may be 
explained by a number of factors. For clinical diagnostic purposes, CD38 positivity is set at 20-30% 
of positive cells within a clone, so a negative sample may still express CD38 that could be detected 
by Western blot analysis, especially with lysates produced from a high concentration of cells. Also, 
samples with a low % of positivity are demonstrated to show CD38 expression in figure 6-3, such as 
CLL23.  Finally, flow cytometry data indicated that CLL28 CD38 positivity was 97.06% but clinical 
data classed the patient as negative, besides human error, a clinical explanation may clarify this; 
the levels of CD38 can vary throughout the course of B-CLL within a given patient (Malavasi et al. 
2008) and the clinical data may state the negative status of the first clinical test when the patient 
attended the clinic (flow cytometry analysis performed at the University of Westminster was done 
immediately after receiving the samples every week). 
Overall, an heterogeneous expression can be determined for CD38 in different B-CLL populations 
that has not direct or inverse relationship with ZFP36L1 expression, as seen by the blot data (fig. 6-
3) and by the percentage of CD38 positive cells data (table 6-3). Some samples with a small 
percentage of cells positive for CD38 seemed to have also low expression levels of the other 
proteins analysed (CLL7, CLL29), other low percentage CD38 positive samples showed medium 
expression levels of the ZFP36L1 (CLL18 and CLL10). Without a more complete clinical data the 
analysis could not be pursued further. 
 
6.6  Discussion 
 
This study has looked at the presence of ZFP36L1 and its role regarding one of its putative targets, 
BCL2 mRNA ARE. The BCL2 gene codes for BCL2, a known oncogenic protein with regulatory 
functions in promoting cell survival and preventing programmed cell death, apoptosis. Dysregulation 
of this gene is associated with B-CLL and other cancerous processes (Thomadaki and Scorilas, 
2006). 
 
The expression of the ZFP36 protein family in cell lines representing different B cell development 
stages showed that ZFP36L1 was low/not detected and ZFP36L2 was expressed at higher levels 
although at different levels in different cell lines. Results showed heterogeneous patterns and levels 
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of expression of ZFP36L2 and BCL2. Nasir 2012 and Nasir et al. 2012 looked at ZFP36L1 mRNA 
levels in cell lines representing different B cell stages, similarly to table 6.1 they used cell lines 
representing pre-B cells to plasma cells. QRTPCR showed that ZFP36L1 mRNA levels were higher 
in early B cell stages and generally lower in mature and plasma cell stages, myeloma cells had 
lower (JJN3) or no levels (MM1S) detected. Western blot analysis results in table 6-1 did not detect 
bands for the ZFP36L1 protein in any of the lines including Ramos, a cell line used by Nasir et al. 
2012 that resulted in the highest levels of ZFP36L1 mRNA. The discrepancy in results could be due 
to further modification at mRNA level that may lead to handicapping ZFP36L1 protein viability but is 
possibly due to the different sensitivities of the assays and further protein expression level analysis 
should be done. Absence of ZFP36L1 in the later stages of B cell development, but its expression in 
early, non differentiated B cells suggests down regulation of the protein once differentiation signal 
have been received. ZFP36L2 was detected in varying levels within cell lines representing the same 
developmental stages but although further analysing would be needed, the summary table could 
indicate that ZFP36L2 levels are lower at early stages of B cell development and generally increase 
in mature B cells. To confirm this affirmation further blots should be performed and QRTPCR 
assessment carried out for ZFP36L2 levels. However it may be possible that the expression levels 
of ZFP36L2  in differnet cells lines representing the same stage of B cell development is variable 
since the clones may differ in their genetic/clinical profile, for multiple myeloma the heterogeneity is 
widely reported (Bianchi and M Ghobrial 2014, de Mel et al. 2014, Bianchi and Munshi 2015), just 
as it happens with B-CLL cases.  Also as Nasir et al. 2012 have shown for BLIMP1 and ZFP36L1, it 
may be possible for ZFP36L2 that varying levels of the protein in different B cell stages are 
explained by the regulatory function of the protein on targets with a key role in B cell maturation or 
differentiation. Cells lines are useful tools for research but they may not represent the original 
tumours profiles due to continued culture, passaging and accumulated mutations; it would be useful 
to perform the analysis of ZFP36 proteins in primary B cell representing different B cell development 
stages.  
 
In B-CLL cells expression of ZFP36L2 was not observed or faintly detected, and expression of 
ZFP36L1 was detected in a heterogeneous pattern with different levels of ZFP36L1 found in 
different B-CLL cells populations. Analysis of ZFP36 expression showed bands in all B-CLL cells 
populations with more homogeneity in its expression levels amongst the B-CLL cells populations 
compared to ZFP36L1. Some heterogeneity in expression levels was also detected for BCL2 in the 
B-CLL cells and although in some B-CLL cell populations an inverse relationship in the expression 
levels of ZFP36L1 and BCL2 was apparent; this was not a consistent finding overall in the different 
B-CLL populations studied. ZFP36 was found expressed at low/medium level in all B-CLL its pattern 
of expression was very homogeneous across all B-CLL populations. 
 
Analysis of CD38 revealed similar results to those of the ZFP36 proteins and BCL2 expression 
analysis, different levels of CD38 were detected in different B-CLL samples, and within these 
samples levels of ZFP6L1 varied. Samples with high levels of expression of ZFP36L1 could have 





The characteristic heterogeneity of B-CLL could account for the different levels of ZFP36L1 found in 
different B-CLL populations. Clinical data was looked at to assess if there are clinical features 
shared amongst patients that relate to results obtained from protein expression analysis and may 
provide further information on ZFP36L1 expression levels in the different B-CLL cells populations. 
This study was attempted but the clinical data provided for the B-CLL samples (table 6-3) proved 
insufficient to draw any conclusion.  
 
In summary, no clear inverse relationship is seen between levels of expression of BCL2 or CD38 
and ZFP36L1 protein.  
 
Further experiments could be done such as QRTPCR to compare mRNA levels of ZFP36, 
ZFP36L1, ZFP36L2 and BCL2 in different B-CLL cell populations. One area that could be looked at 
is miRNAs in B-CLL cells. Micro RNAs signatures not only distinguish normal B cells from malignant 
B-CLL cells, their profile also gives information on the indolence of the disease, patients with high 
miR21 and miR15 have a higher risk of death compared to those with low expression; miR181b 
detection serves as a time to treatments predictor, and non-responders to treatment also offer a 
specific miRNA profile, expression of miR148a, miR122, miR21 (Balatti et al. 2015). Of the 
microRNAs that are involved in B-CLL two are connected with the ZFP36 proteins. miR15a  and 
miR16-1, and both of these  are frequently deleted or down regulated in B-CLL cells with 13q14 
deletions (Calin et al. 2002). Cimmino et al. 2005 revealed a role for the miR15/16 family negatively 
regulating BCL2 expression and promoting B-CLL cell apoptosis and also provided evidence of the 
miRNAs targeting BCL2 mRNA by binding of its 3’ UTR. About 60% of B-CLL cases showed 
evidence of an inverse correlation between these miRNAs levels and BCL2 level of expression 
(Cimmino et al. 2005).  Alterations in miRNAs in B-CLL cells, with regard to miR-15a and miR-16-
1 deletions, contribute to malignant transformation by up-regulating BCL2. In addition, there is 
evidence of cooperation between microRNAs and the ZFP36 proteins in degradation of mRNAs, as 
reported for miR16 and ZFP36 where the destabilising effect of ZFP36 on TNFα mRNA was not 
observed if miR16 was absent (Jing et al. 2005).  All this makes for an interesting research question 
directed at analysing the profile of expression of the ZFP36 proteins and selected microRNAs, 
specifically mirR16 and 15a in B-CLL, the analysis could be done using different experimental 


















































7.1 General Discussion 
This chapter will start by summarising the results discussed in this thesis aiming to bring them 
together to a final general conclusion. 
 
This thesis has investigated two putative mRNA targets chosen for their relevance in B cell biology, 
specifically B cell malignancies. The results have extended and further strengthen the findings  
investigating the putative targets identified by in silico ARACNe analysis (Nasir et al. 2012, Zekavati 
et al. 2014). The previous chapters have described the experiments done to investigate BCL2 
mRNA and CD38 mRNA as possible targets for ZFP36L1 and have also shown experimental data 
for ZFP3L2 and ZFP36. The project has also measured the expression of ZFP36 family proteins in 
primary cells B-CLL cells and in B cell lines representing different developmental B cell stages.  
 
The role of ZFP36L1 in promoting cell apoptosis has been reported by several groups (Ning et al. 
1996, Johnson and Blackwell 2002, Baou et al. 2009b), a possible route by which this pro-apoptotic 
function may function might be the regulation of key pro-survival proteins like those of the BCL2 
family. The prototype, BCL2, has an ARE in its mRNA which has been highlighted as a possible 
target for the proteins (Zekavati et al. 2014). A role for ZFP36L1 in negative regulation of B 
plasmacytoid differentiation by targeting of the BLIMP1 mRNA was also previously reported (Nasir 
et al. 2012). 
 
This project has provided evidence that the three ZFP36 proteins interact with the 3’ UTR ARE of 
BCL2 mRNA. For ZFP36L1 a mutant version, with an amino acid change in the zinc finger domain, 
did not lead to the degradation of the 3’ UTR ARE of BCL2 mRNA. The ZF mutant form of ZFP36L1 
therefore served as a negative control in the 3’UTR luciferase reporter assays and also confirmed 
that intact ZF domains are required for ZFP36L1 to bind to the BCL2 ARE. Another strategy used to 
study the interaction of the ZFP36 family proteins with the ARE in BCL2 mRNA was to use a BCL2 
ARE where the core ARE sequence was absent in a mutated form of the BCL2 ARE. ZFP36L1 was 
unable to interact with the mutant BCL2 ARE indicating that ZFP36L1 recognition of the BCL2 
3’UTR is via the AUUUA sequences in the ARE. Results from analysing the interaction of the other 
two family members, ZFP36L2 and ZFP36, also indicated that they degraded the BCL2 3’UTR ARE 
and not its mutated version. No ZF domain mutants of the ZFP36L2 and ZFP36 proteins were 
available; however, using mutant versions of these proteins in further 3‘UTR luciferase reporter 
assays would be useful to further strengthen the findings of the study and support that all three 
ZFP36 family proteins can interact with the BCL2 ARE. REMSA assays had already shown the 
interaction between ZFP36L1 and the BCL2 ARE (Zekavati 2009, Zekavati et al. 2014). REMSA 
experiments could also be carried out to analyse the interaction of ZFP36L2 and ZFP36 proteins 
with the BCL2 ARE to possibly further strengthen the results of the present study. 
 
The possibility that CD38 mRNA is  a target for ZFP36 proteins has never been studied before 
although in silico analysis had previously highlighted it as a putative ZFP36L1 target mRNA (Nasir 
et al. 2012). Using a similar strategy to that put in place with BCL2 3’UTR ARE, this project looked 
at investigating if there was a direct and functional interaction between ZFP36 proteins and the 
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CD38 3’ UTR ARE. The 3’UTR luciferase reporter assays described in this thesis have provided the 
first in vtro experimental evidence of a direct interaction between ZFP36L1 and the 3’UTR ARE of 
CD38 mRNA. ZF domain mutant ZFP36L1 was unable to bind to the 3’ UTR ARE but wild type 
ZFP36L1, ZFP36L2 and ZFP36 led to reduced luminescence levels of the reporter gene containing 
the CD38 3’ UTR ARE. A mutant CD38 ARE was unavailable. The 3’UTR luciferase reporter assays  
could be expanded and strengthen by using mutant versions of the ZFP36 family proteins and the 
CD38 3’ UTR ARE target.  
 
To further analyse the possible regulation of CD38 mRNA by ZFP36L1, the expression level of the 
ZFP36L1 protein was down regulated in HeLa by siRNAs, and the levels of CD38 expression were 
assessed by immunofluorescence and flow cytometry and by Western blot analysis. In cells with a 
down regulation of ZFP36L1 expression, CD38 expression levels were increased and there was an 
indication that the lower the level of ZFP36L1 expression in the cells, the higher the level of CD38 
was observed. One limitation to take into account in the case of these results is that a phenotype 
rescue (expressing a siRNA resistant form of the gene that has been knocked down, rescue of the 
knockdown phenotype indicates siRNA specificity) would have added another layer of certainty to 
the siRNA effect. Also QRTPCR measurements of mRNA for ZFP36L1 and CD38 would provide 
additional quantitative information regarding changes in both mRNAs that could potentially support 
the Western blot protein level analyses that was carried out. To further extend the study to immune 
cells siRNA-mediated knockdown of ZFP36L1 expression could be performed in primary B cells or 
B cell lines that are positive for ZFP36L1 and CD38 expression. Knockdown experiments were 
attempted in B-CLL cells (data not shown) but the results regarding successful siRNA transfection 
were variable and inconsistent and therefore this approach was abandoned. 
 
Analysis of expression of ZFP36L1, BCL2 and CD38 in lymphoid tissue by IHC showed that 
detectable levels of ZFP36L1 expression were confined to GC. BCL2 expression was absent or 
very low in GCs of normal tonsils but more highly expressed in the mantle zone. The same strategy 
was used to analyse the proteins in malignant lymphoid tissue. Results obtained from 
immunohistochemistry analysis of FL showed that ZFP36L1 was expressed in follicle centres where 
BCL2 is reportedly also highly expressed. Unfortunately, BCL2 expression was not detected in FL in 
the present study due to a technical problem. In the vast majority of FLs BCL2 is translocated 
(t14:18), translocation) placed under the control of the IgHV promoter and is therefore highly up 
regulated. ZFP36L1 expression was detected at the same level in normal tissue GCs as in the 
malignant follicular centres. One possibility is that since the translocation would mean that the level 
of BCL2 is highly up regulated in FL B cells, the normal negative regulatory control of ZFP36L1 over 
BCL2 expression would be overcome by the abnormal increased expression of BCL2.  
 
These IHC results, especially non-malignant  tissue showing  ZFP36L1 detected in GCs where 
BCL2 is very lowly/not  expressed, must be considered alongside the luciferase assay results 
discussed in chapter 3. Chapter 3 evidences the interaction of the ZFP36 proteins, especially 
ZFP36L1, with the BCL2 3’UTR ARE. In addition, data recently published on the role of the ARE in 
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the regulation of BCL2 from in vivo studies (Díaz-Muñoz et al. 2015) and the evidence provided in 
(Zekavati et al. 2014) are  consistent with ZFP36L1 targeting  BCL2 mRNA in vivo. 
 
CD38 is a marker with relevance in B cell development and is an important plasma cell marker. It 
has already been shown  ZFP36L1 targets BLIMP1 (Nasir et al. 2012), to negatively regulate B cell 
plasmacytoid differentiation. In the study, CD38 mRNA was also highlighted by in silico  analysis as 
a putative ZFP36L1 mRNA target (Nasir et al. 2012). The IHC results in chapter 5 show that there is 
a low level CD38 expressing cells in GCs where ZFP36L1 is mainly expressed, but in tissue areas 
where CD38 was highly expressed, there was no detectable ZFP36L1 expression.   
 
For CD38, the IHC results, together with  the 3’UTR luciferase reporter assay results and the 
upregulation of CD38 expression  after down regulating ZFP36L1 in HeLa cells, support the 
hypothesis that  ZFP36L1 targets  CD38 mRNA  and thereby negatively regulates its expression by 
transcriptional mechanisms. 
 
The last results chapter of this thesis showed the analysis of expression of the ZFP36 family of 
proteins in B cell lines representing B cells of different developmental stages and primary B-CLL 
cells. The results showed that across the B cell lines, ZFP36L1 was expressed at low levels or not 
detected, but ZFP36L2 was generally higher expressed although at different levels in different B cell 
lines. In B-CLL cells the opposite was seen, ZFP36L2 was not expressed, or very faintly detected, 
and the expression level of ZFP36L1 varied amongst the different B-CLL cell populations, the 
protein was markedly heterogeneous in its level of expression. The ZFP36 protein showed fairly 
homogeneous expression levels in all B-CLL populations tested. For the B-CLL populations, the 
expression of BCL2 was also analysed and the protein was detected at different levels in different 
B-CLL cell populations. There did not seem to be an inverse relationship between levels of 
ZFP36L1 and BCL2 in B-CLL. The lack of a direct inverse relationship seen in Western blots in B-
CLL cells could stem from the deregulation of BCL2 in B-CLL (Tzifi et al. 2011).  Furthermore, in B-
CLL the clinical stage and disease markers vary between different patients (Kampalath et al. 2003, 
Rodríguez-Vicente et al. 2013).  This clinical variability in B-CLL may account for the different levels 
of ZFP36L1 and BCL2 expressed in different B-CLL populations. Clinical data available for the B-
CLL patients was incomplete in the present study and therefore could not be used to make further 
assessments that may explain or provide insights into the reasons for the heterogeneity of 
ZFP36L1, ZFP36L2 and BCL2 expression levels in B-CLL. 
 
CD38 expression was also found to be heterogeneous and without an evident direct or inverse 
relationship with ZFP36L1 levels. B-CLL cells with high ZFP36L1 showed high levels of CD38 and 
low/no CD38 expression, the same was seen for B-CLL cells with no ZFP36L1 expression. 
 
Cell lines representing mature B cells and plasma cells such as myeloma did not express or 
expressed very low detectable levels of ZFP36L1. This could be seen as reasonably consistent with 
immunohistochemistry findings, where  ZFP36L1 was detected in GCs of normal tissue and in FL 
but at a relatively low level of expression. The finding of absent or low level of ZFP36L1 in myeloma 
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cells has previously been reported although a more extensive analysis was done in the present 
study (Nasir et al. 2012). 
 
As in previous studies other methods to assess the level of expression of ZFP36L1 in B-CLL cells 
and in B cell lines could be used (Nasir et al. 2012), e.g. measuring mRNA levels by QRTPCR. An 
optimised histological analysis such as fluorescence in situ hybridisation could also be done to 
compare data with the results obtained in the present study, this could provide clearer assessment 
of which B cells are positive for ZFP36L1 in tissue sections. 
 
Further extensions of the studies presented here could involve attempting to isolate mRNA targets 
from B cells for ZFP36L1 (and possibly ZFP36 and ZFP36L2) on a global scale using newly 
described protocols such as iCLIP (individual nucleotide resolution cross linking and 
immunoprecipitation) (König et al. 2012) or PARclip (Photoactivatable Ribonucleoside-Enhanced 
Crosslinking and Immunoprecipitation)(Spitzer et al. 2014). These methodologies are potentially 
very powerful and important novel mRNA targets identified using these strategies could be further 
validated by similar approaches to those presented in this project. Iin the light of studies presented 
here and also the evidence that the promoters of the ZFP36 and ZFP36L1 genes are targeted for 
transcriptional repression by the BCL6 oncogene in GCs (Basso et al. 2010) it would also be useful 
to examine in more detail GC formation and B cell subpopulations alongside the formation of 
plasma cells in the GC in ZFP36L1 mouse knockout animals.  
 
 
7.1. 2 Model of ZFP36L1 function in late B cell development  
Overall, the evidence is indicating a role of ZFP36L1 in the regulation of mRNAs key in 
immunobiology, although the role may be shared with the other ZFP36 family members to the point 
that it has been reported that the loss of one protein may be compensate by another family 
member. There is evidence that in mice with deficient ZFP36L1, ZFP36 may compensate for its 
loss. ZFP36L1 is induced upon infection, but deficient ZFP36L1 mice have not indicated changes of 
lung cytokine production, bacteria clearance is not altered either as well as there is not a change in 
increased inflammatory lung injury. Data from ZFP36 deficient mice seem to indicate that ZFP36 
and not ZFP36L1 is the major negative regulator of cytokine expression in macrophages. The 
authors concluded that ZFP36 may compensate for the loss of ZFP36L1 in these experiments 
(Hyatt et al. 2014). 
 
The role of the ZFP36 proteins as tumour suppressors in immunological malignancies was initially 
reported in mast cell tumours (Stoecklin et al. 2003). ZFP36 is downregulated in a number of 
cancers (Brennan et al. 2009). Lack of ZFP36 destabilising function on mRNAs led to 
overproduction of TNFα, VEGF and overall tumour progression (Suswam et al. 2008). VEGF mRNA 
is also regulated by ZFP36L1 (Bell et al. 2006). Mice lacking ZFP36L1 and ZFP36 developed T-AL 
L and increased levels of NOTCH1 are observed (Hodson et al. 2010). Genome sequence analysis 





Differentiation might be controlled by ZFP36L1 at early stages as evidenced by data from mESCs 
where ZFP36L1 seems able to negatively regulate factors such as Nanog, a transcription factor 
critically involved with self-renewal of undifferentiated embryonic stem cells (Tan and Elowitz 2014). 
In B cells, ZFP36L1 negatively regulates plasmacytoid differentiation by targeting BLIMP1 (Nasir et 
al. 2012) and evidence obtained in this research project suggest that ZFP36L1 might extend its 
post-transcriptional regulator role to CD38 and BCL2 in  late B cell development; a model of 







Figure 7-1 Proposed model of ZFP36L1 function in late B cell development 
B cells can differentiate to plasma cells, primed for survival by BCL2 and expression of CD38 will increase in 
plasmablasts/plasma cells.  The remaining of B cells die by apoptosis. BLIMP1 was shown to be a target for ZFP36L1 (Nasir 
et al. 2012). BLIMP1 expressions starts after activation of a naive B cell and increases driving differentiation into  plasma 
cells. ZFP36L1 targets the 3’UTR ARE of BCL2 and CD38 mRNAs leading to degradation and downregulation of the 
proteins.  BCL2 cannot induce anti-apoptotic effects and cells will not survive to differentiate to plasma cells. CD38 will also 
be downregulated and affect BCR signalling and cell survival. BLIMP1 is also negatively regulated by ZFP36L1, lack of 










7.3 Final Conclusion 
This project has studied two putative mRNA targets for the ZFP36 family of post-transcriptional 
regulator proteins. BCL2 and CD38 are important proteins in B cell development and B cell 
malignancy:  Using a 3’UTR luciferase reporter assay, ZFP36L1 was found to interact with BCL2 
ARE and CD38 ARE constructs. The zinc finger domains of ZFP36L1 are required for this 
interaction. ZFP36 and ZFP36L2, the two other members of the protein family, were also shown to 
interact with BCL2 ARE and CD38 ARE constructs. Down-regulation of ZFP36L1 expression in 
HeLa cells by siRNAs was accompanied by increased expression of CD38. In B-CLL, no obvious 
inverse expression relationship was found between ZFP36L1 expression levels and BCL2 
expression levels or ZFP36L1 expression levels and CD38 expression levels. IHC analysis of 
normal tonsils and FL showed that ZFP36L1 was generally expressed at a detectable level in 
normal GC, where BCL2 expression is absent or very low. But ZFP36L1 expression was also found 
in the abnormal GC/follicle centres found in FL where BCL2 levels are reported to be highly 
expressed. CD38 was generally highly expressed in areas of lymphoid tissues where ZFP36L1 
expression was very low.  
 
Taken together, the evidence presented in the project, supports a role for the ZFP36 family proteins 
as post-transcriptional regulators of BCL2 mRNA and CD38 mRNA. These observations also 
support the view that the ZFP36 protein family mediated post-transcriptional control mechanisms 
have an important role in regulating normal and malignant B cell development and differentiation, 





















Appendix A mRNA targets for ZFP36 proteins 
 
A-1 Reported mRNA targets for the ZFP36 family of proteins, as referred to in section 1.1.5 
A review by (Baou et al. 2009a) had previously summarised and published a list of possible and 
confirmed targets for the three ZFP36 proteins. The list is shown below  
 
Table A-1 Reporter mRNA targets for ZFP36 proteins 
Protein Reported mRNA targets 
 
                Reference 
ZFP36,  TNF  mRNA stability (Carballo et al. 1998) 
 
GM-CSF mRNA stability (Carballo et al. 2000) 
 
IL-3 mRNA stability (Stoecklin et al. 2000) 
 
IL-6 mRNA stability (Stoecklin et al. 2001) 
 
cyclooxygenase mRNA stability (Sawaoka et al. 2003) 
 
PAI type 2 mRNA stability (Yu et al. 2003) 
 
Pitx2 mRNA stability (Briata et al. 2003) 
 
TIS11 mRNA stability (Brooks et al. 2004) 
 
IL-2 mRNA stability (Ogilvie et al. 2005) 
 
1,4galactosyltransferase mRNA stability (Gringhuis et al. 2005) 
 
IL-12 ? (Jalonen et al. 2006a) 
 
Ccl2 mRNA stability (Sauer et al. 2006) 
 
Ccl3 mRNA stability (Sauer et al. 2006) 
 
c-Myc mRNA stability (Marderosian et al. 2006) 
 
cyclin D1 mRNA stability (Marderosian et al. 2006) 
 
Fos mRNA stability (Patino et al. 2006) 
 
Ier3 mRNA stability (Lai et al. 2006) 
 
Genome analysis 250 mRNAs mRNA stability (Lai et al. 2006) 
 
MIP-2 ? (Jalonen et al. 2006a) 
 
p21 mRNA stability Patino et al. 2006) 
 
E47 mRNA stability (Frasca et al. 2007) 
 
VEGF mRNA stability (Essafi-Benkhadir et al. 2007) 
 
IL-10 mRNA stability (Stoecklin et al. 2008) 
 
Genome analysis 137 mRNAs mRNA stability Stoecklin et al. 2008) 
 
polo-like kinase 3 mRNA stability (Horner et al. 2009) 
    
ZFP36L1 TNF mRNA stability (Lai et al. 2000) 
 
GMCSF mRNA stability (Lai and Blackshear 2001) 
 
IL-3 mRNA stability (Stoecklin et al. 2002)[ 
 
VEGF mRNA stability (Ciais et al. 2004) 
 
c-IAP2 mRNA stability (Lee et al. 2005) 
 
VEGF translation (Bell et al. 2006) 
 
STAR mRNA stability Duan et al. 2009) 
    
ZFP36L2 TNF mRNA stability Lai et al. 2000) 
 
GM-CSF mRNA stability Lai and Blackshear 2001) 
 
IL-3 mRNA stability Lai and Blackshear 2001) 







A-2 Inferred target mRNAs for ZFP36 family members.  
(Zekavati et al. 2014) provided a list of possible targets for each ZFP36 family member, the list is 
not reproduced here due to its length but it may be found in the paper’s supplementary data. The 
authors highlight BCL2 as a possible target. The paper also highlights other anti-apoptotic possible 
targets for the ZFP36 proteins such as those shown below: 
 




















 Gene_symbol Description 
BCL2 B-cell CLL/lymphoma 2 
BNIP2 BCL2/adenovirus E1B 19kDa interacting protein 2 
ZFP36 TARGETS 
 Gene_symbol Description 
BCL2 B-cell CLL/lymphoma 2 




BCL10 B-cell CLL/lymphoma 10 
BNIP2 BCL2/adenovirus E1B 19kDa interacting protein 2 
BIRC3 baculoviral IAP repeat containing 3 
NOTCH2 notch 2 
HDAC1 histone deacetylase 1 







A-3 ZFP36L1 targets involved in B cell late development inferred from ARACNe analysis 
(Nasir et al. 2012) looked at possible targets for ZFP36L1 in B cell differentiation. In the following list 
from this paper CD38 is highlighted as a possible target.  
 
Table A-3 Suggested ZFP36L1 targets involved in late B cell development 
Gene Description 
SEL1L sel-1 suppressor of lin-12-like (C. elegans) 
PLOD1 procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1 
CD38 CD38 molecule 
ABCB9 ATP-binding cassette, sub-family B (MDR/TAP), member 9 
LMF1 lipase maturation factor 1 
GAS6 similar to growth arrest-specific 6; growth arrest-specific 6 
TIMP2 TIMP metallopeptidase inhibitor 2 
APOE hypothetical LOC100129500; apolipoprotein E 
GFI1 growth factor independent 1 transcription repressor 
VDR vitamin D (1,25- dihydroxyvitamin D3) receptor 
PPT2 palmitoyl-protein thioesterase 2 
HMGA1 hypothetical LOC100130009; high mobility group AT-hook 1 
DTX3 deltex homolog 3 (Drosophila) 
BLIMP1 PR domain containing 1, with ZNF domain 
AMPD1 adenosine monophosphate deaminase 1 (isoform M) 
SERPING1 serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 
DPEP1 dipeptidase 1 (renal) 
ZCCHC24 zinc finger, CCHC domain containing 24 
C12orf47 chromosome 12 open reading frame 47 
MED27 
similar to cofactor required for Sp1 transcriptional activation, subunit 8, 34kDa; mediator complex subunit 
27; CRSP8 pseudogene 
MVD mevalonate (diphospho) decarboxylase 
LMNA lamin A/C 












Appendix B B cell development 
As referred to in section 1.2.1 a range of transcription factors control early B cell development, a 
figure with indications to key transcription factors in B cell development can be found here 
  
 
Figure B-1 B cell development stages with Ig, transcription factors and cell markers expression.  







Appendix C Plasmids Information 
This appendix section shows the maps of the plasmids used in the experiments of this research 
 
C-1 pGemT Easy vector map 
The amplified ARE (BCL2 and CD38) from stock plasmids were initially cloned into the pGem T 
Easy vector, from Promega. The pGemT Easy constructs were then analysed for positive clones 




Figure C-1 pGem T Easy vector map 


















C-2 pmirGLO Vector  
The pmirGLO Vector is designed with a Firefly luciferase as the primary reporter gene; the vector 
was originally designed to study miRNAs function. Reduced firefly luciferase expression indicates 
the binding of endogenous or introduced miRNAs to the cloned miRNA target sequence. Firefly 
luciferase (luc2) is the primary reporter and renilla luciferase (hRluc-neo) acts as a control reporter 
for normalization and selection (Image from Promega, 2013 a). Instead of miRNA, the 3’UTR of 
putative targets can be cloned into the reporting vector as shown in chapter 3 and 4 of this thesis for 
the BCL2 3’UTR ARE and CD38 3’UTR ARE. 
 
 
Figure C-2 Mechanism of action of pmirGLO reporter vector. 
Putative ZFP36L1 targets have been cloned onto pmirGLO /Dual reporter vector to analyse recognition/binding of target 
















The map of the vector is shown below: 
 
Figure C-3 Map of pmirGLO vector and key features 
pmirGLO has a reporter gene and a control gene (luciferase and renilla respectively). MCS=Multiple 

















C-3 pcDNA6ZFP36L1 and pcDNA6mutZFP36L1 
The pcDNA6/His.ZFP36L1 and the ZFP36L1 mutant expression construct was kindly provided by 
Dr. Christoph Moroni, University of Basel, Switzerland and constructed by inserting DNA sequences 
corresponding to the human ZFP36L1 mRNA ORF region into BamHIEcoRV sites of the plasmid 
pcDNA6/His.A (Invitrogen, Cat. No. V22220).  The pcDNA6/His.ZFP3636L1 mutant which was 
constructed by site directed mutagenesis (changing the first cysteine residue of either zinc finger 
domain to an arginine). Details on these constructs, pcDNA6/His.zfp36l1 and pcDNA6/His.zfp36l1 
referred as bsdHisBRF1WT and bsdHisBRF1C120R, can be found in(Stoecklin et al. 2002). The 
constructs were used in the dual luciferase reporter assays as seen in chapters 3 and 4. 
 
The sequences for pcDNA6/His™ A, B, and C are available in www.invitrogen.com. 
 











Table C-1 Features of pcDNA6/His  

















pDEST26ZFP36L2 was purchased from Source Bioscience, the construct was used in the dual 




Figure C-5 pDEST26 vector map.  

















C-5 pcSPORT6 ZFP36 
pcSPORT6ZFP36 construct was donated by Dr Manfred Frick and used in the dual luciferase 
reporter assays as seen in chapters 3 and 4. The pcSPORT6 plasmid map is shown below. 
 
Figure C-6 pcSPORT6 vector map 



















Appendix D DNA Sequences 
DNA Sequencing results to confirm the correct DNA sequence of clones used in the dual luciferase 
reporter assays, chapters 3 and 4. The sequences have mutations highlighted in red. 
 
D-1 pcDNA6 ZFP36L1- wild type sequence: 
NNNNNNNNNN NNNNNNNNNN NGGGGNNNNC NNCNNCATCN TCATCATGGT ATGGCTAGCA        60 
TGACTGGNGN NCAGCAAATG GGTCGGGATC TGNACGACGA TGACGATAAG GTANNNNNNA       120 
TCCCCACCAC CCTCGTGTCT GCCACCNTCT TCNACTTGAG NNAANTTTTA TGCAAGGGTA       180 
ACAAGATGCT CAACTATAGT GCTCCCANNG NANGGGGTTG CCTGCTGGAC AGAAAGGCAG       240 
TGNNCACCCC TGCNNNNNNN GGCTTCCCTC GGAGGCACTC ANTCACCCTG CCCANCTCCA       300 
ANTTCCACCA NAACCAGCTC CTCNNCAGCC TNNNGGGTGA GCCAGCCCCC GCTCTGAGCT       360 
CGNGAGACAG CCGCTTCCGA GACCGCTCCT TCTCGGAAGG GGGCGAGCGG CTGCTGCCCA       420 
CCCAGAAGCA NCNNGGGGGC GGCCAGNTCA ACTCCAGCCN CNACAANACG GAGCTGTGCC       480 
NCCCCTTTGA NGAAAACGGT GCCTGTAAGT ACGGGGACAA GTGCCNNNNN NCACACGGCA       540 
TCCACGAGCT CCGCAGCCTG ACCCGCCACC CCAANTNNNA GACGGAGCTG TGCCGCACCT       600 
TCNACACCNN NNGCTTTTGC CCCTACGGGC CCCGCTGCNN NTTNNNCCAN AACGNTGAAN       660 
ANCGCCNTGC CCTGNCCGGG GCCCGGNACC TCTCCGCTGA CCGTNNNNNN CTCCNNNATA       720 
NCTTTANCTT TGTTGGGTTT NN                                                742 
 
 
D-2 pcDNA6 ZFP36L1 – mutant, showing base pair change in zinc finger region causing a 
mutation from Cysteine to Arginine: 
NNNNNNNNNN NNNNNNNNNN NGGGGNTNNN NTCNTCNTNN TNATCATGGT ATGGCTAGCA        60 
TGACTGGTGG ACAGCAAATG GGTCGGGATC TGTACGACGA TGACGATAAG GTACCTANGA       120 
TCCCCACCAC CCTCGTGTCT GCCACCATCT TCGACTTGAG CGAANTTTTA TGCAAGGGTA       180 
ACAAGATGCT CAACTATAGT GCTCCCAGTG CAGGGGGTTG CCTGCTGGAC AGAAAGGCAG       240 
TGGGCACCCC TGCTNNNGNN GGCTTCCCTC GGAGGCACTC ANTCNCCCTG CCCAGCTCCN       300 
AGTTCCACCA GAACCAGCTC CTCAGCAGCC TCAAGGGTGA GCCAGCCCCC GCTCTGAGCT       360 
CGCGAGACAG CCGCTTCCNA NACCGCTCCT TCTCGGAAGG GGGCGAGCGG CTGCTGCCCA       420 
CCCANAAGCA GCCCGGGGGC GGCCAGGTCA ACTCCAGCCG CTACAAGACG GAGCTGTGCC       480 
NCCCCTTTNA NGAAAACGGT GCCTGTAAGT ACGGGGACAA GTGCCNNTTC NCACACGGCA       540 
TCCACGAGCT CCGCAGCCTG ACCCGCCACC CCAANTACAA GACGGANCTG CGCCGCACCT       600 
TCNANNNNAT CGGNTTTTGC CCCTACGGGC CCCGCTGCNN NTTCATCCAC AANNNTNAAN       660 
AGCGCCGTGC CCTGGCCGGG GCCCGGGNNC TCTCCGCTGA CCGTCCCCGC CTCCNNCATA       720 
NCTTNANCTT TGCTGGNNTT TCCCAGTGCC GCTGCNNCCG CCGCTGCNAN CNNGGCTGCN       780 
GGACAGCCCC ACNTCNATCA CCCCACCCNC NATTCTGAGC GCNATGANNT CNNGNGCTCA       840 
 
Figure D-1 ZFP36L1 plasmids sequences show a single nucleotide change in a the zinc finer mutant 
pcDNA6ZFP36L1, a gift from DR Christoph Moroni and was produced by introducing the ORF region of the human ZFP36L1 
mRNA within BamH1-EcoRV in a pcDNA6/His.A from Invitrogen, Cat. N. V22220. The mutated version of the construct was 
















D-3 pmirGLO BCL2- wild type sequence: 
 
NNNNNNNNNN NNNNTNNNAA NGCNGTAGNA ATAATATGCA TTGTCNGTGA TGTACCATGA        60 
AACAAAGCTG CAGGCTGTTT AAGAAAAAAT AACACACATA TAAACATCAC ACACACAGAC       120 
AGACACACAC ACACACAACA ATTAACAGTC TTCAGGCAAA ACGTCGAATC AGCTATTTAC       180 
TGCCAAAGGG AAATATCATT TATTTTTTAC ATTATTAAGA AAAAAAGATT TATTTATTTA       240 
AGACAGTCCC ATCAAAACTC CTGTCTTTGG AAATCCGACC ACTAATTGCC AAGCACCGCT       300 
TCGTGTGGCT CCACCTGGAT GTTCTGTGCC TGTAAACATA GATTCGCTTT CCATGTTGTT       360 
GGCCGGATCA CCTCTAGAGT CGACCTGCAG GCATGCAAGC TGATCCGGCT GCTAACAAAG       420 
CCCGAAAGGA AGCTGAGTTG GCTGCTGCCA CCGCTGAGCA ATAACTAGCA TAACCCCTTG       480 
GGGCGGCCGC TTCGAGCAGA CATGATAAGA TACATTGATG AGTTTGGACA AACCACAACT       540 
AGAATGCAGT GAAAAAAATG CTTTATTTGT GAAATTTGTG ATGCTATTGC TTTATTTGTA       600 
ACCATTATAA GCTGCAATAA ACAAGTTAAC AACAACAATT GCATTCATTT                  650 
 
 
D-4 pmirGLO BCL2- mutant sequence.  
The area where the sequence highlighted above is missing has been left blank in the image below 
 
 
NNNNNNNNNN NNNNTNNNAA NGCNGTAGNA ATAATATGCA TTGTCNGTGA TGTACCATGA        60 
AACAAAGCTG CAGGCTGTTT AAGAAAAAAT AACACACATA TAAACATCAC ACACACAGAC       120 
AGACACACAC ACACACAACA ATTAACAGTC TTCAGGCAAA ACGTCGAATC AGCTATTTAC       180 
TGCCAAAGGG AAATATCATT TATTTTTTAC ATTATTAAGA AAAAAAGATT TATTTATTTA       240 
AGACAGTCCC ATCAAAACTC CTGTCTTTGG AAATCCGACC ACTAATTGCC AAGCACCGCT       300 
TCGTGTGGCT CCACCTGGAT GTTCTGTGCC TGTAAACATA GATTCGCTTT CCATGTTGTT       360 
GGCCGGATCA CCTCTAGAGT CGACCTGCAG GCATGCAAGC TGATCCGGCT GCTAACAAAG       420 
CCCGAAAGGA AGCTGAGTTG GCTGCTGCCA CCGCTGAGCA ATAACTAGCA TAACCCCTTG       480 
GGGCGGCCGC TTCGAGCAGA CATGATAAGA TACATTGATG AGTTTGGACA AACCACAACT       540 
AGAATGCAGT GAAAAAAATG CTTTATTTGT GAAATTTGTG ATGCTATTGC TTTATTTGTA       600 
 
 
Figure D-2 DNA sequencing analysis of plasmids.  
Sequencing results are shown in this figure. BCL2 ARE wild type and mutant BCL2 ARE differ in a 
section in the centre of their sequence, this section is not present in the mutant BCL2 ARE (Lapucci 
et al. 2002). PcDNA6ZFP36L1 and its mutant version differ in their zinc finger region, the mutant 
ZFP36L1 has a change in its sequence, the first Cysteine (TGC) in the zinc finger changes to an 
Arginine (CGC) (Stoecklin et al. 2002 ). 
 
D-5 pmirGLOCD38 sequence:  
 
NNNNNNNNNG AGCTCANAAT TCAAGNNATC GCCCTGAGGA TTCATCTTGC ACATCTGAGA        60 
TCTGAGCCAG TCGCTGTGGT TGTTTTAGCT CCTTGACTCC TTGTGGTTTA TGTCATCATA       120 
CATGACTCAG CATACCTGCT GGTGCAGAGC TGAAGATTTT GGAGGGTCCT CCACAATAAG       180 
GTCAATGCCA GAGACGGAAG CCTTTTTCCC CAAAGTCTTA AAATAACTTA TATCATCAGC       240 
ATACCTTTAT TGTGATCTAT CAATAGTCAA GAAAAATTAT TGTATAAGAT TAGAATGAAA       300 
ATTGTATGTT AAGTTACTTC ACTTTAATTC TCATGTGATC CTTTTATGTT ATTTATATAT       360 
TGGTAACATC CTTTCTATTG AAAAATCACC ACACCAAACC TCTCTTATTA GAACAGGCAA       420 
GTGAAGAAAA GTGAATGCTC AAGTTTTTCA GAAAGCATTA CATTTCCAAA TGAATGACCT       480 
TGTTGCATGA TGTATTTTTG TACCCTTCCT ACAGATAGTC AAACCACGCG TAAGCGGCNN       540 
CNGCATCTAG ATTCGAANNN AANNNNNN                                          568 
 
 
Figure D-3  CD38 3’UTR sequence cloned into pmirGLO.  
The figure shows the sequence of 3’UTR of CD38 mRNA  cloned into the pmirGLO vector; ARE motifs are highlighted in red 
and shaded. The sequence shown matches the reference sequence of NM_001775 for CD38 3’ UTR SC206546 3'UTR 




Appendix E FL grading systems 
This appendix section provides details on the different grading system used for FL, as mentioned in 
section 5.1 
 
E-1 World Health Organisation Classification of Tumours of Haematopoietic and Lymphoid 
Tissues 
The World Health Organization (WHO) classification of lymphoid neoplasms updated in 2008 
represents a worldwide consensus on the diagnosis of these tumours and is based on the 
recognition of distinct diseases, using a multidisciplinary approach (Swerdllow et al. 2008).   
 
The WHO classification of FL (non-Hodgkin) recommends that grading be carried out according to 
the counting method proposed by Mann and Berard to define 3 grades based on the number of 
centroblasts (large or small) per 40x high-power field. Patients are categorised in groups and start 
of treatment and type of therapy is influenced by this categorisation. A classification of FL grade 3 
suggests that the patient is at high-risk for disease progression. FL grade 3 is divided into grades 
3A and 3B based on the presence of centrocytes, it signifies a high risk for disease progression, 
treatment guidelines state that treatment guidelines for DLBCL should be followed (bioncology.com 
2015)- World Health Organisation guidelines-. 
 
Table E-1 WHO classification of histological grades grades 
 




   
 
E-2 Ann Arbor staging system 
It is primarily based on the distribution of lymphatic involvement and presence of extra lymphatic 
organ involvement. It does not reflect spread of disease and it does not account for extra nodal 
involvement 
 
Table E-2 Ann Arbor staging system for FL 
 
Table and information from bioncology.com (2015) 
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